

CBM 96-1

Cervical Cancer

January 1993 through March 1996

926 Citations

Prepared by

Lori J. Klein, M.A.L.S., National Library of Medicine
Edward L. Trimble, M.D., M.P.H., National Cancer Institute

**U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES**

Public Health Service
National Institutes of Health

National Library of Medicine
Reference Section
8600 Rockville Pike
Bethesda, Maryland 20894

1996

National Library of Medicine Cataloging in Publication

Klein, Lori

Cervical cancer : January 1993 through March 1996 :
926 citations / prepared by Lori J. Klein, Edward L.
Trimble. -- Bethesda, Md. (8600 Rockville Pike, Bethesda
20894) : U.S. Dept. of Health and Human Services, Public
Health Service, National Institutes of Health, National
Library of Medicine, Reference Section ; Pittsburgh, PA :
Sold by the Supt. of Docs., U.S. G.P.O., 1996.
-- (Current bibliographies in medicine ; 96-1)

Prepared in support of the National Institutes of Health
Consensus Development Conference on Cervical Cancer, held in
Bethesda, Md., April 1-3, 1996.

1. Cervix Neoplasms - bibliography I. Trimble, Edward L.
II. National Library of Medicine (U.S.). Reference Section
III. National Institutes of Health Consensus Development
Conference on Cervical Cancer (1996 : Bethesda, Md.) IV.
Title V. Series

02NLM: ZW 1 N272 no.96-1

SERIES NOTE

Current Bibliographies in Medicine (CBM) is a continuation in part of the National Library of Medicine's Literature Search Series, which ceased in 1987 with No. 87-15. In 1989 it also subsumed the *Specialized Bibliography Series*. Each bibliography in the new series covers a distinct subject area of biomedicine and is intended to fulfill a current awareness function. Citations are usually derived from searching a variety of online databases. NLM databases utilized include MEDLINE®, AVLINE®, BIOETHICSLINE®, CANCERLIT®, CATLINE®, HEALTH, POPLINE™ and TOXLINE®. The only criterion for the inclusion of a particular published work is its relevance to the topic being presented; the format, ownership, or location of the material is not considered.

Comments and suggestions on this series may be addressed to:

Karen Patrias, Editor
Current Bibliographies in Medicine
Reference Section
National Library of Medicine
Bethesda, MD 20894
Phone: 301-496-6097
Fax: 301-402-1384
Internet: patrias@nlm.nih.gov

Ordering Information:

Current Bibliographies in Medicine is sold by the Superintendent of Documents, U.S. Government Printing Office, P.O. 371954, Pittsburgh, PA 15250-7954. To order the entire CBM series for calendar year 1996 (approximately 10 bibliographies), send \$47.00 (\$58.75 foreign) to the Superintendent of Documents citing GPO List ID: CBM96. For your convenience an order blank is given inside the back cover. Orders for individual bibliographies in the series (\$5.50, \$6.88 foreign) should be sent to the Superintendent of Documents citing the title, CBM number, and the GPO List ID given above.

Internet Access:

The *Current Bibliographies in Medicine* series is also available at no cost to anyone with Internet access through FTP (File Transfer Protocol). FTP to [nlmpubs.nlm.nih.gov](ftp://nlmpubs.nlm.nih.gov) and login as anonymous. The index file in the "bibs" directory provides information on the bibliographies available.

Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 1996.

CERVICAL CANCER

The introduction of the Papanicolaou (Pap) test fifty years ago has led to a steep decline in deaths from cervical cancer. Nonetheless, this form of cancer accounts for 65% of all malignancies in American women and 5,000 cancer deaths in the United States each year. Worldwide, cervical cancer remains the leading cause of cancer deaths among women.

This bibliography was prepared for the National Institutes of Health Consensus Development Conference on Cervical Cancer held in Bethesda, MD on April 1-3, 1996. The conference focused on treatment and quality-of-life issues for women with cervical cancer. For women with early-stage disease, these include pretreatment imaging, the role of lymph node resection, primary surgery and radiotherapy, and adjuvant treatment. For women with advanced-stage disease, critical issues include optimal radiotherapy techniques, neoadjuvant and concomitant chemotherapy, pelvic exenteration, and palliative treatment.

Many unanswered questions remain as to how best to treat women with preinvasive disease of the cervix. Although the issues were reviewed at the Consensus Conference, the main focus of the Conference was cervical cancer. The bibliography, therefore, concentrates on treatment issues in invasive disease. Included are journal articles, conference proceedings and papers, and dissertations from 1993 through early 1996 related to the subject matter. The bibliography has been organized along the same lines as the conference, with the first small section dealing with improving and strengthening efforts to prevent cervical cancer. The next sections cover the management of early-stage disease, then advanced-stage and recurrent cervical cancer. The last section includes references to new directions in research. Most references are included only under a single category.

The compilers wish to thank Adam Glazer, National Library of Medicine, for his production assistance.

SEARCH STRATEGY

A variety of online databases are usually searched in preparing bibliographies in the CBM series. To assist you in updating or otherwise manipulating the material in this search, the strategy used for the NLM's MEDLINE database is given below. Please note that the search strategies presented here differ from individual demand searches in that they are generally broadly formulated and irrelevant citations edited out prior to printing.

SS 1 = CERVIX NEOPLASMS AND THERAPY& (PX)

SS 2 = *CERVIX NEOPLASMS

SS 3 = (TW) CERVIX OR CERVICAL

SS 4 = NEOPLASMS (PX)

SS 5 = (TW) ALL INVAD: OR ALL INVAS: OR STAGE OR STAGING OR STAGES OR FIGO

SS 6 = 3 AND 4 AND 5

SS 7 = CERVICAL INTRAEPITHELIAL NEOPLASIA OR CERVIX DYSPLASIA OR
PRECANCEROUS CONDITIONS OR EXP THYROID NEOPLASMS

SS 8 = 6 AND NOT 7

SS 9 = 1 OR 2 OR 8

SS 10 = 9 AND HUMAN

GRATEFUL MED® and INTERNET GRATEFUL MED®

To make online searching easier and more efficient, the Library offers GRATEFUL MED, microcomputer-based software that provides a user-friendly interface to most NLM databases. This software was specifically developed for health professionals and features multiple choice menus and "fill in the blank" screens for easy search preparation. GRATEFUL MED runs on an IBM PC (or IBM-compatible) with DOS 2.0 or a Macintosh, and requires a Hayes (or Hayes-compatible) modem. It may be purchased from the National Technical Information Service in Springfield, Virginia, for \$29.95 (plus \$3.00 per order for shipping). For your convenience, an order blank has been enclosed at the back of this bibliography.

INTERNET GRATEFUL MED is available from the World Wide Web. The user with Internet access and an NLM user account need only point a compatible Web browser

(Netscape Navigator is strongly recommended) to <http://www.igm.nlm.nih.gov>. No other software at the user end is required. At present, MEDLINE is the only NLM database available through INTERNET GRATEFUL MED, but the Library expects to add access to other files rapidly.

SAMPLE CITATIONS

Citations in this bibliographic series are formatted according to the rules established for *Index Medicus*^{®*}. Sample journal and monograph citations appear below. For journal articles written in a foreign language, the English translation of the title is placed in brackets; for monographs, the title is given in the original language. In both cases the language of publication is shown by a three letter abbreviation appearing at the end of the citation.

Journal Article:

<i>Authors</i>	<i>Article Title</i>
Hopkins MP, Morley GW.	Microinvasive squamous cell carcinoma of the cervix.
J Reprod Med 1994 Sep;39(9):671-3.	
<i>Abbreviated Journal Title</i>	<i>Date Volume Issue Pages</i>

Dissertation:

<i>Author</i>	<i>Title</i>	<i>Place of Institution</i>
Sun Y.	Serologic markers of human papillomavirus associated cervical cancer [dissertation]. [Baltimore (MD)]: Johns Hopkins Univ.; 1994. 193 p.	Available from: University Microfilms International, Ann Arbor, MI; AAD94-29578.

<i>Institution</i>	<i>Date of Degree</i>	<i>Total No. of Pages</i>	<i>Availability</i>
--------------------	-----------------------	---------------------------	---------------------

Conference Paper:

<i>Author</i>	<i>Paper Title</i>	<i>Editors</i>
Taguchi T.	Clinical studies of CPT-11 in Japan.	In: Banzet P, Holland JF, Khayat D, Weil M, editors. Cancer treatment: an update. Presentations given at the 4th International Congress on Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France. Paris: Springer-Verlag; 1994. p. 809-12.
<i>Book Title</i>	<i>Date & Place of Conference</i>	<i>Place of Publication</i>
<i>Date</i>	<i>Pages</i>	<i>Publisher</i>

*For details of the formats used for references, see the following publication:

Patrias, Karen. *National Library of Medicine recommended formats for bibliographic citation*. Bethesda (MD): The Library; 1991 Apr. Available from: NTIS, Springfield, VA; PB91-182030.

TABLE OF CONTENTS

	<i>page</i>	
EFFORTS TO PREVENT CERVICAL CANCER		
Epidemiology	1	
Screening Patterns	3	
Screening	7	
Prevention	8	
MANAGEMENT OF LOW-STAGE CERVICAL CANCER (FIGO I-IIA)		
Pathology and Prognostic factors	9	
Imaging	13	
Surgical Assessment and Resection of Lymph Nodes		15
Diagnosis and Management of Stage IA1	16	
Primary Surgery, Including Treatment in Pregnancy		17
Primary Radiotherapy	20	
Quality of Life Considerations	21	
New Surgical Approaches	22	
Adjuvant Therapy After Hysterectomy	23	
Adjuvant Surgery After Radiotherapy	25	
MANAGEMENT OF ADVANCED-STAGE AND RECURRENT CERVICAL CANCER		
Radiotherapy	25	
High- or Low-Dose Rate Brachytherapy		28
Presurgical Neoadjuvant Chemotherapy or Concomittant Chemotherapy with Radiotherapy	30	
Potential Improvements in Radiobiology	35	
Radiotherapy ± Chemotherapy for Locally Recurrent Disease		37
Surgery for Locally Recurrent Disease	38	
Chemotherapy for Stage IVB and Recurrent Metastatic Disease		39
Palliative Radiotherapy for Stage IVB Disease	42	
NEW DIRECTIONS FOR RESEARCH IN CERVICAL CANCER		
Radiation Biology	43	
HPV Biology	43	
HPV Immunology and Vaccine Prospects		45

EFFORTS TO PREVENT CERVICAL CANCER

Epidemiology

- Aareleid T, Pukkala E, Thomson H, Hakama M. Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population. *Eur J Cancer* 1993;29A(5):745-9.
- Agarwal SS, Sehgal A, Sardana S, Kumar A, Luthra UK. Role of male behavior in cervical carcinogenesis among women with one lifetime sexual partner. *Cancer* 1993 Sep 1;72(5):1666-9.
- Ali S, Astley SB, Sheldon TA, Peel KR, Wells M. Detection and measurement of DNA adducts in the cervix of smokers and non-smokers. *Int J Gynecol Cancer* 1994; 4(3):188-93.
- Azevedo G, Mendonca S. [Cancer in the female population in Brazil]. *Rev Saude Publica* 1993 Feb;27(1):68-75. (Por).
- Batieha AM, Armenian HK, Norkus EP, Morris JS, Spate VE, Comstock GW. Serum micronutrients and the subsequent risk of cervical cancer in a population-based nested case-control study. *Cancer Epidemiol Biomarkers Prev* 1993 Jul-Aug;2(4):335-9.
- Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR, Cadell DM, Kurman RJ, Manos MM. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. *Sex Transm Dis* 1993 Sep-Oct;20(5):274-8.
- Becker TM, Wheeler CM, McGough NS, Parmenter CA, Stidley CA, Jamison SF, Jordan SW. Cigarette smoking and other risk factors for cervical dysplasia in southwestern Hispanic and non-Hispanic white women. *Cancer Epidemiol Biomarkers Prev* 1994;3(2):113-9.
- Beral V, Hermon C, Munoz N, Devesa SS. Cervical cancer. *Cancer Surv* 1994;19-20:265-85.
- Berry G, MacLennan R, Shearman R, Jelihovsky T, Cooper Booth J, Molina R, Martinez L, Salas O, Dabancens A, Zhiheng C, Yun T, Wei HY, Cuadros A, Aristizabal N, Modan B, Ron E, Alfandary E, Mati JG, Kenya P, et al. Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study. *Int J Cancer* 1993;55(2):228-36.
- Birley HD. Human papillomaviruses, cervical cancer and the developing world. *Ann Trop Med Parasitol* 1995 Oct; 89(5):453-63.
- Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. *J Natl Cancer Inst* 1995 Jun 7;87(11):796-802. Comment in: *J Natl Cancer Inst* 1995 Jun 7;87(11):779-80.
- Bosch FX, Munoz N, de Sanjose S, Guerrerro E, Gaffari AM, Kaldor J, Castellsague X, Shah KV, Chaffari AM [corrected to Gaffari AM]. Importance of human papillomavirus endemicity in the incidence of cervical cancer: an extension of the hypothesis on sexual behavior. *Cancer Epidemiol Biomarkers Prev* 1994 Jul-Aug;3(5):375-9. Published erratum appears in *Cancer Epidemiol Biomarkers Prev* 1994 Dec;3(8):718.
- Bosch FX, Munoz N, de Sanjose S, Navarro C, Moreo P, Ascunce N, Gonzalez LC, Tafur L, Gili M, Larranaga I, et al. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. *Cancer Epidemiol Biomarkers Prev* 1993 Sep-Oct;2(5):415-22.
- Brinton LA, Herrero R, Reeves WC, de Britton RC, Gaitan E, Tenorio F. Risk factors for cervical cancer by histology. *Gynecol Oncol* 1993 Dec;51(3):301-6. Comment in: *Gynecol Oncol* 1993 Dec;51(3):299-300.
- Cavalcanti SM, Frugulhetti IC, Passos MR, Fonseca ME, Oliveira LH. Prevalence of human papillomavirus DNA in female cervical lesions from Rio de Janeiro, Brazil. *Mem Inst Oswaldo Cruz* 1994 Oct-Dec;89(4):575-80.
- Cortit LI. Etiopathology of gynecological neoplasia and contraception. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Cote T, Schiffman M, Biggar R, Goedert J, Blattner W, et al. Invasive cervical cancer among women with AIDS: results of registry linkage [abstract]. *Proc Annu Meet Am Assoc Cancer Res* 1993;34:A1546.
- Cote T, Schiffman M, Biggar R, Goedert J, Virgo P, Blattner W. Invasive cervical cancer among women with AIDS: results of registry linkage. NACMR Study Group. *Int Conf AIDS* 1993 Jun 6-11;9(1):408 (abstract no. PO-B14-1637).
- Crook T, Farthing A. Human papillomavirus and cervical cancer. *Br J Hosp Med* 1993 Jan 20-Feb 2;49(2):131-2.
- Das BC, Gopalkrishna V, Das DK, Sharma JK, Singh V, Luthra UK. Human papillomavirus DNA sequences in adenocarcinoma of the uterine cervix in Indian women. *Cancer* 1993 Jul 1;72(1):147-53.
- DeBritton RC, Hildesheim A, De Lao SL, Brinton LA, Sathya P, Reeves WC. Human papillomaviruses and other influences on survival from cervical cancer in Panama. *Obstet Gynecol* 1993 Jan;81(1):19-24.

Eluf-Neto J, Booth M, Munoz N, Bosch FX, Meijer CJ, Walboomers JM. Human papillomavirus and invasive cervical cancer in Brazil. *Br J Cancer* 1994 Jan;69(1): 114-9.

Fernandez C, Sharrard RM, Talbot M, Reed BD, Monks N. Evaluation of the significance of polyamines and their oxidases in the aetiology of human cervical carcinoma. *Br J Cancer* 1995 Nov;72(5):1194-9.

- Gardner JW, Sanborn JS, Slattery ML. Behavioral factors explaining the low risk for cervical carcinoma in Utah Mormon women. *Epidemiology* 1995 Mar;6(2):187-9.
- Guo WD, Hsing AW, Li JY, Chen JS, Chow WH, Blot WJ. Correlation of cervical cancer mortality with reproductive and dietary factors, and serum markers in China. *Int J Epidemiol* 1994 Dec;23(6):1127-32.
- Hernandez F, Herruzo A, Aguera J, Gomez T, Calderon MA, Rodriguez-Oliver MA, Marcos C. [Risk factors for cervical cancer in women younger than 20 years]. *Prog Obstet Ginecol* 1995;38(7):458-64. (Spa).
- Herrero R, Brinton LA, Hartge P, Reeves WC, Brenes MM, Urcuyo R, Pacheco M, Fuster F, Sierra R. Determinants of the geographic variation of invasive cervical cancer in Costa Rica. *Bull Pan Am Health Organ* 1993;27(1):15-25.
- Hildesheim A, Gravitt P, Schiffman MH, Kurman RJ, Barnes W, Jones S, Tchabo JG, Brinton LA, Copeland C, Epp J, et al. Determinants of genital human papillomavirus infection in low-income women in Washington, D.C. *Sex Transm Dis* 1993 Sep-Oct;20(5): 279-85.
- Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, Kahn T, Kiviat N, Lancaster W, Mavromara-Nazos P, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. *J Virol* 1993 Nov;67(11):6413-23.
- Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. *Int J Cancer* 1993 Sep 9;55(2):228-36.
- Jones WB, Shingleton HM, Russell A, Chmiel JS, Fremgen AM, Clive RE, Zuber-Ocwieja KE, Winchester DP. Patterns of care for invasive cervical cancer: results of a National Survey of 1984 and 1990. *Cancer* 1995; 76(10 Suppl):1934-47.
- Kjaer SK, Engholm G, Dahl C, Bock JE, Lynge E, Jensen OM. Case-control study of risk factors for cervical squamous-cell neoplasia in Denmark. III. Role of oral contraceptive use. *Cancer Causes Control* 1993 Nov;4(6): 513-9.
- Klevens RM, Fleming PL, Mays M, Frey R. Characteristics of HIV-infected women with invasive cervical cancer (ICC), United States. In: Program and abstracts of the HIV Infection in Women Conference: Setting a new agenda; 1995 Feb 22-24; Washington, DC. Richmond (VA): Philadelphia Sciences Group; 1995. p. 103.
- Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. *Semin Surg Oncol* 1994 Jan-Feb;10(1):31-46.
- Kristiansen E, Jenkins A, Kristensen G, Ask E, Kaern J, Abeler V, Lindqvist BH, Trope C, Kristiansen BE. Human papillomavirus infection in Norwegian women with cervical cancer. *APMIS* 1994 Feb;102(2):122-8.
- La Vecchia C. Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia. *Contraception* 1994 Mar;49(3):223-30.
- La Vecchia C, Negri E, Franceschi S, Parazzini F. Long-term impact of reproductive factors on cancer risk. *Int J Cancer* 1993;53(2):215-9.
- Lazcano-Ponce EC, Rojas-Martinez R, Lopez-Acuna MP, Lopez-Carrillo L, Hernandez-Avila M. [Reproductive risk factors and uterine cervix cancer in Mexico City]. *Salud Publica Mex* 1993 Jan-Feb;35(1):65-73. (Spa).
- Modifications in the staging for stage I vulvar and stage I cervical cancer. Report of the FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. *Int J Gynaecol Obstet* 1995 Aug;50(2):215-6.
- Montana GS, Hanlon AL, Brickner TJ, Owen JB, Hanks GE, Ling CC, Komaki R, Marcial VA, Thomas GM, Lanciano R. Carcinoma of the cervix: patterns of care studies: review of 1978, 1983, and 1988-1989 surveys. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1481-6. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Jul 30; 32(5):1535-7.
- 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *JAMA* 1993;269(6):729-30.
- Pao CC, Kao SM, Tang GC, Lee K, Si J, Ruan S. Prevalence of human papillomavirus DNA sequences in an area with very high incidence of cervical carcinoma. *Br J Cancer* 1994 Oct;70(4):694-6.
- Poka R, Juhasz B, Lampe L. Cervical cancer in young women: a poorer prognosis? *Int J Gynaecol Obstet* 1994 Jul;46(1):33-7.
- Robertson D, Fedorkow DM, Stuart GC, McGregor SE, Duggan MA, Nation G. Age is prognostic variable in cervical squamous cell carcinoma. *Eur J Gynaecol Oncol* 1993;14(4):283-91.
- Rose PG, Fraire AE. Multiple primary gynecologic neoplasms in a young HIV-positive patient. *J Surg Oncol* 1993 Aug;53(4):269-72.
- Saint-Paul MT, Bremond A, Rochet Y. [Cervical cancer before 35 years of age: epidemiological and prognostic aspects. Retrospective study of 46 cases of cervical cancer before 35 years of age in a series of 449 cases in stages IA2 and IV]. *J Gynecol Obstet Biol Reprod (Paris)*

1993;22(7):737-42. (Fre).

Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. *Cancer* 1995;76(10 Suppl):1888-901.

Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. *Obstet Gynecol* 1995 May;85(5 Pt 1):793-801.

Serur E, Fruchter RG, Maiman M, McGuire J, Arrastia CD, Gibbon D. Age, substance abuse, and survival of patients with cervical carcinoma. *Cancer* 1995 May 15;75(10): 2530-8.

Sparen P, Gustafsson L, Friberg LG, Ponten J, Bergstrom R, Adami HO. Improved control of invasive cervical cancer in Sweden over six decades by earlier clinical detection and better treatment. *J Clin Oncol* 1995 Mar;13(3): 715-25.

Stone KM, Zaidi A, Rosero-Bixby L, Oberle MW, Reynolds G, Larsen S, Nahmias AJ, Lee FK, Schachter J, Guinan ME. Sexual behavior, sexually transmitted diseases, and risk of cervical cancer. *Epidemiology* 1995 Jul;6(4):409-14.

Weiss LK, Kau TY, Sparks BT, Swanson GM. Trends in cervical cancer incidence among young black and white women in metropolitan Detroit. *Cancer* 1994 Apr 1;73(7): 1849-54.

Williams MA, Kenya PR, Mati JK, Thomas DB. Risk factors for invasive cervical cancer in Kenyan women. *Int J Epidemiol* 1994 Oct;23(5):906-12.

Zhang ZF, Begg CB. Is *Trichomonas vaginalis* a cause of cervical neoplasia? Results from a combined analysis of 24 studies. *Int J Epidemiol* 1994 Aug;23(4):682-90.

Zhang ZF, Graham S, Yu SZ, Marshall J, Zielezny M, Chen YX, Sun M, Tang SL, Liao CS, Xu JL, et al. *Trichomonas vaginalis* and cervical cancer. A prospective study in China. *Ann Epidemiol* 1995 Jul;5(4):325-32.

Screening Patterns

Adami HO, Ponten J, Sparen P, Bergstrom R, Gustafsson L, Friberg LG. Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening. 1960-1984. *Cancer* 1994 Jan 1;73(1):140-7.

Agarwal SS, Murthy NS, Sharma S, Sharma KC, Das DK. Evaluation of a hospital based cytology screening programme for reduction in life time risk of cervical cancer. *Neoplasma* 1995;42(2):93-6.

Anderson LM, May DS. Has the use of cervical, breast, and colorectal cancer screening increased in the United States? *Am J Public Health* 1995 Jun;85(6):840-2.

Andrews HF, Kerner JF, Zauber AG, Mandelblatt J, Pittman J, Struening E. Using census and mortality data to target small areas for breast, colorectal, and cervical cancer screening. *Am J Public Health* 1994 Jan;84(1): 56-61.

Ansell D, Lacey L, Whitman S, Chen E, Phillips C. A nurse-delivered intervention to reduce barriers to breast and cervical cancer screening in Chicago inner city clinics. *Public Health Rep* 1994 Jan-Feb;109(1):104-11.

Ashford AR, Neugut AI, Lantigua R, Gemson D, Bloch S, Saxon J, Perez B. Attitudes towards cancer screening among primary care physicians practicing in urban minority communities [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A337.

Austoker J. Cancer prevention in primary care. Screening for cervical cancer. *BMJ* 1994 Jul 23;309(6949):241-8. Published erratum appears in *BMJ* 1994 Aug 13; 309(6952):452.

Azeem Majeed F, Cook DG, Anderson HR, Hilton S, Bunn S, Stones C. Using patient and general practice characteristics to explain variations in cervical smear uptake rates. *Br Med J* 1994;308(6939):1272-6.

Baillie R, Barron P, Learmonth G. Towards a rational cervical cytology screening strategy. Case study of a peri-urban settlement. *S Afr Med J* 1995 Jan;85(1):30-3.

Banner RO, DeCambra H, Enos R, Gotay C, Hammond OW, Hedlung N, Issell BF, Matsunaga DS, Tsark JA. A breast and cervical cancer project in a native Hawaiian community: Wai'anae cancer research project. *Prev Med* 1995 Sep;24(5):447-53.

Berman BA, Bastani R, Nisenbaum R, Henneman CA, Marcus AC. Cervical cancer screening among a low-income multiethnic population of women. *J Womens Health* 1994;3(1):33-43.

Bjorge T, Gunbjorud AB, Langmark F, Skare GB, Thoresen SO. Cervical mass screening in Norway--510,000 smears a year. *Cancer Detect Prev* 1994;18(6):463-70.

- Bonaldi A, Crescini C, Giarolo MA, Baldone T, Artuso A, Pezzica E. Results of an 'active call system' for early detection of cervical carcinoma by postage of personalized invitations to Pap smears. *Cervix Low Female Genital Tract* 1993;11(2):53-7.
- Boon ME, Beck S, Wijsman-Grootendorst A. Involving the general practitioner in screening for cervical cancer. *Cytopathology* 1994 Apr;5(2):69-75.
- Bradley SM, Friedman EH. Cervical cytology screening: a comparison of uptake among 'Asian' and 'non-Asian' women in Oldham. *J Public Health Med* 1993;15(1): 46-51.
- Breast and cervical cancer screening among underserved women. Baseline survey results from six states. The National Cancer Institute Cancer Screening Consortium for Underserved Women. *Arch Fam Med* 1995 Jul;4(7): 617-24.
- Burger RA, Monk BJ, Van Nostrand KM, Greep N, Anton-Culver H, Manetta A. Single-visit program for cervical cancer prevention in a high-risk population. *Obstet Gynecol* 1995 Oct;86(4 Pt 1):491-8.
- Burnett CB, Steakley CS, Tefft MC. Low-income, minority women. Barriers to cancer screening. *Ann N Y Acad Sci* 1995 Sep 30;768:277-80.
- Byles JE, Redman S, Sanson-Fisher RW, Boyle CA. Effectiveness of two direct-mail strategies to encourage women to have cervical (Pap) smears. *Health Promot Int* 1995;10(1):5-16.
- Calle EE, Flanders WD, Thun MJ, Martin LM. Demographic predictors of mammography and Pap smear screening in US women. *Am J Public Health* 1993;83(1): 53-69.
- Carey P, Gjerdingen DK. Follow-up of abnormal Papanicolaou smears among women of different races. *J Fam Pract* 1993 Dec;37(6):583-7.
- Chang AR. Some aspects of cervical screening in southern New Zealand; the situation before implementation of the national cervical cancer prevention programme. *Cytopathology* 1993;4(2):67-76.
- Chavez LR, Hubbell FA, McMullin JM, Martinez RG, Mishra SI. Structure and meaning in models of breast and cervical cancer risk factors: a comparison of perceptions among Latinas, Anglo women, and physicians. *Med Anthropol Q* 1995 Mar;9(1):40-74. Comments in: *Med Anthropol Q* 1995 Mar;9(1):75-9; *Med Anthropol Q* 1995 Mar;9(1):77-9.
- Chen F, Trapido EJ, Davis K. Differences in stage at presentation of breast and gynecologic cancers among whites, blacks, and Hispanics. *Cancer* 1994 Jun 1;73(11): 2838-42.
- Crombie IK, Orbell S, Johnston G, Robertson AJ, Kenicer M. Women's experiences at cervical screening. *Scott Med J* 1995;40(3):81-2.
- Davis DT, Bustamante A, Brown CP, Wolde-Tsadik G, Savage EW, Cheng X, Howland L. The urban church and cancer control: a source of social influence in minority communities. *Public Health Rep* 1994 Jul-Aug; 109(4):500-6.
- Dhamija S, Sehgal A, Luthra UK, Sehgal K. Factors associated with awareness and knowledge of cervical cancer in a community: implication for health education programmes in developing countries. *J R Soc Health* 1993 Aug;113(4):184-6.
- Dignan M, Michielutte R, Wells HB, Bahnson J. The Forsyth County Cervical Cancer Prevention Project--I. Cervical cancer screening for black women. *Health Educ Res* 1994 Dec;9(4):411-20.
- Dignan M, Sharp P, Blinson K, Michielutte R, Konen J, Bell R, Lane C. Development of a cervical cancer education program for native American women in North Carolina. *J Cancer Educ* 1995 Winter;9(4):235-42.
- Franks P, Clancy CM. Physician gender bias in clinical decisionmaking: screening for cancer in primary care. *Med Care* 1993 Mar;31(3):213-8.
- Gilbert TJ, Sugarman JR, Cobb N. Abnormal Papanicolaou smears and colposcopic follow-up among American Indian and Alaska Native women in the Pacific northwest. *J Am Board Fam Pract* 1995 May-Jun;8(3):183-8.
- Goldman DA, Simpson DM. Survey of El Paso physicians' breast and cervical cancer screening attitudes and practices. *J Community Health* 1994 Apr;19(2):75-85.
- Gregg J, Curry RH. Explanatory models for cancer among African-American women at two Atlanta neighborhood health centers: the implications for a cancer screening program. *Soc Sci Med* 1994 Aug;39(4):519-26.
- Hakama M. Potential contribution of screening to cancer mortality reduction. *Cancer Detect Prev* 1993;17(4-5): 513-20.
- Harris JM Jr. Papanicolaou smear recommendations, patient complaints, and patient satisfaction in managed-care medical organizations. *Med Care* 1995 Mar;33(3):272-9.
- Himmelstein DU, Woolhandler S. Care denied: US residents who are unable to obtain needed medical services. *Am J Public Health* 1995;85(3):341-4.
- Hojgaard Nielsen N, Jensen H. Screening for cancer of the uterine cervix in Greenland. *APMIS* 1993;101(4):290-4.
- Holland BK, Foster JD, Louria DB. Cervical cancer and health care resources in Newark, New Jersey, 1970 to 1988. *Am J Public Health* 1993 Jan;83(1):45-8.
- Howe HL, Lehnerr M, Qualls RY. Using central cancer-registry data to monitor progress in

- early detection of breast and cervical cancer (Illinois, United States). *Cancer Causes Control* 1995 Mar;6(2):155-63.
- Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM, Meigs JW, Merino MJ, Flannery JT, Polednak AP. The screening histories of women with invasive cervical cancer, Connecticut. *Am J Public Health* 1995 Jun;85(6): 791-4. Comment in: *Am J Public Health* 1995 Jun;85(6): 762-3.
- Jayant K, Rao RS, Nene BM, Dale PS. Early diagnosis of cervical cancers. Our experience at the Rural Cancer Registry, Barshi, India. *Indian J Cancer* 1994 Jun;31(2): 59-63.
- Jayant K, Rao RS, Nene BM, Dale PS. Improved stage at diagnosis of cervical cancer with increased cancer awareness in a rural Indian population. *Int J Cancer* 1995 Oct 9;63(2):161-3.
- Kang SH, Bloom JR, Romano PS. Cancer screening among African-American women: their use of tests and social support. *Am J Public Health* 1994 Jan;84(1):101-3.
- Kaplan CP, Bastani R, Marcus A, Breslow L, Nasseri K, Chen L. Low-income women with cervical abnormalities: individual and system factors affecting follow-up. *J Womens Health* 1995;4(2):179-88.
- Katz SJ, Hofer TP. Socioeconomic disparities in preventive care persist despite universal coverage. Breast and cervical cancer screening in Ontario and the United States. *JAMA* 1994 Aug 17;272(7):530-4.
- Klassen AC, Celentano DD, Weisman CS. Cervical cancer screening in hospitals: the efficacy of legislation in Maryland. *Am J Public Health* 1993 Sep;83(9):1316-20.
- Kottke TE, Trapp MA, Fores MM, Kelly AW, Jung SH, Novotny PJ, Panser LA. Cancer screening behaviors and attitudes of women in southeastern Minnesota. *JAMA* 1995 Apr 12;273(14):1099-105.
- Lamont DW, Symonds RP, Brodie MM, Nwabine NJ, Gillis CR. Age, socio-economic status and survival from cancer of cervix in the West of Scotland 1980-87. *Br J Cancer* 1993 Feb;67(2):351-7. Comment in: *Br J Cancer* 1993 Jul;68(1):213.
- Lantz PM, Stencil D, Lippert MT, Beversdorf S, Jaros L, Remington PL. Breast and cervical cancer screening in a low-income managed care sample: the efficacy of physician letters and phone calls. *Am J Public Health* 1995 Jun;85(6):834-6. Published erratum appears in *Am J Public Health* 1995 Aug;85(8 Pt 1):1063.
- Leslie NS. Role of the nurse practitioner in breast and cervical cancer prevention. *Cancer Nurs* 1995 Aug;18(4): 251-7.
- Levi F, La Vecchia C, Randimbison L, Te VC. Incidence, mortality and survival from invasive cervical cancer in Vaud, Switzerland, 1974-1991. *Ann Oncol* 1994 Oct; 5(8):747-52.
- Lewis D, Mitchell H. An evaluation of cervical screening in general practice. *Med J Aust* 1994 May 16;160(10): 628-32.
- Lobell M, Bay C, Rhoads K, Keske B. Barriers to cancer screening in Hispanic women [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1994;13:A466.
- London L. Pap smear coverage among rural workers. *S Afr Med J* 1993;83(3):172-6.
- Lubitz RM, Litzelman DK, Dittus RS, Tierney WM. Is obesity a barrier to physician screening for cervical cancer? *Am J Med* 1995 May;98(5):491-6.
- Mandelblatt J, Traxler M, Lakin P, Kanetsky P, Kao R. Targeting breast and cervical cancer screening to elderly poor black women: who will participate? The Harlem Study Team. *Prev Med* 1993 Jan;22(1):20-33.
- Mandelblatt J, Traxler M, Lakin P, Kanetsky P, Thomas L, Chauhan P, Matseoane S, Ramsey E. Breast and cervical cancer screening of poor, elderly, black women: clinical results and implications. Harlem Study Team. *Am J Prev Med* 1993 May-Jun;9(3):133-8.
- Mandelblatt J, Traxler M, Lakin P, Thomas L, Chauhan P, Matseoane S, Kanetsky P. A nurse practitioner intervention to increase breast and cervical cancer screening for poor, elderly black women. The Harlem Study Team. *J Gen Intern Med* 1993 Apr;8(4):173-8.
- Matsubara M. [Clinical significance of magnetic resonance imaging (MRI) in evaluation of the extension of uterine cervical cancer]. *Nippon Sanka Fujinka Gakkai Zasshi* 1993 Oct;45(10):1115-22. (Jpn).
- McGonigle KF, Lagasse LD, Karlan BY. Ovarian, uterine, and cervical cancer in the elderly woman. *Clin Geriatr Med* 1993 Feb;9(1):115-30.
- Meshack AF. For health's sake: cervical and breast cancer screening [dissertation]. [Houston]: Univ. of Texas Health Science Center at Houston School of Public Health; 1993. 152 p. Available from: University Microfilms International, Ann Arbor, MI; AAD94-01777.
- Michielutte R, Dignan M, Bahnson J, Wells HB. The Forsyth County Cervical Cancer Prevention Project--II. Compliance with screening follow-up of abnormal cervical smears. *Health Educ Res* 1994 Dec;9(4):421-32.
- Michielutte R, Sharp PC, Dignan MB, Blinson K. Cultural issues in the development of cancer control programs for American Indian populations. *J Health Care Poor Underserved* 1994;5(4):280-96.
- Modiano M, Buller D, Meister J, de Zapien J, Lash S, Villar-Werstler P, Santa Cruz V. Lay health

- educators (promotoras) improve cancer awareness and screening in minority population: the juntos contra el cancer model. Paper presented at: 17th Annual Meeting of the American Society of Preventive Oncology; 1993 Mar 20-23; Tucson, AZ.
- Munoz N, Bosch FX, de Sanjose SD, Shah KV. The role of HPV in the etiology of cervical cancer. *Mutat Res* 1994; 305(2):293-301.
- Murray M, McMillan C. Social and behavioural predictors of women's cancer screening practices in Northern Ireland. *J Public Health Med* 1993 Jun;15(2):147-53.
- Murthy NS, Agarwal SS, Prabhakar AK, Sharma S, Das DK. Estimation of reduction of life-time risk of cervical cancer through one life-time screening. *Neoplasma* 1993; 40(4):255-8.
- Naish J, Brown J, Denton B. Intercultural consultations: investigation of factors that deter non-English speaking women from attending their general practitioners for cervical screening. *BMJ* 1994 Oct 29;309(6962):1126-8. Comment in: *BMJ* 1995 Jan 21;310(6973):194.
- Orbell S, Crombie I, Robertson A, Johnston G, Kenicer M. Assessing the effectiveness of a screening campaign: who is missed by 80% cervical screening coverage? *J R Soc Med* 1995 Jul;88(7):389-94.
- Orr ST, Celentano DD, Hill G, Erozan YS, Shediak M, Correa-Villasenor A, Matanoski G. Use of laboratory reports to assess cervical cancer screening in a community. *Am J Prev Med* 1994 Jul-Aug;10(4):235-7.
- Palm BT, Kant AC, van den Bosch WJ, Vooijs GP, van Weel C. Preliminary results of a general practice based call system for cervical cancer screening in The Netherlands. *Br J Gen Pract* 1993 Dec;43(377):503-6.
- Popovic D, Komaromi M, Popovic M. [Attitudes of spouses toward examinations for the early detection of cervical and breast carcinoma]. *Med Pregl* 1993;46(3-4):128-32. (Scr).
- Pritchard DA, Straton JA, Hyndman J. Cervical screening in general practice. *Aust J Public Health* 1995 Apr;19(2): 167-72. Comment in: *Aust J Public Health* 1995 Apr; 19(2):115-7.
- Results from the National Breast and Cervical Cancer Early Detection Program, October 31, 1991-September 30, 1993. *MMWR Morb Mortal Wkly Rep* 1994 Jul 29; 43(29):530-4.
- Rudolph A, Kahan V, Bordeu M. Cervical cancer prevention project for inner city black and Latina women. *Public Health Rep* 1993 Mar-Apr;108(2):156-60.
- Seibt AC. Information sources influencing urban Mexican-American women's cancer screening participation [dissertation]. [Houston]: Univ. of Texas Health Science Center at Houston School of Public Health; 1993. 237 p. Available from: University Microfilms International, Ann Arbor, MI; AAD94-22050.
- Seow A, Lee HP. Prevalence and determinants of cervical cancer screening: a community-based study in Singapore. *Ann Acad Med Singapore* 1994 May;23(3):342-7.
- Seow A, Wong ML, Smith WC, Lee HP. Beliefs and attitudes as determinants of cervical cancer screening: a community-based study in Singapore. *Prev Med* 1995 Mar;24(2):134-41.
- Sheridan-Leos N. Women's Health Loteria: a new cervical cancer education tool for Hispanic females. *Oncol Nurs Forum* 1995 May;22(4):697-701.
- Slater DN. Multifactorial audit of invasive cervical cancer: key lessons for the National Screening Programme. *J Clin Pathol* 1995 May;48(5):405-7.
- Slater DN, Milner PC, Radley H. Audit of deaths from cervical cancer: proposal for an essential component of the National Screening Programme. *J Clin Pathol* 1994 Jan;47(1):27-8. Comment in: *J Clin Pathol* 1994 Sep; 47(9):867.
- Smith MK. Implementing annual cancer screenings for elderly women. *J Gerontol Nurs* 1995 Jul;21(7):12-7.
- Stillwater B, Echavarria VA, Lanier AP. Pilot test of a cervical cancer prevention video developed for Alaska Native women. *Public Health Rep* 1995 Mar-Apr;110(2): 211-4.
- Straton JA, Holman CD, Edwards BM. Cervical cancer screening in Western Australia in 1992: progress since 1983. *Med J Aust* 1993 Nov 15;159(10):657-61.
- Straton JA, Sutherland GJ, Hyndman JC. Cervical cancer screening for hospital inpatients: report of an intervention study. *Aust J Public Health* 1995 Jun;19(3):288-93.
- Suarez L, Lloyd L, Weiss N, Rainbolt T, Pulley L. Effect of social networks on cancer-screening behavior of older Mexican-American women. *J Natl Cancer Inst* 1994; 86(10):775-9.
- Summers A, Fullard B. Improving the coverage and quality of cervical screening: women's views. *J Public Health Med* 1995;17(3):277-81.
- Swaddiwudhipong W, Chaovakiratipong C, Nguntra P, Mahasakpan P, Lerdlukanavongse P, Koonchote S. Effect of a mobile unit on changes in knowledge and use of cervical cancer screening among rural Thai women. *Int J Epidemiol* 1995 Jun;24(3):493-8.
- Thomas SM, Fick AC. Women's health: early detection and screening practices for breast and cervical cancer. *J La State Med Soc* 1994 Apr;146(4):152-8.
- Watrang W, Binstock M, Hackett J, Pretorius G,

Screening

- Anguiano H, Hyatt J, Bredt A. Cervical cancer screening in a large HMO: effects of evidence-based clinical practice guideline (CPG) on pap smear utilization [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1994;13: A473.
- Watson EJ. Decision-making style, motivation, and use of papanicolaou screening tests in women age 35 and older [dissertation]. [Columbia]: Univ. of South Carolina; 1993. 292 p. Available from: University Microfilms International, Ann Arbor, MI; AAD93-22004.
- Webb J. Health promotion. Cervical screening update. *Nurs Times* 1994 Oct 26-Nov 1;90(43):37.
- Weinrich S, Coker AL, Weinrich M, Eleazer GP, Greene FL. Predictors of Pap smear screening in socioeconomically disadvantaged elderly women. *J Am Geriatr Soc* 1995 Mar;43(3):267-70.
- White GE. Older women's attitudes to cervical screening and cervical cancer: a New Zealand experience. *J Adv Nurs* 1995 Apr;21(4):659-66.
- White JE, Begg L, Fishman NW, Guthrie B, Fagan JK. Increasing cervical cancer screening among minority elderly. Education and on-site services increase screening. *J Gerontol Nurs* 1993 May;19(5):28-34.
- Whitman S, Lacey L, Ansell D, Chen EH, Dell J, Phillips CW. Do chart reviews and interviews provide the same information about breast and cervical cancer screening? *Int J Epidemiol* 1993 Jun;22(3):393-7.
- Whitman S, Lacey L, Ansell D, Dell J, Chen E, Phillips CW. An intervention to increase breast and cervical cancer screening in low-income African-American women. *Fam Community Health* 1994 Apr;17(1):56-63.
- Wilcox LS, Mosher WD. Factors associated with obtaining health screening among women of reproductive age. *Public Health Rep* 1993 Jan-Feb;108(1):76-86.
- Yajima A, Yaegashi N, Sato S. Cervical cancer control in Japan. *Arch STD HIV Res* 1994;8(1-2):89-99.
- Yancey AK, Tanjasiri SP, Klein M, Tunder J. Increased cancer screening behavior in women of color by culturally sensitive video exposure. *Prev Med* 1995 Mar; 24(2):142-8.
- Yancey AK, Walden L. Stimulating cancer screening among Latinas and African-American women. A community case study. *J Cancer Educ* 1994;9(1):46-52.
- Yi JK. Factors associated with cervical cancer screening behavior among Vietnamese women. *J Community Health* 1994 Jun;19(3):189-200.
- Allen KA, Zaleski MS, Cohen MB. Laboratory use of the diagnosis reactive/reparative in gynecologic smears: impact of CLIA '88. *Mod Pathol* 1995 Apr;8(3):266-9.
- Aponte-Cipriani SL, Teplitz C, Rorat E, Savino A, Jacobs AJ. Cervical smears prepared by an automated device versus the conventional method. A comparative analysis. *Acta Cytol* 1995 Jul-Aug;39(4):623-30.
- Ashfaq R, Liang Y, Saboorian MH. Evaluation of PAPNET(TM) system for rescreening of negative cervical smears. *Diagn Cytopathol* 1995;13(1):31-6.
- Awen C, Hathway S, Eddy W, Voskuil R, Janes C, Hutchinson M. Efficacy of ThinPrep (R) preparation of cervical smears: a 1,000-case, investigator-sponsored study. *Diagn Cytopathol* 1994;11(1):33-7.
- Baldauf JJ, Dreyfus M, Lehmann M, Ritter J, Philippe E. Cervical cancer screening with cervicography and cytology. *Eur J Obstet Gynecol Reprod Biol* 1995 Jan; 58(1):33-9.
- Boon ME, Schut JJ, Benita EM, Kok LP. Confocal optical sectioning and three-dimensional reconstruction of carcinoma fragments in Pap smears using sophisticated image data processing. *Diagn Cytopathol* 1994;10(3): 268-75.
- Bur M, Knowles K, Pekow P, Corral O, Donovan J. Comparison of ThinPrep preparations with conventional cervicovaginal smears. Practical considerations. *Acta Cytol* 1995 Jul-Aug;39(4):631-42.
- Burkman RT, Ward R, Balchandani K, Kini S. A continuous quality improvement project to improve the quality of cervical Papanicolaou smears. *Obstet Gynecol* 1994; 84(3):470-5.
- Carothers A, McGoogan E, Vooijs P, Bird C, Colquhoun M, Eason P, McKie M, Nieuwenhuis F, Pitt P, Rutovitz D, Stark M, Tucker J, Van Orsouw A. A collaborative trial of a semi-automatic system for slide preparation and screening in cervical cytopathology. *Anal Cell Pathol* 1994;7(4):261-74.
- Chudleigh MF. Hazard analysis of a computer based medical diagnostic system. *Comput Methods Programs Biomed* 1994 Jul;44(1):45-54.
- Hailey DM, Lea AR. New technologies in cervical cancer screening--realities for a national program [abstract]. *Annu Meet Int Soc Technol Assess Health Care* 1994: [Abstract No. 044].
- Hutchinson ML, Isenstein LM, Goodman A, Hurley AA, Douglass KL, Mui KK, Patten FW, Zahniser DJ. Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep Processor. *Am J Clin Pathol* 1994

Feb;101(2):215-9. Comment in: Am J Clin Pathol 1994 Feb;101(2):121-2.

Koss LG, Lin E, Schreiber K, Elgert P, Mango L. Evaluation of the PAPNET cytologic screening system for quality control of cervical smears. Am J Clin Pathol 1994 Feb;101(2):220-9.

Lavery CR, Thurloe JK, Redman NL, Farnsworth A. An Australian trial of ThinPrep: a new cytopreparatory technique. Cytopathology 1995 Jun;6(3):140-8.

Sherman ME, Mango LJ, Kelly D, Paull G, Ludin V, Copeland C, Solomon D, Schiffman MH. PAPNET analysis of reportedly negative smears preceding the diagnosis of a high-grade squamous intraepithelial lesion or carcinoma. Mod Pathol 1994 Jun;7(5):578-81.

Slagel DD, Zaleski S, Cohen MB. Efficacy of automated cervical cytology screening. Diagn Cytopathol 1995; 13(1):26-30.

Wilbur DC, Cibas ES, Merritt S, James LP, Berger BM, Bonfiglio TA. ThinPrep Processor. Clinical trials demonstrate an increased detection rate of abnormal cervical cytologic specimens. Am J Clin Pathol 1994 Feb;101(2):209-14. Comments in: Am J Clin Pathol 1994 Feb;101(2):121-2; Am J Clin Pathol 1994 Oct; 102(4):557-8.

Prevention

Alvarez RD, Helm CW, Edwards RP, Naumann RW, Partridge EE, Shingleton HM, McGee JA, Hall JB, Higgins RV, Malone JM Jr. Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. Gynecol Oncol 1994 Feb;52(2): 175-9.

Andersen ES, Pedersen B, Nielsen K. Laser conization: the results of treatment of cervical intraepithelial neoplasia. Gynecol Oncol 1994 Aug;54(2):201-4.

Backe J, Roos T, Kaesemann H, Martius J, Ott M. [Local therapy and adjuvant interferon therapy in genital papilloma virus infections]. Gynakol Geburtshilfliche Rundsch 1995;35(2):79-84. (Ger).

Bergstrom R, Adami HO, Gustafsson L, Ponten J, Sparen P. Detection of preinvasive cancer of the cervix and the subsequent reduction in invasive cancer. J Natl Cancer Inst 1993 Jul 7;85(13):1050-7. Comment in: J Natl Cancer Inst 1993 Jul 7;85(13):1018-9.

Bigrigg A, Haffenden DK, Sheehan AL, Codling BW, Read MD. Efficacy and safety of large-loop excision of the transformation zone. Lancet 1994 Jan 1;343(8888):32-4.

Brady JL, Fish ANJ, Woolas RP, Brown CL, Oram DH. Large loop diathermy of the transformation zone: is 'see and treat' an acceptable option for the management of women with abnormal cervical smears? J Obstet Gynecol 1994;14(1):44-9.

Chen RD. [Chemoprevention of cervical cancer--intervention study of cervical precancerous lesions by retinamide II and riboflavin]. Chung Hua Chung Liu Tsa Chih 1993 Jul;15(4):272-4. (Chi).

Chen RD, Ding AH, Han R. [A study on chemoprevention of retinamide II from cervical precancerous lesions]. Chung Hua Yu Fang I Hsueh Tsa Chih 1994 Mar;28(2):75-7. (Chi).

Chen RJ, Lee EF, Shih JC. Does the loop electrosurgical excision procedure adversely affect the histopathological interpretation of cervical conization specimens? Acta Obstet Gynecol Scand 1994 Oct;73(9):726-9.

Childers JM, Chu J, Voigt LF, Feigl P, Tamimi HK, Franklin EW, Alberts DS, Meyskens FL Jr. Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 1995 Mar;4(2):155-9.

Harper DM, Roach MS. Cervical intraepithelial neoplasia in pregnancy. J Fam Pract 1996 Jan;42(1):79-83.

Lie AK, Skjeldestad FE, Hagen B, Haugen OA. Occurrence of human papillomavirus infection

in cervical intraepithelial neoplasia. A retrospective histopathological study of 317 cases treated by laser conization. *APMIS* 1995 Oct;103(10):693-8.

Meyskens F, Surwit E, Childers J, Moon T, Shell M, Davis J, Alberts DS. Phase III randomized trial of trans-retinoic acid to prevent progression of cervical intraepithelial neoplasia (CIN): would new biomarkers have helped along the way? Paper presented at: CCPC-93: 2nd International Cancer Chemo Prevention Conference; 1993 Apr 28-30; Berlin, Germany.

Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, Alberts DS. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. *J Natl Cancer Inst* 1994 Apr 6;86(7):539-43. Comment in: *J Natl Cancer Inst* 1994 Apr 6;86(7):476-7.

Meyskens FL Jr, Surwit E, Moon TE, Davis J, Alberts DS. A placebo-controlled, randomized phase III trial of locally applied beta-trans-retinoic acid (vitamin A acid, RA) in cervical intraepithelial neoplasia (CIN): favorable effect on CIN II (moderate dysplasia) [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A465.

Mitchell MF, Hittelman WK, Lotan R, Nishioka K, Tortolero-Luna G, Richards-Kortum R, Wharton JT, Hong WK. Chemoprevention trials and surrogate end point biomarkers in the cervix. *Cancer* 1995; 76(10 Suppl):1956-77.

Mitchell MF, Hittelman WN, Hong WK, Lotan R, Schottenfeld D. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. *Cancer Epidemiol Biomarkers Prev* 1994 Oct-Nov;3(7):619-26.

Puig-Tintore LM, Jou P. Laser or conization for treatment of CIN III long-term results. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.

Wright TC Jr, Richart RM. Loop excision of the uterine cervix. *Curr Opin Obstet Gynecol* 1995;7(1):30-4.

MANAGEMENT OF LOW-STAGE CERVICAL CANCER (FIGO I-IIA)

Pathology and Prognostic factors

Abeler VM, Holm R, Nesland JM, Kjorstad KE. Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. *Cancer* 1994 Feb 1;73(3):672-7.

al-Nafussi AI, Hughes DE. Histological features of CIN3 and their value in predicting invasive microinvasive squamous carcinoma. *J Clin Pathol* 1994 Sep;47(9):799-804.

al-Nafussi AI, Klys HS, Rebello G, Kelly C, Kerr G, Cowie V. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in the uterine cervix and cervical squamous neoplasia. *Int J Gynecol Cancer* 1993; 3(3):154-8.

al-Saleh W, Delvenne P, Arrese JE, Nikkels AF, Pierard GE, Boniver J. Inverse modulation of intraepithelial Langerhans' cells and stromal macrophage/dendrocyte populations in human papillomavirus-associated squamous intraepithelial lesions of the cervix. *Virchows Arch* 1995; 427(1):41-8.

Allen DG, Roovers JPW, Van Lindert ACM, Heintz APM. Early stage cervical cancer: a multivariate analysis of histopathological prognostic factors. *Aust N Z J Obstet Gynaecol* 1994;34(5):553-6.

Arai T, Nakano T, Oka K. Local control prediction by histologic grading or radiation effects with drill biopsy specimens for uterine cervical cancer. *Int J Radiat Oncol Biol Phys* 1993 Nov 15;27(4):811-6.

Attanoos R, Nahar K, Bigrigg A, Roberts S, Newcombe RG, Ismail SM. Primary adenocarcinoma of the cervix. A clinicopathologic study of prognostic variables in 55 cases. *Int J Gynecol Cancer* 1995;5(3):179-86.

Beynon DWG, Lopes A, Robertson G, Daras V, Monaghan JM. Squamous cell carcinoma antigen: pretreatment levels as an indicator of advanced or metastatic disease. *Int J Gynecol Cancer* 1994;4(3):206-10.

Bichel P, Jakobsen A, Nielsen K, Holund B, Visfeldt J. Prediction of lymph node metastases in patients with early squamous cell carcinoma of the cervix uteri by histopathological grading and flow cytometry. *Eur J Cancer* 1993;29A(3):337-40.

Bolli JA, Doering DL, Bosscher JR, Day TG Jr, Rao CV, Owens K, Kelly B, Goldsmith J. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. *Gynecol Oncol* 1994 Nov;55(2):169-73.

Bremer GL, Tiebosch AT, van der Putten HW, de Haan J, Arends JW. Basement membranes in

- cervical cancer: relationship to pelvic lymph node metastasis and prognosis. *Gynecol Oncol* 1995 Jun;57(3):351-5.
- Burke TW. Clinical and pathological risk factors in stage I cervical cancer. *Clin Consult Obstet Gynecol* 1995;7(2): 118-25.
- Carter PG, Iles RK, Neven P, Ind TE, Shepherd JH, Chard T. The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix. *Gynecol Oncol* 1994 Nov;55(2):271-6.
- Chen CA, Wu CC, Chen TM, Lui LT, Chang CF, Hsieh CY. Cell kinetics and radiosensitivity of cervical squamous cell carcinoma. *Cancer Lett* 1994 Jul 29;82(2): 135-40.
- Chou CY, Wang ST, Kuo HC, Tzeng CC, Yao BL. Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer. *Cancer* 1994 Nov 1;74(9):2497-501.
- Connor JP, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR. Flow cytometric evaluation of early invasive cervical cancer. *Obstet Gynecol* 1993 Mar;81(3): 367-71.
- Costa MJ, Walls J, Trelford JD. c-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. *Am J Clin Pathol* 1995 Dec;104(6):634-42.
- Davidson SE, Ngan R, Wilks DP, Moore JV, West CML. A comparison of four methods for assessing tumour vascularity in carcinoma of the cervix. *Int J Oncol* 1994; 5(3):639-45.
- Duk JM, Groenier KH, ten Hoor KA, Aalders JG, de Bruijn HW. SCC-antigen, a new prognostic factor in cervical cancer [abstract]. *Proc Annu Meet Am Assoc Cancer Res* 1995;36:A1456.
- Elliott P. Lymph node metastases, cell type, age, HPV status and type, neoadjuvant chemotherapy and treatment failures in cervical cancer. *Int J Gynaecol Obstet* 1995 Jul;49 Suppl:S17-25.
- Fujimoto I, Umezawa S, Hirai Y, Hasumi K. Behavioral analysis of microinvasive carcinoma of uterine cervix [abstract]. *Proc Annu Meet Am Assoc Cancer Res* 1994; 35:A1216.
- Gerdin E, Cnattingius S, Johnson P, Pettersson B. Prognostic factors and relapse patterns in early-stage cervical carcinoma after brachytherapy and radical hysterectomy. *Gynecol Oncol* 1994 Jun;53(3):314-9.
- Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. *J Clin Pathol* 1993 Feb;46(2):149-53.
- Helm CW, Kinney WK, Keeney G, Lawrence WD, Frank TS, Gore H, Reynolds RK, Soong SJ, Partridge EE, Roberts J, Podratz K, Shingleton HM. A matched study of surgically treated stage IB adenosquamous carcinoma and adenocarcinoma of the uterine cervix. *Int J Gynecol Cancer* 1993;3(4):245-9.
- Himmelmann A, Ferno M, Langstrom-Einarsson E, Stendahl U, Trope C, Willen R. The influence of risk factors and treatment on survival in invasive squamous cervical carcinoma [abstract]. *Br J Radiol* 1993;66 Suppl: 50.
- Ikenberg H, Sauerbrei W, Schottmuller U, Spitz C, Pfeleiderer A. Human papillomavirus DNA in cervical carcinoma--correlation with clinical data and influence on prognosis. *Int J Cancer* 1994 Nov 1;59(3):322-6.
- Im DD, Duska LR, Rosenshein NB. Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. *Gynecol Oncol* 1995 Nov; 59(2):179-82.
- Jelen I, Valente PT, Gautreaux L, Clark GM. Deoxyribonucleic acid ploidy and S-phase fraction are not significant prognostic factors for patients with cervical cancer. *Am J Obstet Gynecol* 1994 Dec;171(6):1511-6; discussion 1516-8.
- Kainz C, Gitsch G, Tempfer C, Heinzl H, Koelbl H, Breitecker G, Reinthaller A. Vascular space invasion and inflammatory stromal reaction as prognostic factors in patients with surgically treated cervical cancer stage IB to IIB. *Anticancer Res* 1994 Sep-Oct;14(5B):2245-8.
- Kainz C, Kohlberger P, Gitsch G, Sliutz G, Breitenacker G, Reinthaller A. Mutant p53 in patients with invasive cervical cancer stages IB to IIB. *Gynecol Oncol* 1995 May;57(2):212-4.
- Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G, Reinthaller A, Breitenacker G. Prognostic value of CD44 splice variants in human stage III cervical cancer. *Eur J Cancer* 1995 Sep;31A(10):1706-9.
- Kainz C, Speiser P, Wanner C, Obermair A, Tempfer C, Sliutz G, Reinthaller A, Breitenacker G. Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. *Anticancer Res* 1995 Jul-Aug; 15(4):1549-51.
- Kainz C, Zeisler H, Kohlberger P, Gitsch G, Heinzl H, Breitenacker G, Reinthaller A. Prognostic value of cytokeratins and carcinoembryonic antigen expression in primary surgically treated cervical cancer. *Anticancer Res* 1994 Mar-Apr;14(2B):667-71.
- Kamura T, Tsukamoto N, Tsuruchi N, Kaku T, Saito T, To N, Akazawa K, Nakano H. Histopathologic prognostic factors in stage IIB cervical carcinoma treated with radical hysterectomy and pelvic-node dissection - an analysis with mathematical statistics. *Int J Gynecol Cancer* 1993; 3(4):219-25.
- Kaspar HG, Dinh TV, Doherty MG, Hannigan EV, Kumar D. Clinical implications of tumor volume

- measurement in stage I adenocarcinoma of the cervix. *Obstet Gynecol* 1993 Feb;81(2):296-300.
- Kenter GG, Cornelisse CJ, Jiwa NM, Aartsen EJ, Hermans J, Mooi W, Heintz AP, Fleuren GJ. Human papillomavirus type 16 in tumor tissue of low-stage squamous carcinoma of the uterine cervix in relation to ploidy grade and prognosis. *Cancer* 1993 Jan 15;71(2): 397-401.
- Kim YT, Nam JH, Mok JE. The use of PCR with consensus primer sets for the detection of human papilloma viruses in archival cervical cancer specimens [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A733.
- Kobayashi H, Fujishiro S, Terao T. Biochemical markers as a predictor for lymph node involvement in patients with cervical cancer of the uterus. *Int J Oncol* 1994;4(5): 1053-9.
- Koehli OR, Sevin BU, Nadji M, Lu Y, Averette HE. Multivariate analysis of prognostic factors of early stage cervical cancer in patients undergoing radical hysterectomy [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A807.
- Kohno Y, Iwanari O, Kitao M. Prognostic importance of histologic vascular density in cervical cancer treated with hypertensive intraarterial chemotherapy. *Cancer* 1993 Oct 15;72(8):2394-400.
- Konski A, Domenico D, Irving D, Tyrkus M, Neisler J, Phibbs G, Bishop K, Mah J, Eggleston W. Flow cytometric DNA content analysis of paraffin-embedded tissue derived from cervical carcinoma. *Int J Radiat Oncol Biol Phys* 1994 Nov 15;30(4):839-43.
- Kristensen GB, Kaern J, Abeler VM, Hagmar B, Trope CG, Pettersen EO. No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients. *Gynecol Oncol* 1995 Apr;57(1):79-85.
- Lai CH, Chang HC, Chang TC, Hsueh S, Tang SG. Prognostic factors and impacts of adjuvant therapy in early-stage cervical carcinoma with pelvic node metastases. *Gynecol Oncol* 1993 Dec;51(3):390-6.
- Lai CH, Hsueh S, Huang MY, Chang MF, Soong YK. The uses and limitations of DNA flow cytometry in stage IB or II cervical carcinoma. *Cancer* 1993 Dec 15;72(12): 3655-62.
- Landoni F, Bocciolone L, Perego P, Maneo A, Bratina G, Mangioni C. Cancer of the cervix, FIGO stages IB and IIA: patterns of local growth and paracervical extension. *Int J Gynecol Cancer* 1995;5(5):329-34.
- Lara PC, Rey-Baltar D, Rivera D, Apolinario R, Alarcon I, Rodriguez T, Hernandez MA, Gonzalez G, Ruiz A, Clavo B, Lopez-Bonilla A, Falcon Vizcaino O. [Squamous cell antigen (SCC-Ag) and cervical cancer. Modifications induced by radiation]. *Neoplasia* 1995; 12(3):91-5. (Spa).
- Leung KM, Chan WY, Hui PK. Invasive squamous cell carcinoma and cervical intraepithelial neoplasia III of uterine cervix. Morphologic differences other than stromal invasion. *Am J Clin Pathol* 1994 Apr;101(4): 508-13.
- Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts SA, Chadwick C, Wilks DP, Potten CS, Hendry JH, Hunter RD, West CM. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. *Radiother Oncol* 1995 Oct;37(1):1-9.
- Li XY, Jiao SZ. [Significance of DNA content and S-phase fraction in cervical adenocarcinoma]. *Chung Kuo Chung Liu Lin Chuang* 1995;22(2):81-3. (Chi).
- Maassen V, Dieckhoff R, Baltzer J, Kindermann G. [Risk of hematogenous metastasis of cancer of the uterine cervix]. *Geburtshilfe Frauenheilkd* 1994 Dec;54(12):656-61. (Ger).
- Mariani L, Iacovelli A, Vincenzoni C, Diotallevi FF, Atlante M, Lombardi A. Cervical carcinoma in young patients: clinical and pathological variables. *Int J Gynaecol Obstet* 1993 Apr;41(1):61-6.
- Minagawa Y, Kigawa J, Kanamori Y, Itamochi H, Terakawa N. Tumor cell kinetics in elderly patients with cervical cancer. *Obstet Gynecol* 1993 Apr;81(4):610-4.
- Ngan HY, Cheng GT, Yeung WS, Wong LC, Ma HK. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix. *Gynecol Oncol* 1994 Jan;52(1): 63-8.
- Nguyen HN, Sevin BU, Averette HE, Ganjei P, Perras J, Ramos R, Angioli R, Donato D, Penalver M. The role of DNA index as a prognostic factor in early cervical carcinoma. *Gynecol Oncol* 1993 Jul;50(1):54-9.
- Nguyen HN, Sevin BU, Averette HE, Ramos R, Ganjei P, Perras J. Evidence of tumor heterogeneity in cervical cancers and lymph node metastases as determined by flow cytometry. *Cancer* 1993 Apr 15;71(8):2543-50.
- Oka K, Nakano T, Arai T. c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. *Cancer* 1994 Feb 1;73(3): 664-71.
- Rose BR, Thompson CH, Simpson JM, Jarrett CS, Elliott PM, Tattersall MH, Dalrymple C, Cossart YE. Human papillomavirus deoxyribonucleic acid as a prognostic indicator in early-stage cervical cancer: a possible role for type 18. *Am J Obstet Gynecol* 1995 Nov;173(5):1461-8.
- Rose PG, Baker S, Fournier L, Nelson BE, Hunter RE. Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence. *Am J Obstet Gynecol* 1993 Mar;168(3 Pt 1):942-6.

- Schlenger K, Hockel M, Mitze M, Schaffer U, Weikel W, Knapstein PG, Lambert A. Tumor vascularity--a novel prognostic factor in advanced cervical carcinoma. *Gynecol Oncol* 1995 Oct;59(1):57-66.
- Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. *Cancer Res* 1995 Nov 1;55(21):4757-9.
- Sevin BU, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli OR, Averette HE. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. *Cancer* 1995;76(10 Suppl):1978-86.
- Shingleton HM, Bell MC, Fremgen A, Chmiel JS, Russell AH, Jones WB, Winchester DP, Clive RE. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? *Cancer* 1995;76(10 Suppl): 1948-55.
- Sproston AR, Roberts SA, Davidson SE, Hunter RD, West CM. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. *Br J Cancer* 1995 Dec;72(6):1536-40.
- Stock RJ, Zaino R, Bundy BN, Askin FB, Woodward J, Fetter B, Paulson JA, DiSaia PJ, Stehman FB. Evaluation and comparison of histopathologic grading systems of epithelial carcinoma of the uterine cervix: Gynecologic Oncology Group studies. *Int J Gynecol Pathol* 1994 Apr; 13(2):99-108.
- Tang GJ, Sun CF, Lin FJ, Tsao KC. The role of flow cytometry in non-resected cervical carcinoma. *Br J Radiol* 1995 Mar;68(807):283-90.
- Tsang RW, Fyles AW, Kirkbride P, Levin W, Manchul LA, Milosevic MF, Rawlings GA, Banerjee D, Pintilie M, Wilson GD. Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. *Int J Radiat Oncol Biol Phys* 1995 Jul 30; 32(5):1319-29. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1539-41.
- Unger ER, Vernon SD, Thoms WW, Nisenbaum R, Spann CO, Horowitz IR, Icenogle JP, Reeves WC. Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer. *J Infect Dis* 1995 Nov;172(5):1184-90.
- van Bommel PF, Kenemans P, Helmerhorst TJ, Gallee MP, Ivanyi D. Expression of cytokeratin 10, 13, and involucrin as prognostic factors in low stage squamous cell carcinoma of the uterine cervix. *Cancer* 1994 Oct 15; 74(8):2314-20.
- van Bommel PF, van den Brule AJ, Helmerhorst TJ, Gallee MP, Gaarenstroom KN, Walboomers JM, Meijer CJ, Kenemans P. HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancer. *Gynecol Oncol* 1993 Mar;48(3):333-7.
- Werner-Wasik M, Schmid CH, Bornstein L, Ball HG, Smith DM, Madoc-Jones H. Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1309-17.
- Wheeler JA, Stephens LC, Tornos C, Eifel PJ, Ang KK, Milas L, Allen PK, Meyn RE Jr. ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1487-93.
- Wiggins DL, Granai CO, Steinhoff MM, Calabresi P. Tumor angiogenesis as a prognostic factor in cervical carcinoma. *Gynecol Oncol* 1995 Mar;56(3):353-6.
- Wilailak S, Tangtrakul S, Srisupundit S, Bullangpoti S, Linasmita V, Bhamarapravati Y. Prognostic factors associated with recurrence in stage IB cervical carcinoma after radical hysterectomy and pelvic lymphadenectomy. *J Med Assoc Thai* 1993 Jan;76 Suppl 1:74-7.
- Willen R, Himmelmann A, Langstrom-Einarsson E, Ferno M, Ranstam J, Baldetorp B, Skjaeris J, Prien-Larsen J, Trope C, Stendahl U. Prospective malignancy grading, flow cytometry DNA-measurements and adjuvant chemotherapy for invasive squamous cell carcinoma of the uterine cervix. *Anticancer Res* 1993 Jul-Aug;13(4):1187-96.
- Wong YF, Chung TK, Cheung TH, Lam SK, Xu YG, Chang AM. Frequent ras gene mutations in squamous cell cervical cancer. *Cancer Lett* 1995 Aug 16;95(1-2):29-32.
- Yoshioka T, Inoue Y, Hoshiai H, Noda K. [Prognostic factors in uterine cervical and corpus cancer]. *Gan To Kagaku Ryoho* 1995 Sep;22(10):1417-22. (Jpn).
- Zhang WH. [Adenocarcinoma of the uterine cervix. An analysis of 121 cases]. *Chung Hua Chung Liu Tsa Chih* 1993 Jan;15(1):61-4. (Chi).
- Zolzer F, Alberti W, Pelzer T, Lamberti G, Hulskamp FH, Streffer C. Changes in S-phase fraction and micronucleus frequency as prognostic factors in radiotherapy of cervical carcinoma. *Radiother Oncol* 1995 Aug;36(2): 128-32.

Imaging

- Arimoto T. Significance of computed tomography-measured volume in the prognosis of cervical carcinoma. *Cancer* 1993 Oct 15;72(8):2383-8.
- Bautz W, Merl T, Kersting-Sommerhoff B. [Computerized tomography staging of carcinomas of the uterus]. *Radiologe* 1994 Jul;34(7):370-6. (Ger).
- Beyersdorff D, Bahnsen J, Frischbier HJ. Nodal involvement in cancer of the uterine cervix: value of lymphography and MRI. *Eur J Gynaecol Oncol* 1995;16(4):274-7.
- Bragg DG, Hricak H. Imaging in gynecologic malignancies. *Cancer* 1993 Feb 15;71(4 Suppl):1648-51.
- Carter JR, Lau M, Twiggs LB. A comparison of vascular pulsatility and resistive indices in gynecological tumor detection using transvaginal ultrasound. *Vasc Surg* 1995; 29(1):29-35.
- Collins CD, Constant O, Fryatt I, Blake PR, Parsons CA. Relationship of computed tomography tumour volume to patient survival in carcinoma of the cervix treated by radical radiotherapy. *Br J Radiol* 1994 Mar;67(795): 252-6.
- Dudarev AL, Vinokurov VL, Shelkoplias EN, Goritskaia IV. [Magnetic resonance tomography in oncologic gynecology]. *Vestn Rentgenol Radiol* 1993 Sep-Oct;(5): 14-5. (Rus).
- Ebner F, Tamussino K, Kressel HY. Magnetic resonance imaging in cervical carcinoma: diagnosis, staging, and follow-up. *Magn Reson Q* 1994 Mar;10(1):22-42.
- Fernando IN, Moskovic E, Fryatt I, Glaholm J, Blake PR. Is there still a role for lymphography in the management of early stage carcinoma of the cervix? *Br J Radiol* 1994 Nov;67(803):1052-6.
- Fischetti SG, Politi G, Lomeo E, Garozzo G, Di Leo S, Nuciforo G. [Carcinoma of the uterine cervical canal. Staging and biometric assessment with magnetic resonance]. *Radiol Med (Torino)* 1994 Oct;88(4):445-52. (Ita).
- Fujita T, Ito K, Choji T, Honma Y, Nakaki H, Uchisako H, Tanaka N, Kuramitsu T, Hatanaka M, Matsumoto T, et al. [Usefulness of 2D FLASH multislice dynamic MR imaging for evaluation of parametrial invasion in cervical carcinoma]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1993 Apr 25;53(4):472-4. (Jpn).
- Genolet PM, Hanggi W, Dreher E. [Evaluation of tumor extension in invasive cancer of the uterine cervix. Diagnostic evaluation of cervix cancer]. *Gynakol Geburtshilfliche Rundsch* 1993;33(3):180-4. (Fre).
- Gochev G, Totsev N, Vasilev D, Simeonova L, Ianev N, Elenchev L. [The potentials of computed axial tomography (CAT) in the diagnosis of carcinoma of the cervix uteri]. *Akush Ginekol (Sofia)* 1994;33(3):25-6. (Bul).
- Hanabayashi T, Imai A, Itoh N, Tamaya T. Enhanced magnetic resonance imaging evaluation for spread of cervical carcinoma. *Int J Gynaecol Obstet* 1993 Dec; 43(3):297-304.
- Hawnaur JM, Johnson RJ, Buckley CH, Tindall V, Isherwood I. Staging, volume estimation and assessment of nodal status in carcinoma of the cervix: comparison of magnetic resonance imaging with surgical findings. *Clin Radiol* 1994 Jul;49(7):443-52.
- Houvenaeghel G, Delpero JR, Rosello R, Resbeut M, Viens P, Jacquemier J, Noirclerc M, Guerinel G. Results of a prospective study with comparison of clinical, endosonographic, computed tomography, magnetic resonance imaging and pathologic staging of advanced gynecologic carcinoma and recurrence. *Surg Gynecol Obstet* 1993 Sep;177(3):231-6.
- Houvenaeghel G, Martino M, Resbeut M, Rosello R, Perez T, Delpero JR, Jacquemier J, Guerinel G. Pelvic staging of advanced and recurrent gynecologic cancers: contribution of endosonography. *Gynecol Oncol* 1994 Dec;55(3 Pt 1):393-400.
- Hricak H. [Magnetic resonance imaging of the female pelvis]. *Lijec Vjesn* 1994 May-Jun;116(5-6):149-54. (Scr).
- Hricak H, Quivey JM, Campos Z, Gildengorin V, Hindmarsh T, Bis KG, Stern JL, Phillips TL. Carcinoma of the cervix: predictive value of clinical and magnetic resonance (MR) imaging assessment of prognostic factors. *Int J Radiat Oncol Biol Phys* 1993 Nov 15;27(4): 791-801. Comment in: *Int J Radiat Oncol Biol Phys* 1993 Nov 15;27(4):981-3.
- Hricak H, Swift PS, Campos Z, Quivey JM, Gildengorin V, Goranson H. Irradiation of the cervix uteri: value of unenhanced and contrast-enhanced MR imaging. *Radiology* 1993 Nov;189(2):381-8.
- Hsieh CY, Wu CC, Chen TM, Chen CA, Chen CL, Wang JF, Chang CF, Hsieh FJ. Clinical significance of intratumoral blood flow in cervical carcinoma assessed by color Doppler ultrasound. *Cancer* 1995 May 15;75(10): 2518-22.
- Kaji Y, Sugimura K, Kitao M, Ishida T. Histopathology of uterine cervical carcinoma: diagnostic comparison of endorectal surface coil and standard body coil MRI. *J Comput Assist Tomogr* 1994 Sep-Oct;18(5):785-92.
- Kawakami K, Fushiki M, Sho K, Matsui A, Suyama S, Murata K, Morita R. MR evaluation of the uterine cervical cancer before, during and after radiation therapy [abstract]. In: *ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology;*

1993. p. 328.
- Kim KH, Lee BH, Do YS, Chin SY, Park SY, Kim BG, Jang JJ. Stage Ib cervical carcinoma: MR evaluation of effect of intraarterial chemotherapy. *Radiology* 1994 Jul; 192(1):61-5.
- Kim SH, Choi BI, Han JK, Kim HD, Lee HP, Kang SB, Lee JY, Han MC. Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. *J Comput Assist Tomogr* 1993 Jul-Aug;17(4):633-40.
- Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. *Radiology* 1994 Mar;190(3):807-11.
- Kitagaki H. [MR imaging-evaluation of therapeutic effect of radiotherapy for uterine cervix cancer]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1995 Mar;55(4):215-21. (Jpn).
- Lien HH, Blomlie V, Iversen T, Trope C, Sundfor K, Abeler VM. Clinical stage I carcinoma of the cervix. Value of MR imaging in determining invasion into the parametrium. *Acta Radiol* 1993 Mar;34(2):130-2.
- Mamsen A, Ledertoug S, Horlyck A, Knudsen HJ, Rasmussen KL, Nyland MH, Jakobsen A. The possible role of ultrasound in early cervical cancer. *Gynecol Oncol* 1995 Feb;56(2):187-90.
- Marano P, Summaria V, Smaniotto D, Danza FM, Specca S, Valentini AL, Greggi S, Lancia M, Cellini N. [Experience with the combined diagnosis and therapy of locally advanced carcinoma of the uterine cervix (stage FIGO IIB-III). Transrectal ultrasonography and CT in the staging and in follow-up after therapy. Preliminary results]. *Radiol Med (Torino)* 1993 Nov;86(5):630-8. (Ita).
- Martin AJ, Poon CS, Thomas GM, Kapusta LR, Shaw PA, Henkelman RM. MR evaluation of cervical cancer in hysterectomy specimens: correlation of quantitative T2 measurement and histology. *J Magn Reson Imaging* 1994 Nov-Dec;4(6):779-86.
- Mayr NA, Tali ET, Yuh WT, Brown BP, Wen BC, Buller RE, Anderson B, Hussey DH. Cervical cancer: application of MR imaging in radiation therapy. *Radiology* 1993 Nov;189(2):601-8.
- Mezrich R. Magnetic resonance imaging applications in uterine cervical cancer. *Magn Reson Imaging Clin N Am* 1994 May;2(2):211-43.
- Montana GS, Hanlon AL, Brickner TJ, Owen JB, Hanks GE, Ling CC, Komaki R, Marcial VA, Thomas GM, Lanciano R. Carcinoma of the cervix: patterns of care studies: review of 1978, 1983, and 1988-1989 surveys. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1481-6. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Jul 30; 32(5):1535-7.
- Monzen Y, Mori H, Matsumoto A, Yoshida S, Wakisaka M, Komatsu E, Tashiro M, Hori Y. [Uterine cervical cancer: usefulness of MR imaging after the initial radiation therapy]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1995 Sep;55(11):745-50. (Jpn).
- Moore DH. Evaluation and staging of cervical carcinoma. *Clin Consult Obstet Gynecol* 1995;7(2):111-7.
- Omigbodun AO, Thomas JO, Adewole IF. Cytologic detection of urinary bladder involvement in cervical cancer. *Int J Gynecol Cancer* 1994;4(6):401-3.
- Pendlebury SC, Cahill S, Crandon AJ, Bull CA. Role of bipedal lymphangiogram in radiation treatment planning for cervix cancer. *Int J Radiat Oncol Biol Phys* 1993 Nov 15;27(4):959-62.
- Pirhonen JP, Grenman SA, Bredbacka AB, Bahado-Singh RO, Salmi TA. Effects of external radiotherapy on uterine blood flow in patients with advanced cervical carcinoma assessed by color Doppler ultrasonography. *Cancer* 1995; 76(1):67-71.
- Poka R, Szluha K, Hernadi Z, Juhasz B, Lampe L. Are pre-operative lymphographic results reflected in the survival of stage Ib and IIa cervical cancer? *J Obstet Gynecol* 1994;14(5):352-4.
- Rutgers JL, Mattox TF, Vargas MP. Angiogenesis in uterine cervical squamous cell carcinoma. *Int J Gynecol Pathol* 1995;14(2):114-8.
- Schmitz MJ, Nahhas WA, Clark MA, Brown M. Stage IB carcinoma of the cervix: are all staging tests and procedures necessary? *Eur J Gynaecol Oncol* 1994; 15(3):199-204.
- Schnall MD. Magnetic resonance evaluation of uterine malignancies. *Semin Ultrasound CT MR* 1994 Feb;15(1): 27-37.
- Shepherd SF, Collins CD, Fryatt IJ, Parsons CA, Blake PR. Computerized axial tomographic scan measurements as prognostic indicators in patients with cervical carcinoma. *Br J Radiol* 1995 Jun;68(810):600-3.
- Sironi S, De Cobelli F, Scarfone G, Colombo E, Bolis G, Ferrari A, DelMaschio A. Carcinoma of the cervix: value of plain and gadolinium-enhanced MR imaging in assessing degree of invasiveness. *Radiology* 1993 Sep; 188(3):797-801.
- Stummvoll W, Ruschitzka G, Hammer J. [Color doppler ultrasonography of uterine vessels during radiotherapy of advanced cervix cancers]. *Gynakol Geburtshilfliche Rundsch* 1994;34(2):102-5. (Ger).
- Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. *Obstet Gynecol* 1995 Jul;86(1):43-50.

- Toita T, Nakano M, Higashi M, Sakumoto K, Kanazawa K. Prognostic value of cervical size and pelvic lymph node status assessed by computed tomography for patients with uterine cervical cancer treated by radical radiation therapy. *Int J Radiat Oncol Biol Phys* 1995 Nov 1;33(4): 843-9.
- Varpula M, Kilholma P, Klemi P. CT and ultra low field (0.02 T) MR imaging of uterine cervical carcinoma. *Acta Radiol* 1994 Jul;35(4):361-6.
- Varpula MJ. Ultra low field (0.02 t) magnetic resonance imaging of the female pelvis [dissertation]. Turku, Finland: Turun Yliopisto; 1993. 132 p.
- Vijaykumar DK, Prahlad S, Chaturvedi HK. Ultrasound evaluation of pelvic nodes in cervical carcinoma. *Eur J Gynaecol Oncol* 1995;16(3):224-7.
- Weber TM, Sostman HD, Spritzer CE, Ballard RL, Meyer GA, Clark-Pearson DL, Soper JT. Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging. *Radiology* 1995 Jan;194(1): 135-9.
- Westhofen M, Reichel C, Nadjmi D. [Colour Doppler imaging in the indication of cervical lymph node surgery]. *Otorinolaringologia* 1994;4(5-6):285-91. (Ger).
- Wong WL, Studholme C, Lewis P, Raju KS, Beaney RP, Tonge K, Nunnan T, Hawkes DJ, Pemberton J. Combined MR, CT and PET imaging in oncological patients [abstract]. *Br J Radiol* 1993;66 Suppl:33-4.
- Surgical Assessment and Resection of Lymph Nodes**
- Altintas A, Vardar MA, Evruke C, Aridogan N. Is it essential to perform complete para-aortic lymph node dissection if no metastases have been shown in the lower part of the aorta? *Eur J Gynaecol Oncol* 1995;16(2): 120-2.
- Benedetti-Panici P, Greggi S, Scambia G, Maneschi F, Baiocchi G, Amoroso MA, Rabitti C, Mancuso S. Anatomical study of para-aortic and pelvic lymph nodes in gynecologic malignancies. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Benedetti-Panici P, Maneschi F, Scambia G, Greggi S, Mancuso S. Anatomic abnormalities of the retroperitoneum encountered during aortic and pelvic lymphadenectomy. *Am J Obstet Gynecol* 1994 Jan; 170(1 Pt 1):111-6.
- Bjornsson BL, Nelson BE, Reale FR, Rose PG. Accuracy of frozen section for lymph node metastasis in patients undergoing radical hysterectomy for carcinoma of the cervix. *Gynecol Oncol* 1993 Oct;51(1):50-3.
- Fowler JM, Carter JR, Carlson JW, Maslonkowski R, Byers LJ, Carson LF, Twiggs LB. Lymph node yield from laparoscopic lymphadenectomy in cervical cancer: a comparative study. *Gynecol Oncol* 1993 Nov;51(2): 187-92.
- Girardi F, Haas J. The importance of the histologic processing of pelvic lymph nodes in the treatment of cervical cancer. *Int J Gynecol Cancer* 1993;3(1):12-7.
- Girardi F, Pickel H, Winter R. Pelvic and parametrial lymph nodes in the quality control of the surgical treatment of cervical cancer. *Gynecol Oncol* 1993 Sep;50(3):330-3.
- Hacker NF, Wain GV, Nicklin JL. Resection of bulky positive lymph nodes in patients with cervical carcinoma. *Int J Gynecol Cancer* 1995;5(4):250-6.
- Hackett TE, Olt G, Sorosky JI, Podczaski E, Harrison TA, Mortel R. Surgical predictors of para-aortic metastases in early-stage cervical carcinoma. *Gynecol Oncol* 1995 Oct; 59(1):15-9.
- Hording U, Ravn V, Knudsen J, Visfeldt J. The use of polymerase chain reaction to detect metastatic cancer cells within lymph nodes stage I cervical carcinoma. *Int J Gynecol Pathol* 1995;14(4):339-43.
- Kinney WK, Hodge DO, Egorshin EV, Ballard DJ, Podratz KC. Surgical treatment of patients with stages IB and IIA carcinoma of the cervix and palpably positive pelvic lymph nodes. *Gynecol Oncol* 1995 May;57(2):145-9.
- Lanciano RM, Corn BW. The role of surgical staging

for cervical cancer. *Semin Radiat Oncol* 1994;4(1):46-51.

Park JS, Chee YH, Namkoong SE, Han SK, Kim TE, Lee HY, Kim SJ. Human papillomavirus detection in cervical carcinoma tissues and paraaortic lymph nodes by the polymerase chain reaction. *Gynecol Oncol* 1994 Jun; 53(3):344-51.

Patsner B. Extraperitoneal staging lymphadenectomy for locally advanced cervical cancer. Effective, cost-effective and minimally invasive. *Eur J Gynaecol Oncol* 1994; 15(6):460-3.

Potter ME, Spencer S, Soong SJ, Hatch KD. The influence of staging laparotomy for cervical cancer on patterns of recurrence and survival. *Int J Gynecol Cancer* 1993;3(3): 169-74.

Renolleau C, Laroussinie MP, Mosseri V, Fenton J, de la Rochefordiere A, Clough KB, Hamelin JP, Durand JC. [Pelvic lymph node invasion in cancer of the uterine cervix]. *Bull Cancer (Paris)* 1995;82(5):377-83. (Fre).

Romanini C, Garzetti GG. Role of pelvic and paraaortic lymphadenectomy in radical surgery for early stage cervical carcinoma: a randomized clinical study. *Ital J Gynaecol Obstet* 1993;5(4):159-64.

Rose BR, Thompson CH, Jiang XM, Tattersall MH, Elliott PM, Dalrymple C, Cossart YE. Detection of human papillomavirus type 16 E6/E7 transcripts in histologically cancer-free pelvic lymph nodes of patients with cervical carcinoma. *Gynecol Oncol* 1994 Feb;52(2):212-7.

Satoh C. [A clinical and pathological study on paraaortic lymph node metastasis in uterine cervical carcinoma]. *Nippon Sanka Fujinka Gakkai Zasshi* 1994 Dec;46(12): 1343-50. (Jpn).

Schatten C, Vavra N, Nagele F, Barrada M, Aygun M, Enzensberger H, Sevelde P. [The prognostic effect of scintigraphy-guided lymphadenectomy in therapy of stage Ib cervix carcinoma]. *Geburtshilfe Frauenheilkd* 1995 Aug;55(8):441-6. (Ger).

Diagnosis and Management of Stage IA1

Andersen ES, Husth M, Joergensen A, Nielsen K. Laser conization for microinvasive carcinoma of the cervix. Short-term results. *Int J Gynecol Cancer* 1993;3(3):183-5.

Andersen ES, Nielsen K, Pedersen B. The reliability of preconization diagnostic evaluation in patients with cervical intraepithelial neoplasia and microinvasive carcinoma. *Gynecol Oncol* 1995 Oct;59(1):143-7.

Anderson MC. Invasive carcinoma of the cervix following local destructive treatment for cervical intraepithelial neoplasia. *Br J Obstet Gynaecol* 1993 Jul;100(7):657-63.

Girardi F, Burghardt E, Pickel H. Small FIGO stage IB cervical cancer. *Gynecol Oncol* 1994 Dec;55(3 Pt 1): 427-32.

Hopkins MP, Morley GW. Microinvasive squamous cell carcinoma of the cervix. *J Reprod Med* 1994 Sep;39(9): 671-3.

Jones WB, Mercer GO, Lewis JL Jr, Rubin SC, Hoskins WJ. Early invasive carcinoma of the cervix. *Gynecol Oncol* 1993 Oct;51(1):26-32.

Kennedy AW, Belinson JL, Wirth S, Taylor J. The role of the loop electrosurgical excision procedure in the diagnosis and management of early invasive cervical cancer. *Int J Gynecol Cancer* 1995;5(2):117-20.

Kinney WK, Hodge DO, Egorshin EV, Ballard DJ, Podratz KC. Identification of a low-risk subset of patients with stage IB invasive squamous cancer of the cervix possibly suited to less radical surgical treatment. *Gynecol Oncol* 1995 Apr;57(1):3-6. Comment in: *Gynecol Oncol* 1995 Apr;57(1):1-2.

Morgan PR, Anderson MC, Buckley CH, Murdoch JB, Lopes A, Duncan ID, Monaghan JM. The Royal College of Obstetricians and Gynaecologists micro-invasive carcinoma of the cervix study: preliminary results. *Br J Obstet Gynaecol* 1993 Jul;100(7):664-8.

Morris M, Mitchell MF, Silva EG, Copeland LJ, Gershenson DM. Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix. *Gynecol Oncol* 1993 Nov;51(2):193-6.

Orlandi C, Costa S, Terzano P, Martinelli GN, Comerci G, Guerra B, Martellini L. Presurgical assessment and therapy of microinvasive carcinoma of the cervix. *Gynecol Oncol* 1995 Nov;59(2):255-60.

Ostor AG. Studies on 200 cases of early squamous cell carcinoma of the cervix. *Int J Gynecol Pathol* 1993 Jul; 12(3):193-207.

Ostor AG, Rome RM. Micro-invasive squamous cell carcinoma of the cervix: a clinico-pathologic

- study of 200 cases with long-term follow-up. *Int J Gynecol Cancer* 1994;4(4):257-64.
- Peng ZL. [Stage Ia cervical cancer]. *Chung Hua Fu Chan Ko Tsa Chih* 1993 Jun;28(6):346-8, 381. (Chi).
- Rodriguez-Oliver A, Hernandez F, Rojas R, Gomez T, Menjon S, Herruzo A. [Treatment and follow-up of women with microinvasive carcinoma of cervix]. *Oncologia* 1994;17(7):31-5. (Spa).
- Ruiz Ortiz E, Gonzalez Lira G, Escudero de los Rios P, Sebastian Mauricio R. [Microinvasive cervico-uterine cancer. Diagnosis and treatment]. *Ginecol Obstet Mex* 1994 Aug;62:237-42. (Spa).
- Sugimori H, Iwasaka T. Cervical microcarcinoma: differential diagnosis. *Arch STD HIV Res* 1994;8(1-2): 155-67.
- Ueki M, Okamoto Y, Misaki O, Seiki Y, Kitsuki K, Ueda M, Sugimoto O. Conservative therapy for microinvasive carcinoma of the uterine cervix. *Gynecol Oncol* 1994 Apr;53(1):109-13.
- Vavra N, Nagele F, Rosen A, Klein M, Barrada M, Buxbaum P, Sevelde P. [Conisation in stage Ia cervix cancer]. *Geburtshilfe Frauenheilkd* 1994 Jul;54(7): 397-400. (Ger).
- Yaegashi N, Sato S, Inoue Y, Noda K, Yajima A. Conservative surgical treatment in cervical cancer with 3 to 5 mm stromal invasion in the absence of confluent invasion and lymphovascular space involvement. *Gynecol Oncol* 1994 Sep;54(3):333-7.
- Primary Surgery, Including Treatment in Pregnancy**
- Alvarez RD, Gelder MS, Gore H, Soong SJ, Partridge EE. Radical hysterectomy in the treatment of patients with bulky early stage carcinoma of the cervix uteri. *Surg Gynecol Obstet* 1993 Jun;176(6):539-42.
- Anderson B, LaPolla J, Turner D, Chapman G, Buller R. Ovarian transposition in cervical cancer. *Gynecol Oncol* 1993 May;49(2):206-14.
- Averette HE, Nguyen HN, Donato DM, Penalver MA, Sevin BU, Estape R, Little WA. Radical hysterectomy for invasive cervical cancer. A 25-year prospective experience with the Miami technique. *Cancer* 1993 Feb 15;71(4 Suppl):1422-37.
- Benedetti-Panici P, Scambia G, Baiocchi G, Maneschi F, Greggi S, Mancuso S. Radical hysterectomy: a randomized study comparing two techniques for resection of the cardinal ligament. *Gynecol Oncol* 1993 Aug;50(2): 226-31.
- Bidzinski M, Lemieszczuk B, Zielinski J. Evaluation of the hormonal function and features of the ultrasound picture of transposed ovary in cervical cancer patients after surgery and pelvic irradiation. *Eur J Gynaecol Oncol* 1993;14 Suppl:77-80.
- Bissett D, Lamont DW, Nwabaneli NJ, Brodie MM, Symonds RP. The treatment of stage I carcinoma of the cervix in the west of Scotland 1980-1987. *Br J Obstet Gynaecol* 1994 Jul;101(7):615-20.
- Bosze P, Meszaros I, Palfalvi L, Ungar L. Perioperative complications of 116 radical hysterectomies and pelvic node dissections. *Eur J Surg Oncol* 1993 Dec;19(6): 605-8.
- Burke TW. Treatment options in stage IB cervical cancer: radical hysterectomy and radiotherapy. *Semin Radiat Oncol* 1994;4(1):34-40.
- Carvalho JP, Souen JS, Carramao S da S, Yeu WL, Pinotti JA. Wertheim-Meigs radical hysterectomy. *Rev Paul Med* 1994 Apr-Jun;112(2):539-42.
- Cheng J. [Clinical application of extraperitoneal ovarian transposition in cervical cancer]. *Chung Hua Fu Chan Ko Tsa Chih* 1993 Sep;28(9):542-4, 570. (Chi).
- Cobanoglu O, Gurkan Zorlu C, Kuscu E, Ergun Y, Aydogdu T, Gokmen O. Clinical experience of 115 early stage cervical cancer. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Connor JP, Morris PC, Alagoz T, Anderson B, Bottles K, Buller RE. Intraoperative autologous

- blood collection and autotransfusion in the surgical management of early cancers of the uterine cervix. *Obstet Gynecol* 1995 Sep; 86(3):373-8.
- Covens A, Rosen B, Gibbons A, Osborne R, Murphy J, DePetrillo A, Lickrish G, Shaw P, Colgan T. Differences in the morbidity of radical hysterectomy between gynecological oncologists. *Gynecol Oncol* 1993 Oct; 51(1):39-45.
- Debus-Thiede G, Maassen V, Dimpfl T, Klosterhalfen T, Kindermann G. [Late disorders of bladder function after Wertheim operation--an analysis of urodynamic parameters with reference to surgical radicality]. *Geburtshilfe Frauenheilkd* 1993 Aug;53(8):525-31. (Ger).
- Duggan B, Muderspach LI, Roman LD, Curtin JP, d'Ablaing G 3d, Morrow CP. Cervical cancer in pregnancy: reporting on planned delay in therapy. *Obstet Gynecol* 1993 Oct;82(4 Pt 1):598-602.
- Fanning J, Hilgers RD, Palabrica C. Surgical stapling technique for radical hysterectomy. *Gynecol Oncol* 1994 Nov;55(2):179-84.
- Feeney DD, Moore DH, Look KY, Stehman FB, Sutton GP. The fate of the ovaries after radical hysterectomy and ovarian transposition. *Gynecol Oncol* 1995 Jan;56(1):3-7. Comment in: *Gynecol Oncol* 1995 Jan;56(1):1-2.
- Fotiou SK, Tserkezoglou AJ, Steinhauer G, Papailiou J, Tavernarakis A. Pelvic lymphocysts after radical hysterectomy and lymphadenectomy. *Eur J Gynaecol Oncol* 1994;15(6):449-54.
- Harrison TA, Sevin BU, Koechli O, Nguyen HN, Averette HE, Penalver M, Donato DM, Nadji M. Adenosquamous carcinoma of the cervix: prognosis in early stage disease treated by radical hysterectomy. *Gynecol Oncol* 1993 Sep;50(3):310-5.
- Jensen JK, Lucci JA 3d, DiSaia PJ, Manetta A, Berman ML. To drain or not to drain: a retrospective study of closed-suction drainage following radical hysterectomy with pelvic lymphadenectomy. *Gynecol Oncol* 1993;51(1):46-9.
- Kennedy AW, Peterson G, Tuason LJ, Belinson JL, Webster KD. Radical hysterectomy for cervical cancer: the effect of shorter length of stay on outcome. *Cleve Clin J Med* 1995 May-Jun;62(3):193-7.
- Knudsen HJ, Rasmussen KL, Ledertoug S, Mamsen A, Nyland MH, Jakobsen A. A comparison of survival and side effects in two periods with a different approach to radical hysterectomy as treatment of cervical cancer stages Ib and IIa. *Zentralbl Gynakol* 1995;117(9):476-80.
- Kralj B, Lukanovic A. Treatment of micturition disturbances after radical hysterectomy due to changes of cystometric curve. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Lewandowski GS, Vaccarello L, Copeland LJ. Surgical issues in the management of carcinoma of the cervix in pregnancy. *Surg Clin North Am* 1995 Feb;75(1):89-100.
- Magrina JF. Complications of irradiation and radical surgery for gynecologic malignancies. *Obstet Gynecol Surv* 1993 Aug;48(8):571-5.
- Matthews CM, Burke TW, Tornos C, Eifel PJ, Atkinson EN, Stringer CA, Morris M, Silva EG. Stage I cervical adenocarcinoma: prognostic evaluation of surgically treated patients. *Gynecol Oncol* 1993 Apr;49(1):19-23.
- McLellan R, Dillon MB, Woodruff JD, Heatley GJ, Fields AL, Rosenshein NB. Long-term follow-up of stage I cervical adenocarcinoma treated by radical surgery. *Gynecol Oncol* 1994 Feb;52(2):253-9.
- Monk BJ, Tewari K, Gamboa-Vujicic G, Burger RA, Manetta A, Berman ML. Does perioperative blood transfusion affect survival in patients with cervical cancer treated with radical hysterectomy? *Obstet Gynecol* 1995 Mar;85(3):343-8.
- Montz FJ, Holschneider CH, Solh S, Schuricht LC, Monk BJ. Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings. *Gynecol Oncol* 1994 Apr;53(1):114-20.
- Morris PC, Haugen J, Tomjack J, Anderson B, Buller RE. Blood transfusion and the risk of recurrence in stage IB cervical cancer. *Gynecol Oncol* 1995 Jun;57(3):401-6.
- Nevin J, Soeters R, Dehaeck K, Bloch B, Van Wyk L. Advanced cervical carcinoma associated with pregnancy. *Int J Gynecol Cancer* 1993;3(1):57-63.
- Nwabineli NJ, Walsh DJ, Davis JA. Urinary drainage following radical hysterectomy for cervical carcinoma - a pilot comparison of urethral and suprapubic routes. *Int J Gynecol Cancer* 1993;3(4):208-10.
- O'Callaghan DJ, Dwyer PL. Clinical and urodynamic follow-up of women with established urinary dysfunction after radical hysterectomy. *Aust N Z J Obstet Gynaecol* 1994; 34(5):557-61.
- Orr JW Jr, Orr PJ, Bolen DD, Holimon JL. Radical hysterectomy: does the type of incision matter? *Am J Obstet Gynecol* 1995 Aug;173(2):399-405; discussion 405-6.
- Parker M, Bosscher J, Barnhill D, Park R. Ovarian management during radical hysterectomy in the premenopausal patient. *Obstet Gynecol* 1993 Aug; 82(2):187-90. Comments in: *Obstet Gynecol* 1993 Dec;82(6):1042-3; *Obstet Gynecol* 1993 Dec;82(6):1043.

- Pateisky N, Vavra N, Berkemeier H, Barrada M, Senker W, Schatten C. [Isotope nephrogram in follow-up of radically operated cervix cancers]. *Geburtshilfe Frauenheilkd* 1993 Aug;53(8):532-4. (Ger).
- Patsner B. Closed-suction drainage versus no drainage following radical abdominal hysterectomy with pelvic lymphadenectomy for stage IB cervical cancer. *Gynecol Oncol* 1995 May;57(2):232-4.
- Poka R, Hernadi Z, Lampe L. Invasive cervical carcinoma associated with pregnancy. *J Obstet Gynecol* 1993;13(2): 91-4.
- Sartori E, Fallo L, La Face B, Bianchi UA, Pecorelli S. Extended radical hysterectomy in early-stage carcinoma of the uterine cervix: tailoring the radicality. *Int J Gynecol Cancer* 1995;5(2):143-7.
- Schreuder HW, Vierhout ME, Veen HF. [Disabling constipation following Wertheim's radical hysterectomy]. *Ned Tijdschr Geneesk* 1993 May 22;137(21):1059-62. (Dut).
- Sivanesaratnam V, Jayalakshmi P, Loo C. Surgical management of early invasive cancer of the cervix associated with pregnancy. *Gynecol Oncol* 1993 Jan; 48(1):68-75.
- Sivanesaratnam V, Sen DK, Jayalakshmi P, Ong G. Radical hysterectomy and pelvic lymphadenectomy for early invasive cancer of the cervix - 14-year experience. *Int J Gynecol Cancer* 1993;3(4):231-8.
- Sorbe B, Graflund M, Linder A, Forslin L, Wallmo L, Quarfort L, Johnson P. Treatment of cervical carcinoma by Wertheim-Meigs surgery: long-term follow-up results in a well-defined Swedish region. *Int J Oncol* 1995;6(4): 817-23.
- Sorosky JI, Squatrito R, Ndubisi BU, Anderson B, Podczaski ES, Mayr N, Buller RE. Stage I squamous cell cervical carcinoma in pregnancy: planned delay in therapy awaiting fetal maturity. *Gynecol Oncol* 1995 Nov;59(2): 207-10.
- Steren A, Nguyen HN, Averette HE, Estape R, Angioli R, Donato DM, Penalver MA, Sevin BU. Radical hysterectomy for stage IB adenocarcinoma of the cervix: the University of Miami experience. *Gynecol Oncol* 1993 Mar;48(3):355-9.
- van der Vange N, Weverling GJ, Ketting BW, Ankum WM, Samlal R, Lammes FB. The prognosis of cervical cancer associated with pregnancy: a matched cohort study. *Obstet Gynecol* 1995 Jun;85(6):1022-6.
- Vierhout ME, Schreuder HWB, Veen HF. The relation between colorectal and lower urinary tract dysfunction following radical hysterectomy for carcinoma of the cervix. *Int Urogynecol J* 1994;5(2):82-5.
- Weerasekera DS, Gunawardena KK. A retrospective evaluation of early carcinoma of the cervix treated surgically in a Provincial General Hospital. *Ceylon Med J* 1994 Jun;39(2):75-7.
- Wu YX, Qiu S, Meng J. [Careful dissection of the pelvic plexus helps alleviate urinary retention following radical hysterectomy]. *Chunghua Chung Liu Tsa Chih* 1994 Nov;16(6):465-8. (Chi).
- Yamawaki T, Tanaka H, Takeuchi S, Yanase H, Taniguchi H, Toyoda N. Autologous blood transfusion using recombinant human erythropoietin in radical hysterectomy. *Asia Oceania J Obstet Gynaecol* 1994 Jun; 20(2):147-53.
- Zivkovic F, Ralph G, Tamussino K, Schied G, Walz M. Stress-overflow urinary incontinence after radical hysterectomy and radiation therapy for cervical cancer. *Int Urogynecol J* 1994;5(5):305-8.

Primary Radiotherapy

- Acker JC, Marks LB. The lack of impact of pelvic irradiation on small bowel mobility: implications for radiotherapy treatment planning. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1473-5.
- Barillot I, Horiot JC, Cuisenier J, Pigneux J, Schraub S, Rozan R, Pourquier H, Daly N, Vrousos C, Keiling R, et al. Carcinoma of the cervical stump: a review of 213 cases. *Eur J Cancer* 1993;29A(9):1231-6.
- Barillot I, Horiot JC, Maingon P, Bone-Lepinoy MC, Vaillant D, Feutray S. Maximum and mean bladder dose defined from ultrasonography. Comparison with the ICRU reference in gynaecological brachytherapy. *Radiother Oncol* 1994 Mar;30(3):231-8.
- Deshpande DD, Shrivastava SK, Nehru RM, Viswanathan PS, Dinshaw KA. Treatment volume from total reference air kerma (TRAK) in intracavitary applications and its comparison with ICRU reference volume. *Int J Radiat Oncol Biol Phys* 1994 Jan 15;28(2):499-504.
- Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. *Gynecol Oncol* 1995 Oct;59(1):38-44.
- Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1289-300. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1531-4.
- Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys* 1994 Apr 30;29(1):9-16.
- Grigsby PW, Georgiou A, Williamson JF, Perez CA. Anatomic variation of gynecologic brachytherapy prescription points. *Int J Radiat Oncol Biol Phys* 1993 Oct 20;27(3):725-9.
- Grigsby PW, Vest ML, Perez CA. Recurrent carcinoma of the cervix exclusively in the paraaortic nodes following radiation therapy. *Int J Radiat Oncol Biol Phys* 1994 Jan 15;28(2):451-5. Comment in: *Int J Radiat Oncol Biol Phys* 1994 Sep 30;30(2):509.
- Husseinzadeh N, Van Aken ML, Aron B. Ovarian transposition in young patients with invasive cervical cancer receiving radiation therapy. *Int J Gynecol Cancer* 1994;4(1):61-5.
- Kato E, Morita K. [Treatment results of conformation radiotherapy for stage I and II cervical cancer]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1995 Mar;55(4):240-6. (Jpn).
- Kato E, Morita K. [2-axial conformational irradiation for whole-pelvis irradiation of cervical cancer: improvement and evaluation with DVH]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1994 Aug 25;54(9):897-907. (Jpn).
- Kim RY, McGinnis LS, Spencer SA, Meredith RF, Jennelle RL, Salter MM. Conventional four-field pelvic radiotherapy technique without computed tomography-treatment planning in cancer of the cervix: potential geographic miss and its impact on pelvic control. *Int J Radiat Oncol Biol Phys* 1995 Jan 1;31(1):109-12.
- Kim RY, McGinnis LS, Spencer SA, Meredith RF, Jennelle RL, Salter MM. Conventional four-field pelvic radiotherapy technique without CT treatment planning in cancer of the cervix: potential geographic miss. *Radiother Oncol* 1994 Feb;30(2):140-5.
- Kleinerman RA, Boice JD Jr, Storm HH, Sparen P, Andersen A, Pukkala E, Lynch CF, Hankey BF, Flannery JT. Second primary cancer after treatment for cervical cancer: an international cancer registries study. *Cancer* 1995;76(3):442-52.
- Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. *Int J Radiat Oncol Biol Phys* 1993 Feb 15;25(3):391-7.
- Levenback C. Complications of radiotherapy for treatment of cervix cancer. *Clin Consult Obstet Gynecol* 1995;7(2): 152-9.
- Levenback C, Eifel PJ, Burke TW, Morris M, Gershenson DM. Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. *Gynecol Oncol* 1994 Nov; 55(2):206-10.
- Lutgens LC, Schutte B, de Jong JM, Thunnissen FB. DNA content as prognostic factor in cervix carcinoma stage IB-III treated with radiotherapy. *Gynecol Oncol* 1994 Sep; 54(3):275-81.
- McIntyre JF, Eifel PJ, Levenback C, Oswald MJ. Ureteral stricture as a late complication of radiotherapy for stage IB carcinoma of the uterine cervix. *Cancer* 1995 Feb 1; 75(3):836-43.
- Meertens H, van Bunningen BN, Moonen LM, Steggerda MJ, Blom AP, van den Berg AC. Brachytherapy. *Annu Rep Neth Cancer Inst* 1993:92.
- Morita K, Kato E, Fuwa N, Ito Y. Conformational radiotherapy for cervical cancer [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 414.
- Nakano T, Arai T, Morita S, Oka K. Radiation therapy alone for adenocarcinoma of the

Quality of Life Considerations

- uterine cervix. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1331-6. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1543-4.
- Patton TJ, Mitchell MF, Atkinson EN, Eifel P, Gastorf L, Yancey C, Miller D, Wharton JT. Parameters of small bowel dysfunction in cervical cancer patients undergoing radiotherapy. *Int J Gynecol Cancer* 1993;3(3):175-82.
- Pearcey RG, Turner MJ. Inherent radiosensitivity and dna ploidy as predictors of treatment response in patients with carcinoma of the cervix [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 263.
- Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1275-88. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1527-9.
- Pernot M, Hoffstetter S, Peiffert D, Carolus JM, Guillemin F, Verhaeghe JL, Marchal C, Luporsi E, Beckendorf V, Stines J, et al. [Statistical study of a series of 672 cases of carcinoma of the uterine cervix. Results and complications according to age and modalities of treatment]. *Bull Cancer (Paris)* 1995 Jul;82(7):568-81. (Fre).
- Rotman M, Aziz H, Eifel PJ. Irradiation of pelvic and para-aortic nodes in carcinoma of the cervix. *Semin Radiat Oncol* 1994;4(1):23-9.
- Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby PW, Cooper J, John M. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. *JAMA* 1995 Aug 2;274(5): 387-93. Comment in: *JAMA* 1995 Aug 2;274(5):427-8.
- Schwarz R. [Results of radiotherapy of cervix cancer]. *Zentralbl Gynakol* 1993;115(12):537-40. (Ger).
- Sinistrero G, Sismondi P, Rumore A, Zola P. Analysis of complications of cervix carcinoma treated by radiotherapy using the Franco-Italian glossary. *Radiother Oncol* 1993 Mar;26(3):203-11.
- Werner-Wasik M, Schmid CH, Bornstein LE, Madoc-Jones H. Increased risk of second malignant neoplasms outside radiation fields in patients with cervical carcinoma. *Cancer* 1995 May 1;75(9):2281-5.
- Bennetts A, Irwig L, Oldenburg B, Simpson JM, Mock P, Boyes A, Adams K, Weisberg E, Shelley J. PEAPS-Q: a questionnaire to measure the psychosocial effects of having an abnormal pap smear. *J Clin Epidemiol* 1995; 48(10):1235-43.
- Bruner DW, Lanciano R, Keegan M, Corn B, Martin E, Hanks GE. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 1993 Nov 15;27(4):825-30.
- Corney RH, Crowther ME, Everett H, Howells A, Shepherd JH. Psychosexual dysfunction in women with gynaecological cancer following radical pelvic surgery. *Br J Obstet Gynaecol* 1993 Jan;100(1):73-8.
- Cull A, Cowie VJ, Farquharson DI, Livingstone JR, Smart GE, Elton RA. Early stage cervical cancer: psychosocial and sexual outcomes of treatment. *Br J Cancer* 1993 Dec; 68(6):1216-20.
- Flay LD, Matthews JH. The effects of radiotherapy and surgery on the sexual function of women treated for cervical cancer. *Int J Radiat Oncol Biol Phys* 1995 Jan 15;31(2):399-404.
- Krumm S, Lamberti J. Changes in sexual behavior following radiation therapy for cervical cancer. *J Psychosom Obstet Gynaecol* 1993 Mar;14(1):51-63.
- Lalos A, Jacobsson L, Lalos O, Stendahl U. Experiences of the male partner in cervical and endometrial cancer - a prospective interview study. *J Psychosom Obstet Gynaecol* 1995 Sep;16(3):153-65.
- Lambley P. The role of psychological processes in the aetiology and treatment of cervical cancer: a biopsychological perspective. *Br J Med Psychol* 1993 Mar;66 Pt 1:43-60. Published erratum appears in *Br J Med Psychol* 1993 Sep;66(Pt 3):304.
- Peipert JF, Wells CK, Schwartz PE, Feinstein AR. Prognostic value of clinical variables in invasive cervical cancer. *Obstet Gynecol* 1994 Nov;84(5):746-51.
- Peipert JF, Wells CK, Schwartz PE, Feinstein AR. The impact of symptoms and comorbidity on prognosis in stage IB cervical cancer. *Am J Obstet Gynecol* 1993 Sep; 169(3):598-604.
- Rollison B, Strang P. Pain, nausea and anxiety during intra-uterine brachytherapy of cervical carcinomas. *Support Care Cancer* 1995 May;3(3):205-7.
- Specia M, Robinson JW, Goodey E, Frizzell B. Patients evaluate a quality of life scale: whose life is it anyway? *Cancer Pract* 1994 Sep-Oct;2(5):365-70.

Thranov I, Klee M. Sexuality among gynecologic cancer patients--a cross-sectional study. *Gynecol Oncol* 1994 Jan;52(1):14-9. Comment in: *Gynecol Oncol* 1994 Jan; 52(1):10-3.

Werngren-Elgstrom M, Lidman D. Lymphoedema of the lower extremities after surgery and radiotherapy for cancer of the cervix. *Scand J Plast Reconstr Surg Hand Surg* 1994 Dec;28(4):289-93.

New Surgical Approaches

Bolla M, Sarrazin R, Salvat J, Berland E, Schmidt MH, Rolachon I. [Feasibility of retroperitoneal pelvic lymph node exploration in cervix-carcinoma treated by radio-surgery association or a definitive radiotherapy. A retrospective study of 52 cases]. *Bull Cancer Radiother* 1995;82(3):326-31. (Fre).

Childers JM, Nasser A. Minimal access surgery in gynecologic cancer: we can, but should we? *Curr Opin Obstet Gynecol* 1995 Feb;7(1):57-62.

Childers JM, Surwit EA. Current status of operative laparoscopy in gynecologic oncology. *Oncology (Huntingt)* 1993 Nov;7(11):47-51; discussion 53-4, 57.

Clough KB, Renolleau C, Durand JC. [Should laparoscopic lymphadenectomy modify the therapeutic protocols for cancer of the cervix?] *J Gynecol Obstet Biol Reprod (Paris)* 1994;23(6):671-5. (Fre).

Dargent D, Roy M, Keita N, Mathevet P, Adeleine P. The schauta operation: its place in the management of cervical cancer in 1993. Paper presented at: 24th Annual Meeting of the Society of Gynecologic Oncologists; 1993 Feb 7-10; Palm Desert, CA.

Delgado G, Potkul RK, Dolan JR. Retroperitoneal radical hysterectomy. *Gynecol Oncol* 1995 Feb;56(2):191-4.

Fidalgo de Matos CJ, Querleu D, Leblanc E. [Pelvic endoscopic lymphadenectomy in the assessment of early cancer of the uterine neck: survey of 25 French hospital centers]. *Rev Med Brux* 1993 Jun;14(6):163-8. (Fre).

Gallup DG, King LA, Messing MJ, Talledo OE. Paraaortic lymph node sampling by means of an extraperitoneal approach with a supraumbilical transverse sunrise incision. *Am J Obstet Gynecol* 1993 Aug;169(2 Pt 1): 307-11; discussion 311-2.

Hatch KD, Hallum AV 3d, Surwit EA, Childers JM. The role of laparoscopy in gynecologic oncology. *Cancer* 1995;76(10 Suppl):2113-6.

Kadar N. Laparoscopic resection of fixed and enlarged aortic lymph nodes in patients with advanced cervix cancer. *Gynaecol Endosc* 1993;2(4):217-21.

Kadar N. Laparoscopic vaginal radical hysterectomy: an operative technique and its evolution. *Gynaecol Endosc* 1994;3(2):109-22.

Kadar N, Pelosi MA. Can cervical cancer be adequately staged by laparoscopic aortic lymphadenectomy? *Gynaecol Endosc* 1994;3(4):213-6.

Kadar N, Reich H. Laparoscopically assisted radical Schauta hysterectomy and bilateral laparoscopic pelvic lymphadenectomy for the

- treatment of bulky stage IB carcinoma of the cervix. *Gynaecol Endosc* 1993;2(3): 135-42.
- Lee CL, Huang KG, Lai YM, Lai CH, Soong YK. Ureteral injury during laparoscopically assisted radical vaginal hysterectomy. *Hum Reprod* 1995;10(8):2047-9.
- Lichtenegger W. The vaginal radical operation of cervical cancer. *J Obstet Gynaecol* 1995;21(2):179-84.
- Mage G, Canis M, Pouly JL, Wattiez A, Glowaczower E, Raiga J, Bruhat M. [Wertheim hysterectomy]. *Ref Gynecol Obstet* 1994;2(Spec Iss):140-8. (Fre).
- Magrina JF, Serrano L, Cornella JL. Laparoscopic lymphadenectomy and radical or modified radical vaginal hysterectomy for endometrial and cervical carcinoma: preliminary experience. *J Gynecol Surg* 1995;11(3): 147-51.
- Massi G, Savino L, Susini T. Schauta-Amreich vaginal hysterectomy and Wertheim-Meigs abdominal hysterectomy in the treatment of cervical cancer: a retrospective analysis. *Am J Obstet Gynecol* 1993 Mar; 168(3 Pt 1):928-34. Comment in: *Am J Obstet Gynecol* 1994 Jul;171(1):287-8.
- Nezhat CR, Nezhat FR, Burrell MO, Ramirez CE, Welander C, Carrodeguas J, Nezhat CH. Laparoscopic radical hysterectomy and laparoscopically assisted vaginal radical hysterectomy with pelvic and paraaortic node dissection. *J Gynecol Surg* 1993 Summer;9(2):105-20.
- Plante M, Roy M. The use of operative laparoscopy in determining eligibility for pelvic exenteration in patients with recurrent cervical cancer. *Gynecol Oncol* 1995 Dec; 59(3):401-4.
- Querleu D. Laparoscopic paraaortic node sampling in gynecologic oncology: a preliminary experience. *Gynecol Oncol* 1993 Apr;49(1):24-9.
- Querleu D. Laparoscopically assisted radical vaginal hysterectomy. *Gynecol Oncol* 1993 Nov;51(2):248-54.
- Querleu D, Leblanc E, Castelain B, Elhage A. [Celioscopic pelvic and para-aortic lymphadenectomy]. *Chirurgie* 1993-94;119(4):208-11. (Fre).
- Stitt JC, Elg SA. Laparoscopic lymph node dissection in the evaluation and management of patients with pelvic malignancy. *Mil Med* 1995 Sep;160(9):462-4.
- Su TH, Wang KG, Yang YC, Hong BK, Huang SH. Laparoscopic para-aortic lymph node sampling in the staging of invasive cervical carcinoma: including a comparative study of 21 laparotomy cases. *Int J Gynaecol Obstet* 1995;49(3):311-8.
- Wattiez A, Raymond F, Canis M, Chapron C, Pouly JL, Mage G, Bruhat MA. [External iliac lymphadenectomy by celioscopy: surgical technique]. *Ann Chir* 1993;47(6): 523-8. (Fre).
- Wurtz A, Porte H, Gambiez L, Jaillard-Thery S, Chambon JP, Mazeman E. [Value of iliac direct-view retroperitoneoscopy (or extraperitoneal pelviscopy) in the assessment of lymph node invasion by pelvic cancer]. *Ann Chir* 1995;49(5):383-9. (Fre).

Adjuvant Therapy After Hysterectomy

- Atkovar G, Uzel O, Ozsahin M, Koca S, Sahinler I, Okkan S, Uzel R. Postoperative radiotherapy in carcinoma of the cervix: treatment results and prognostic factors. *Radiother Oncol* 1995 Jun;35(3):198-205.
- Chatani M, Matayoshi Y, Masaki N, Narumi Y, Teshima T, Inoue T. Prophylactic irradiation of para-aortic lymph nodes in carcinoma of the uterine cervix. A prospective randomized study. *Strahlenther Onkol* 1995 Nov;171(11): 655-60.
- Fang FM, Yeh CY, Lai YL, Chiou JF, Chang KH. Radiotherapy following simple hysterectomy in patients with invasive carcinoma of the uterine cervix. *J Formos Med Assoc* 1993 May;92(5):420-5.
- Foley M, Lenehan P, Murphy J, Kelehan P. Adjuvant radiotherapy reduces the incidence of central pelvic failure following radical hysterectomy for large cervical tumors. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Frigerio L, Busci L, Rabaiotti E, Mariani A. Adjuvant radiotherapy after radical hysterectomy in high risk early stage cervical carcinoma. Assessment of morbidity and recurrences. *Eur J Gynaecol Oncol* 1994;15(2):132-7.
- Gadducci A, Fabrini MG, Bonuccelli A, Fanucchi A, Perutelli A, Facchini V. Recurrence patterns in patients with early stage cervical cancer treated with radical hysterectomy and external pelvic irradiation. *Anticancer Res* 1995 May-Jun;15(3):1071-7.
- Inoue T, Morita K. Long-term observation of patients treated by postoperative extended-field irradiation for nodal metastases from cervical carcinoma stages IB, IIA, and IIB. *Gynecol Oncol* 1995 Jul;58(1):4-10. Comment in: *Gynecol Oncol* 1995 Jul;58(1):1-3.
- Killackey MA, Boardman L, Carroll DS. Adjuvant chemotherapy and radiation in patients with poor prognostic stage Ib/Ila cervical cancer. *Gynecol Oncol* 1993 Jun;49(3):377-9. Comment in: *Gynecol Oncol* 1995 Jan;56(1):147.
- Li QD, Liu EC, Zhang BL. [Treatment of stage I and II cervical carcinoma by non-radical operation with or without radiation]. *Chung Kuo Chung Liu Lin Chuang* 1995;22(9):654-7. (Chi).
- Mitsuhashi N, Takahashi M, Yamakawa M, Nozaki M, Takahashi T, Sakurai H, Maebayashi K, Hayakawa K, Niibe H. Results of postoperative radiation therapy for patients with carcinoma of the uterine cervix: evaluation of intravaginal cone boost with an electron beam. *Gynecol Oncol* 1995 Jun;57(3):321-6.
- Monk BJ, Cha DS, Walker JL, Burger RA, Ramsinghani NS, Manetta A, DiSaia PJ, Berman ML. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. *Gynecol Oncol* 1994 Jul;54(1):4-9. Comment in: *Gynecol Oncol* 1994 Jul;54(1):1-3.
- Pedulla F, Centurioni MG, Foglia G, Ferrari I, Orsatti M, Vitale V, Ragni N. Treatment of FIGO stage Ib cervical carcinoma with nodal involvement. *Eur J Gynaecol Oncol* 1994;15(1):59-64.
- Perez CA, Grigsby PW, Camel HM, Galakatos AE, Mutch D, Lockett MA. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):703-16. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):1007-8.
- Robertson DI, Paslawski D, Duggan MA, Stuart GC, Nation JG. Estrogen and progesterone receptor, human papillomavirus, and DNA ploidy analysis in invasive carcinoma of the cervix in pregnancy. *Am J Clin Pathol* 1993 Jul;100(1):18-21.
- Roman LD, Morris M, Mitchell MF, Eifel PJ, Burke TW, Atkinson EN. Prognostic factors for patients undergoing simple hysterectomy in the presence of invasive cancer of the cervix. *Gynecol Oncol* 1993 Aug;50(2):179-84.
- Stitt JA. Use of postoperative irradiation for carcinoma of the cervix. *Semin Radiat Oncol* 1994;4(1):41-5.
- Stock RG, Chen AS, Flickinger JC, Kalnicki S, Seski J. Node-positive cervical cancer: impact of pelvic irradiation and patterns of failure. *Int J Radiat Oncol Biol Phys* 1995 Jan 1;31(1):31-6.
- Sutton G, Bundy B, Delgado G, Sevin B, Creasman W, Major F, Zaino R. Evaluation of pelvic radiotherapy following radical hysterectomy in patients with clinical stage IB squamous carcinoma of the cervix: a study of the Gynecologic Oncology Group. Paper presented at: 24th Annual Meeting of the Society of Gynecologic Oncologists; 1993 Feb 7-10; Palm Desert, CA.
- Takamura A, Mizoe J, Arimoto T, Kamada T, Shirato H, Matsuoka Y, Tomita M, Irie G. Is postoperative radiotherapy beneficial in the management of stage I-II squamous-cell carcinoma of the uterine cervix with negative metastatic nodes and positive parametrial involvement? A retrospective review of 70 patients. *Asia Oceania J Obstet Gynaecol* 1993 Jun;19(2):145-51.
- Toita T, Takizawa Y, Sueyama H, Yamaguchi K, Kushi A, Ogawa K, Hara R, Nakano M, Higashi M, Sakumoto K, et al. [Role of postoperative irradiation for carcinoma of the uterine cervix: multivariate analysis of prognostic factors and patterns of failure]. *Nippon Igaku Hoshasen*

Gakkai Zasshi 1994 Feb 25;54(2):163-70.
(Jpn).

Zanetta G, Colombo A, Maneo A, Colombo M, Nava S, Landoni F, Mangioni C. Postoperative treatments for stage Ib-IIa cervical carcinoma with lymph node metastases after primary surgery: complications and efficacy of three different methods. *Ital J Gynaecol Obstet* 1995;7(2):45-50.

Zanetta G, Colombo A, Milani R, Placa F, Mangioni C. Long-term results of sequential postoperative treatment with vincristine, bleomycin, mitomycin C, cis-platin and radiotherapy after surgery for high-risk patients with cervical carcinoma stage IB-IIA. *Int J Gynecol Cancer* 1995;5(1):40-4.

Adjuvant Surgery After Radiotherapy

- Cabrera J, Tirapegui E, Fluxa L, Fernandez M, Perez C, Mucientes F, Klaassen R, Poloni O, Boggiano G. [Results of combined treatment of early cervicouterine cancer]. *Rev Chil Obstet Ginecol* 1994;59(2):128-34. (Spa).
- Fras AP. Residual carcinoma of the uterine cervix after low-dose preoperative intracavitary irradiation. *Radiol Oncol* 1995;29(1):15-8.
- Gerdin E, Cnattingius S, Johnson P. Complications after radiotherapy and radical hysterectomy in early-stage cervical carcinoma. *Acta Obstet Gynecol Scand* 1995 Aug;74(7):554-61.
- Monk BJ, Solh S, Johnson MT, Montz FJ. Radical hysterectomy after pelvic irradiation in patients with high risk cervical cancer or uterine sarcoma: morbidity and outcome. *Eur J Gynaecol Oncol* 1993;14(6):506-11.
- Perez CA, Grigsby PW, Camel HM, Galakatos AE, Mutch D, Lockett MA. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):703-16. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Feb 15; 31(4):1007-8.
- Pernot M, Hoffstetter S, Peiffert D, Carolus JM, Guillemain F, Verhaeghe JL, Marchal C, Luporsi E, Beckendorf V, Stines J, et al. [Statistical study of a series of 672 cases of carcinoma of the uterine cervix. Results and complications according to age and modalities of treatment]. *Bull Cancer (Paris)* 1995 Jul;82(7):568-81. (Fre).
- Poka R, Szluha K, Hernadi Z, Juhasz B, Lampe L. Analysis of survival in stage Ib and Ila cervical cancer treated with or without preoperative local radiotherapy. *Eur J Gynaecol Oncol* 1995;16(3):208-11.
- Scalliet P, Kramar A, Lambin P, Bouzy J, Haie-Meder C, Gerbaulet A, Chassagne D. Prospective registration vs retrospective assessment of side-effects and complications: comparison of two series of patients treated at Institut Gustave Roussy for uterine cervix carcinoma [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 196.
- Srisupundit S, Tangtrakul S, Linasmita V, Bullangpoti S, Kraiphikul P, Pojchanugool L. Combined radiotherapy and hysterectomy in the treatment of high risk stage II invasive carcinoma of the uterine cervix. *Gan To Kagaku Ryoho* 1995 Aug;22 Suppl 3:256-61.

MANAGEMENT OF ADVANCED-STAGE AND RECURRENT CERVICAL CANCER

Radiotherapy

- Antonadou D, Synodinou M, Katsoulis M, Synodinos D, Zis I, Throuvalas N. Evaluation of preoperative versus post-operative combined RT in early carcinoma of the uterine cervix [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 416.
- Arthur D, Kaufman N, Schmidt-Ullrich R, Kavanagh B, Simpson P, Hill M, Ali M. Heuristically derived tumor burden score as a prognostic factor for stage IIIB carcinoma of the cervix. *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):743-51.
- Ash D, Bates T. Report on the clinical effects of inadvertent radiation underdosage in 1045 patients. *Clin Oncol (R Coll Radiol)* 1994;6(4):214-26.
- Baldini B, Lastruccl L, Moncini D, Santoni R, Savino L, Susini T, Taddei GL. Radiation therapy followed by surgery in the treatment of 83 patients with clinical stage IIB cervical carcinoma. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Biswal BM, Mohanti BK, Rath GK, Kumar L, Kriplani A, Ganesh T, Takkar D, Kumar S. Results of radical radiotherapy in carcinoma of the uterine cervix stage I-III. *Clin Oncol (R Coll Radiol)* 1994;6(6):356-60.
- Carl UM, Bahnsen J, Wiegel T. Radiation therapy of para-aortic lymph nodes in cancer of the uterine cervix. *Acta Oncol* 1993;32(1):63-7.
- Choy D, Wong LC, Sham J, Ngan HY, Ma HK. Dose-tumor response of carcinoma of cervix: an analysis of 594 patients treated by radiotherapy. *Gynecol Oncol* 1993 Jun;49(3):311-7.
- Corn BW, Hanlon AL, Pajak TF, Owen J, Hanks GE. Technically accurate intracavitary insertions improve pelvic control and survival among patients with locally advanced carcinoma of the uterine cervix. *Gynecol Oncol* 1994 Jun;53(3):294-300.
- De Neve W, Van den Heuvel F, Coghe M, Verellen D, De Beukeleer M, Roelstraete A, De Roover P, Thon L, Storme G. Interactive use of on-line portal imaging in pelvic radiation. *Int J Radiat Oncol Biol Phys* 1993 Feb 15;25(3):517-24.
- Eifel PJ, Thoms WW Jr, Smith TL, Morris M, Oswald MJ. The relationship between brachytherapy

- dose and outcome in patients with bulky endocervical tumors treated with radiation alone. *Int J Radiat Oncol Biol Phys* 1994 Jan 1;28(1):113-8.
- Eisbruch A, Williamson JF, Dickson DR, Grigsby PW, Perez CA. Estimation of tissue volume irradiated by intracavitary implants. *Int J Radiat Oncol Biol Phys* 1993 Mar 15;25(4):733-44. Comment in: *Int J Radiat Oncol Biol Phys* 1994 Apr 30;29(1):217-8.
- Fine BA, Hempling RE, Piver MS, Baker TR, McAuley M, Driscoll D. Severe radiation morbidity in carcinoma of the cervix: impact of pretherapy surgical staging and previous surgery. *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):717-23. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):1009-10.
- Formenti SC, Meyerowitz BE, Ell K, Muderspach L, Groshen S, Leedham B, Klement V, Morrow PC. Inadequate adherence to radiotherapy in Latina immigrants with carcinoma of the cervix. Potential impact on disease free survival. *Cancer* 1995 Mar 1;75(5): 1135-40.
- Fyles AW, Pintilie M, Kirkbride P, Levin W, Manchul LA, Rawlings GA. Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. *Radiother Oncol* 1995 May;35(2): 107-17.
- Girinsky T, Rey A, Roche B, Haie C, Gerbaulet A, Randrianarivello H, Chassagne D. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. *Int J Radiat Oncol Biol Phys* 1993 Dec 1;27(5):1051-6.
- Hanba K, Nakano T, Hukuhisa K, Morita S, Arai T. Long-term prognosis for patients with cervical cancer treated with intracavitary irradiation [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 274.
- Harrington KJ, Lambert HE, Kelly SA, Lai PS, Price GD. Prostaglandin-induced cervical dilatation prior to intracavitary radiotherapy for carcinoma of the cervix: a pilot study. *Int J Gynecol Cancer* 1994;4(6):404-7.
- Hopkins MP, Morley GW. Prognostic factors in advanced stage squamous cell cancer of the cervix. *Cancer* 1993 Oct 15;72(8):2389-93.
- Horiot JC, Barillot I, Pigneux J, Schraub S, Pourquier H, Daly N, Bolla M, Rozan R. Carcinoma of the uterine cervix treated with radiotherapy alone: prognostic factors and prevention of complications [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 415.
- Komaki R, Brickner TJ, Hanlon AL, Owen JB, Hanks GE. Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978, and 1983: Patterns of Care Study (PCS). *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):973-82.
- Lanciano R, Corn B, Martin E, Schultheiss T, Hogan WM, Rosenblum N. Perioperative morbidity of intracavitary gynecologic brachytherapy. *Int J Radiat Oncol Biol Phys* 1994 Jul 30;29(5):969-74.
- Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. *Int J Radiat Oncol Biol Phys* 1993 Feb 15;25(3): 391-7.
- Ma DM. [Outcome and complications of treatment by intracavitary afterloading radiotherapy in 143 patients with cervical cancer]. *Chung Hua Fu Chan Ko Tsa Chih* 1993 Nov;28(11):646-8, 699. (Chi).
- Marcial VA, Komaki R. Altered fractionation and extended-field irradiation of carcinoma of the cervix. *Cancer* 1995; 76(10 Suppl):2152-8.
- Mitsuhashi N, Takahashi M, Nozaki M, Yamakawa M, Takahashi T, Sakurai H, Hayakawa K, Niibe H. Evaluation of external beam therapy and three brachytherapy fractions for carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys* 1994 Jul 30;29(5): 975-82. Comment in: *Int J Radiat Oncol Biol Phys* 1994 Jul 30;29(5):1195-7.
- Mitsuhashi N, Takahashi M, Nozaki M, Yamakawa M, Takahashi T, Sakurai H, Maebayashi K, Hayakawa K, Niibe H. Squamous cell carcinoma of the uterine cervix: radiation therapy for patients aged 70 years and older. *Radiology* 1995 Jan;194(1):141-5.
- Montana GS, Hanlon AL, Brickner TJ, Owen JB, Hanks GE, Ling CC, Komaki R, Marcial VA, Thomas GM, Lanciano R. Carcinoma of the cervix: patterns of care studies: review of 1978, 1983, and 1988-1989 surveys. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1481-6. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Jul 30; 32(5):1535-7.
- Morita K, Kato E, Fuwa N, Ito Y. Conformational radiotherapy for cervical cancer [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 414.
- Natali M, Chiarlone R, Siccaldi C, Luzi G, Marziano C. Radiotherapy exclusive in the carcinoma of the uterine cervix. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.

- Pedersen D, Bentzen SM, Overgaard J. Continuous or split-course combined external and intracavitary radiotherapy of locally advanced carcinoma of the uterine cervix. *Acta Oncol* 1994;33(5):547-55.
- Pedersen D, Bentzen SM, Overgaard J. Early and late radiotherapeutic morbidity in 442 consecutive patients with locally advanced carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys* 1994 Jul 30;29(5):941-52. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Mar 30; 31(5):1349-51.
- Pedersen D, Bentzen SM, Overgaard J. Reporting radiotherapeutic complications in patients with uterine cervical cancer. The importance of latency and classification system. *Radiother Oncol* 1993 Aug;28(2): 134-41.
- Pedersen D, Sogaard H, Overgaard J, Bentzen SM. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. *Acta Oncol* 1995;34(6):787-95.
- Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, Stitt JA, Thomadsen BR, Buchler DA. The adverse effect of treatment prolongation in cervical carcinoma. *Int J Radiat Oncol Biol Phys* 1995 Jul 30; 32(5):1301-7. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1527-9.
- Prasad KN, Pradhan S, Datta NR. Urinary tract infection in patients of gynecological malignancies undergoing external pelvic radiotherapy. *Gynecol Oncol* 1995 Jun; 57(3):380-2.
- Senanayake LF, Sun SL, Collis C, Tate AT, Skeggs DB, Davy TJ. Conformation therapy using a computer controlled telecobalt unit for advanced cervical carcinoma. *Clin Oncol (R Coll Radiol)* 1994;6(5):308-13.
- Sismondi P, Zola P, Sinistrero G, Rumore A, Katsaros D. Cervical cancer treatment complications: the Italian multicenter study. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Smart GP. Isometric wedge shielding for pelvic boost external beam therapy after Curietron treatments. *Australas Phys Eng Sci Med* 1994 Dec;17(4):221-5.
- Snijders-Keilholz A, van Acht M, de Vroome H, Hermans J, Trimbos JB, Leer JW. Pelvic failure rate and radiation toxicity in relation to total dose of radiation alone for the treatment of cancer of the uterine cervix. *Clin Oncol (R Coll Radiol)* 1993;5(1):6-10.
- To WW, Ngan HY, Wong LC, Choy DT, Ma HK. Use of prophylactic antibiotics in patients with carcinoma of the cervix receiving intracavitary radium insertion. *Eur J Gynaecol Oncol* 1993;14(3):197-201.
- Toita T, Takizawa Y, Nakano M, Sueyama H, Kushi A, Kakihana Y, Ogawa K, Hara R, Higashi M, Sakumoto K, et al. Radical radiation therapy for adenocarcinoma of the uterine cervix. *Strahlenther Onkol* 1994 May;170(5): 277-80.
- Vedula R. Implication of uterine configuration on dosimetry to point A using the Amersham afterloading system. *Int J Radiat Oncol Biol Phys* 1993 Mar 15;25(4):721-31.
- Vermund H. Evolution of brachytherapy in the treatment of uterine cervical carcinoma: a review. *Endocuriether Hyperthermia Oncol* 1995;11(1):1-8.
- Vermund H, Alqaisi ME, Chenier T, Christie KI, Semer DA, Wiley AL Jr. Interstitial and intracavitary brachytherapy in carcinoma of the uterine cervix. *Endocuriether Hyperthermia Oncol* 1995;11(1):43-55.
- Xiang EW. Long term results of ⁶⁰Co HDR afterloading in the treatment of cervical cancer. *Chung Hua Chung Liu Tsa Chih* 1993;15(2):114-7.
- Yeoh E, Horowitz M, Russo A, Muecke T, Ahmad A, Robb T, Chatterton B. A retrospective study of the effects of pelvic irradiation for carcinoma of the cervix on gastrointestinal function. *Int J Radiat Oncol Biol Phys* 1993 May 20;26(2):229-37.

High- or Low-Dose Rate Brachytherapy

- Arterbery VE. High-dose rate brachytherapy for carcinoma of the cervix. *Curr Opin Oncol* 1993 Nov;5(6):1005-9.
- Boothby R, Clark K, Forbes A, Wheppelmann B, Castaldo T. Use of nasopharyngeal (NP) tube as an endocervical sleeve for high dose remote afterloading (HDR) in patients with cervical cancer [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1994;13:A838.
- Chatani M, Matayoshi Y, Masaki N, Teshima T, Inoue T. A prospective randomized study concerning the point A dose in high-dose rate intracavitary therapy for carcinoma of the uterine cervix. The final results. *Strahlenther Onkol* 1994 Nov;170(11):636-42.
- Chatani M, Matayoshi Y, Masaki N, Teshima T, Inoue T. [A prospective randomized study concerning the point A dose in high-dose rate intracavitary therapy for carcinoma of the uterine cervix]. *Rinsho Hoshasen* 1994;39(10):1155-60. (Jpn).
- Chatani M, Matayoshi Y, Masaki N, Teshima T, Inoue T. Long term follow-up results of high-dose rate remote afterloading intracavitary radiation therapy for carcinoma of the uterine cervix. *Strahlenther Onkol* 1994 May;170(5):269-76.
- Chiou JF, Liu MT, Lai YL, Chang KH. High-dose-rate afterloading brachytherapy in carcinoma of the uterine cervix. *J Formos Med Assoc* 1993 Feb;92(2):165-73.
- Cikaric S. HDR brachytherapy of cervix carcinoma applied to 272 younger and 119 older than 60 years patients: comparison of 5-year results and complications [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 275.
- Corn BW, Galvin JM, Soffen EM, Henze G, Schwaibold F. Positional stability of sources during low-dose-rate brachytherapy for cervical carcinoma. *Int J Radiat Oncol Biol Phys* 1993 Jun 15;26(3):513-8.
- Dinshaw KA, Shrivastava SK, Deore SM. Influence of dose-rate on clinical end points: analysis using I-Q model [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 99.
- Fushiki M, Suyama S, Kawakami K, Takahashi M, Matsui A, Sho K, Yabumoto E, Morita R. Previous treatment results and new patterns of care for radiotherapy of the uterine cervical cancer [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 415.
- Gerbaulet A, Lartigau E. Low dose rate and high dose rate brachytherapy [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 96.
- Grigsby PW, Slessinger ED, Teague SP, Williamson JF, Perez CA. Clinical evaluation of an interstitial remote afterloading device for multichannel intracavitary irradiation. *Int J Radiat Oncol Biol Phys* 1995 Feb 15; 31(4):875-81.
- Haie-Meder C, Kramar A, Lambin P, Lancar R, Scalliet P, Bouzy J, Gerbaulet A. Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. *Int J Radiat Oncol Biol Phys* 1994 Jul 30;29(5):953-60. Comments in: *Int J Radiat Oncol Biol Phys* 1994 Jul 30; 29(5):1195-7; *Int J Radiat Oncol Biol Phys* 1995 Mar 30; 31(5):1349-51.
- Hammer J, Zoidl JP, Altendorfer C, Seewald DH, Track C, Stummvoll W, Labeck W. Combined external and high dose rate intracavitary radiotherapy in the primary treatment of cancer of the uterine cervix. *Radiother Oncol* 1993 Apr;27(1):66-8.
- Herrmann T, Christen N, Alheit HD. [Gynecologic brachytherapy--from low-dose-rate to high-tech]. *Strahlenther Onkol* 1993 Mar;169(3):141-51. (Ger).
- Hsu WL, Wu CJ, Jen YM, Yen SH, Lin KT, Ger LP, Kim RY. Twice-per-day fractionated high versus continuous low dose rate intracavitary therapy in the radical treatment of cervical cancer: a nonrandomized comparison of treatment results. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5):1425-31.
- Hunter R. Clinical experience of changing dose rate [abstract]. *Eur J Cancer* 1993;29A Suppl 6:S36.
- Ito H, Kutuki S, Nishiguchi I, Kuribayashi T, Nakayama T, Takemasa K, Uematsu M, Ando Y, Ogawa K. [Radiotherapy for cervical cancer patients with high-dose rate brachytherapy: application of shielded colpostats]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1994 Jan 25; 54(1):46-54. (Jpn).
- Ito H, Kutuki S, Nishiguchi I, Shigematsu N, Kuribayashi T, Uematsu M, Nakayama T, Ka WJ, Takemasa K, Ando Y, et al. Radiotherapy for cervical cancer with high-dose rate brachytherapy--correlation between tumor size, dose and failure. *Radiother Oncol* 1994 Jun;31(3):240-7.
- Itoh H, Ogawa K. [Radiotherapy for cervical cancer

- patients; modification of dose distribution by shielded colpostats]. *Rinsho Hoshasen* 1994;39(6):673-84. (Jpn).
- Jones G, Lukka H, O'Brien B. High dose rate versus low dose rate brachytherapy for squamous cell carcinoma of the cervix: an economic analysis. *Br J Radiol* 1994 Nov; 67(803):1113-20.
- Kim RY, Meyer JT, Plott WE, Spencer SA, Meredith RF, Jennelle RL, Salter MM. Major geometric variations between multiple high-dose-rate applications of brachytherapy in cancer of the cervix: frequency and types of variation. *Radiology* 1995 May;195(2):419-22.
- Kutsutani-Nakamura Y, Furukawa S, Tabushi K, Nakano T, Ishii T, Arai T. Relationship of time dose and fractionation in fractionated high dose rate and low dose rate regimens for intracavitary brachytherapy of the cervix [abstract]. In: *ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan.* [place unknown]: International Society for Radiation Oncology; 1993. p. 377.
- Lambin P, Gerbaulet A, Kramar A, Scalliet P, Haie-Meder C, Malaise EP, Chassagne D. Phase III trial comparing two low dose rates in brachytherapy of cervix carcinoma: report at two years. *Int J Radiat Oncol Biol Phys* 1993 Feb 15;25(3):405-12.
- Lambin P, Gerbaulet A, Kramar A, Scalliet P, Haie-Meder C, Michel G, Prade M, Bouzy J, Malaise EP, Chassagne D. A comparison of early effects with two dose rates in brachytherapy of cervix carcinoma in a prospective randomised trial. *Eur J Cancer* 1994; 30A(3):312-20.
- Lancar R, Kramar A, Haie-Meder C, Lambin P, Bouzy J, Scalliet P, Gerbaulet A. [Method for evaluating long term complications. A study from a phase III trial comparing two low dose rates in gynecologic brachytherapy]. *Bull Cancer (Paris)* 1994 Jul;81(7):632-7. (Fre).
- Le Pechoux C, Akine Y, Sumi M, Tokuyue K, Ikeda H, Yajima M, Yamada T, Tanemura K, Tsunematsu R, Ohmi K, et al. High dose rate brachytherapy for carcinoma of the uterine cervix: comparison of two different fractionation regimens. *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):735-41. Comment in: *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):1011-3.
- Lou HK. [Afterloading intracavitary irradiation therapy for cancer of uterine cervix]. *Chung Hua Fu Chan Ko Tsa Chih* 1993 Nov;28(11):649-50, 699. (Chi).
- Mayer A, Nemeth G, Nemeskeri C, Thalacker U. [Preoperative low-dose-rate versus high-dose-rate brachytherapy in stage IB cervix cancer. An efficacy study]. *Strahlenther Onkol* 1993 Dec;169(12):716-20. (Ger).
- Meden H, Busch M, Bartels U, Tsikuras P, Rath W, Duhmke E, Kuhn W. Experience with a new flexible applicator system for intracavitary radiotherapy of cervical cancer. *Onkologie* 1994;17(6):604-7.
- Nag S, Abitbol AA, Anderson LL, Blasko JC, Flores A, Harrison LB, Hilaris BS, Martinez AA, Mehta MP, Nori D, et al. Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors. Clinical Research Committee, American Endocurietherapy Society. *Int J Radiat Oncol Biol Phys* 1993 Dec 1;27(5):1241-4.
- Nair MT, Cheng MC, Barker A, Rouse BS. High dose rate (HDR) brachytherapy technique: for carcinoma of uterine cervix using Nucletron applicators. *Med Dosim* 1995 Fall;20(3):201-7.
- Niel CG, Koper PC, Visser AG, Sipkema D, Levendag PC. Optimizing brachytherapy for locally advanced cervical cancer. *Int J Radiat Oncol Biol Phys* 1994 Jul 1;29(4): 873-7.
- Noyes WR, Peters NE, Thomadsen BR, Fowler JF, Buchler DA, Stitt JA, Kinsella TJ. Impact of optimized treatment planning for tandem and ring, and tandem and ovoids, using high dose rate brachytherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 1995 Jan 1;31(1):79-86.
- Ogino I, Kitamura T, Okamoto N, Yamasita K, Aikawa Y, Okajima H, Matsubara S. Late rectal complication following high dose rate intracavitary brachytherapy in cancer of the cervix. *Int J Radiat Oncol Biol Phys* 1995 Feb 15;31(4):725-34.
- Okawa T, Sakata S, Kita-Okawa M, Kaneyasu Y, Inoue T, Ikida H, Takekawa Y, Nakano T, Wada S, Fushiki M, et al. Comparison between high dose-rate and low dose-rate brachytherapy for cervix cancer: Japanese experience of treatment results and complication (1975-1985) [abstract]. In: *ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan.* [place unknown]: International Society for Radiation Oncology; 1993. p. 274.
- Patel FD, Sharma SC, Negi PS, Ghoshal S, Gupta BD. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. *Int J Radiat Oncol Biol Phys* 1994 Jan 15;28(2): 335-41.
- Paul B, Baveja R, Mishra SP, Bhandari V, Kumar S, Ghosh R. Analysis of MDR-brachytherapy failures in treatment of carcinoma cervix uteri [abstract]. *Br J Radiol* 1993;66 Suppl:52.
- Sarkaria JN, Petereit DG, Stitt JA, Hartman T, Chappell R, Thomadsen BR, Buchler DA, Fowler JF, Kinsella TJ. A comparison of the efficacy and complication rates of low dose-rate versus high dose-rate brachytherapy in the treatment of uterine cervical carcinoma. *Int J Radiat Oncol Biol Phys* 1994 Aug 30;30(1):75-82; discussion 247.
- Selke P, Roman TN, Souhami L, Freeman CR, Clark

Presurgical Neoadjuvant Chemotherapy or Concomitant Chemotherapy with Radiotherapy

- BG, Evans MD, Pla C, Podgorsak EB. Treatment results of high dose rate brachytherapy in patients with carcinoma of the cervix. *Int J Radiat Oncol Biol Phys* 1993 Nov 15; 27(4):803-9.
- Teshima T, Inoue T, Ikeda H, Miyata Y, Nishiyama K, Inoue T, Murayama S, Yamasaki H, Kozuka T. High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. *Cancer* 1993 Oct 15;72(8):2409-14.
- Teshima T, Inoue T, Inoue T, Ikeda H, Sasaki S, Yamazaki H, Ohtani M, Murayama S, Kozuka T. High-dose rate intracavitary therapy for cervical cancer with a microSelectron: a preliminary report. *Radiat Med* 1993 Nov-Dec;11(6):237-41.
- Teshima T, Inoue T, Inoue T, Ikeda H, Yamazaki H, Ohtani M, Sasaki S, Murayama S, Kozuka T. Mid-dose rate intracavitary therapy for cervical cancer with a Selectron: a preliminary report. *Radiat Med* 1993 Nov-Dec;11(6):242-6.
- Thranov IR, Engelholm SA, Knudsen JB. [Optimization of radiotherapy of cervical cancer. Introduction of an external radiotherapy based on CT and low-dosage afterload technique at the Rikshospitalet]. *Ugeskr Laeger* 1995 May 1;157(18):2569-73. (Dan).
- Uno T, Itami J, Shiina T, Kato H, Sakai M, Arimizu N. High-dose rate intracavitary irradiation for carcinoma of the uterine cervix: risk factors for rectal and bladder complication [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 273.
- Wang XE. [Long-term results of ⁶⁰Co HDR afterloading in the treatment of cervical cancer]. *Chung Hua Chung Liu Tsa Chih* 1993 Mar;15(2):114-7. (Chi).
- Wright J, Jones G, Whelan T, Lukka H. Patient preference for high or low dose rate brachytherapy in carcinoma of the cervix. *Radiother Oncol* 1994 Dec;33(3):187-94.
- Yamazaki H, Inoue T, Ikeda H, Tang JT, Murayama S, Teshima T, Otani M, Kozuka T. High-dose-rate remote afterloading intestinal radiotherapy employing the template technique for recurrent cancer in the pelvic area. *Strahlenther Onkol* 1993 Aug;169(8):481-5.
- Bloss JD, Lucci JA 3rd, DiSaia PJ, Manetta A, Schiano MA, Ramsinghani N, Berman ML. A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix. *Gynecol Oncol* 1995 Oct; 59(1):105-10.
- Brunet J, Alonso C, Llanos M, Lacasta A, Fuentes J, Mendoza LA, Badia JM, Delgado E, Ojeda B. Chemotherapy and radiotherapy in locally advanced cervical cancer. *Acta Oncol* 1995;34(7):941-4.
- Burholt DR, Werts ED, Paljug WR, Polizotto SL, Yann VM. Response of cervical carcinoma cells to radiation-platinum combination [abstract]. *Proc Annu Meet Am Assoc Cancer Res* 1994;35:A3854.
- Cardenas J, Olguin A, Figueroa F, Pena J, Becerra F, Huizar R. A randomized trial of chemotherapy followed by radiotherapy vs radiotherapy alone in stage IIIB cervical carcinoma: preliminary results. Paper presented at: 4th International Congress on Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France.
- Chadha M, Jacobs AJ, Stenson R. Chemotherapy rapidly alternating with accelerated radiotherapy for advanced carcinoma of the uterine cervix. *Int J Gynecol Cancer* 1995;5(4):257-61.
- Chauvergne J, Lhomme C, Rohart J, Heron JF, Ayme Y, Goupil A, Fargeot P, David M. [Neoadjuvant chemotherapy of stage IIb or III cancers of the uterine cervix. Long-term results of a multicenter randomized trial of 151 patients]. *Bull Cancer (Paris)* 1993 Dec; 80(12):1069-79. (Fre).
- Chiara S, Bruzzone M, Merlini L, Bruzzi P, Rosso R, Franzone P, Orsatti M, Vitale V, Foglia G, Odicino F, et al. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIb-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group). *Am J Clin Oncol* 1994 Aug;17(4): 294-7.
- Clark BG, Souhami L, Roman TN, Evans MD, Pla C. Rectal complications in patients with carcinoma of the cervix treated with concomitant cisplatin and external beam irradiation with high dose rate brachytherapy: a dosimetric analysis. *Int J Radiat Oncol Biol Phys* 1994 Mar 30;28(5):1243-50. Comment in: *Int J Radiat Oncol Biol Phys* 1994 Mar 30;28(5):1271-2.
- Cole DJ, Jones AC. The treatment of locally advanced carcinoma of the cervix with radiation, 5-fluorouracil and mitomycin C [abstract]. *Br J Radiol* 1993;66 Suppl:52.

- Colin PH. Concomitant chemotherapy and radiotherapy: theoretical basis and clinical experience. *Anticancer Res* 1994;14(6A):2357-61.
- De Dycker RP. Pelvic arterial chemotherapy in cervical cancer. *Reg Cancer Treat* 1994;7(1):43-6.
- de la Garza J, Castaneda N, Ramirez JL, Lara F, Mota A, Guadarrama A. Ifosfamide + mesna + 5 fluorouracil + radiotherapy: early results in patients with untreated stage IIIB-IV cervical cancer. Paper presented at: 4th International Congress on Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France.
- de la Garza J, Castaneda N, Ramirez JL, Lara F, Mota A, Guadarrama A. Neoadjuvant chemotherapy with ifosfamide + mesna + 5-fluorouracil + radiotherapy. Preliminary results in patients (pts) with untreated stage IIIB-IV cervical cancer [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A835.
- De Santis V, Maffeo A, Graziano R, Frezza P, Ferrari E, Gallo MS. Mitomycin C/5FU and radiation therapy for locally advanced uterine cervical cancer. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Delanian S, Housset M, Maulard-Durdux C, Taurelle R, Lecuru F, Baillet F. [Simultaneous radiochemotherapy in locally advanced cancers of the cervix: a preliminary study]. *Bull Cancer (Paris)* 1995;82(5):371-6. (Fre).
- Eddy GL, Manetta A, Alvarez RD, Williams L, Creasman WT. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. *Gynecol Oncol* 1995 Jun;57(3):412-6.
- Erazo A, Cervantes G, Ortega B, Torrecillas L. A phase II trial of ifosfamide (I), mesna (M) and cisplatin (C) chemotherapy (CT) as neoadjuvant or palliative treatment for cervical cancer [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A850.
- Erazo A, Torrecillas L, Cervantes G, Ortega B. A phase II trial of Neo-Adjuvant chemotherapy (CT) with Ifosfamide (I), Mesna and Cisplatin (C) in stage IIA-IIIB cervical cancer. In: Banzet P, Holland JF, Khayat D, Weil M, editors. *Cancer treatment: an update. Presentations given at the 4th International Congress on Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France. Paris: Springer-Verlag; 1994. p. 485-7.*
- Fushiki H, Fujimura M, Yamakawa Y, Izumi R. [Early evaluation of intra-arterial chemotherapeutic effects for carcinoma of the uterine cervix]. *Nippon Gan Chiryō Gakkai Shi* 1995;30(9):1659-77. (Jpn).
- Gamucci T, Zeuli M, Calabresi F, Conti L, Gandolfo L, Mariani A, Lombardi G. Preoperative chemotherapy for cervicocarcinoma: clinical and biological evaluation [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995; 14:A740.
- Gerson R, Tellez-Bernal E, Figueroa J, Chacon H, Roman E, Torres Lobaton A, Garcia Gonzalez H, Lazaro M, Martinez L, Aguero E. Carboplatin plus radiotherapy in advanced cervical cancer phase II study [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993; 12:A881.
- Glaubitx M, Gunter HH, Luck HJ, Hahn T, Meerpohl HG, Achterrath W, Kuhnle H. Results of carboplatin and ifosfamide combination chemotherapy in the treatment of cervical cancer. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Harima K, Harima Y, Tanaka Y, Tateyama I, Hashii K. Preoperative chemoembolization therapy for uterine carcinoma [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 288.
- Hashii K, Tateyama I, Mori T, Harima K, Harima Y, Fujisawa I. [Evaluation of preoperative intraarterial chemotherapy using CDDP with TAE for advanced cervical cancers. With reference to the Pt tissue concentration and the histological antineoplastic effect in the uterine cervix and the pelvic lymph nodes]. *Nippon Gan Chiryō Gakkai Shi* 1994;29(11):1885-97. (Jpn).
- Hoshino T, Suzuki Y, Adachi T, Takayama M. [Intraarterial infusion therapy with OK-432 and G-CSF for cervical cancer: evaluation and discussion]. *Nippon Gan Chiryō Gakkai Shi* 1994;29(4):720-5. (Jpn).
- Husseinzadeh N, Shrake P, DeEulis T, Rowley K, Aron B. Chemotherapy and extended-field radiation therapy to para-aortic area in patients with histologically proven metastatic cervical cancer to para-aortic nodes: a phase II pilot study. *Gynecol Oncol* 1994 Mar;52(3):326-31.
- Ishigaki T, Nagata Y, Okajima K, Mitsumori M, Fujiwara K, Ohya N, Otsu S, Shibata T, Hiraoka M, Abe M. Transcatheter arterial infusion therapy for uterine cervical cancer [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 288.
- Itoh N, Morishita S, Sawairi M, Hanabayashi T, Mori H, Yamawaki Y, Tamaya T. Neoadjuvant intra-arterial infusion chemotherapy by Cisplatin-containing combination regimens for patients with locally advanced uterine cervical cancer. In: Einhorn J, Nord CE, Norrby SR,

- editors. Recent advances in chemotherapy. Proceedings of the 18th International Congress of Chemotherapy; 1993 Jun 27-Jul 2; Stockholm, Sweden. Washington (DC): American Society for Microbiology; 1993. p. 1007-8.
- Jennings TS, Dottino PR, Stock R, Beddoe AM, Rahaman J. Concomitant interferon alpha-2b (IFN alpha), cisplatin (DDP), and irradiation (RT) for locally advanced cervical cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995;14:A743.
- Jones WB. New approaches to high-risk cervical cancer. *Advanced cervical cancer*. Cancer 1993 Feb 15; 71(4 Suppl):1451-9.
- Katsaros D, Zola P, Sinistrero G, Bergamino T, Rumore A, Ferrero A, Bau MG, Sismondi P. Weekly cisplatin induction chemotherapy in high-risk cervical cancer patients with bulky tumor: a phase II study. *Int J Oncol* 1995;6(5):1033-8.
- Kigawa J, Minagawa Y, Ishihara H, Itamochi H, Tei S, Terakawa N. The role of neoadjuvant intra-arterial infusion chemotherapy for advanced cervical cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994;13: A865.
- Kim SJ. Multimodal treatment for the locally advanced stage IB, IIA, IIB patients of cervical cancer. *Int J Gynaecol Obstet* 1995 Jul;49 Suppl:S49-57.
- Kumar L, Biswal BM, Kumar S, Kriplani A, Rath GK. Randomized phase III study of neo-adjuvant chemotherapy (CT) + radiotherapy (RT) vs RT alone in locally advanced cervical cancer (CA CX) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994;13:A819.
- Kumar L, Kaushal R, Nandy M, Biswal BM, Kumar S, Kriplani A, Singh R, Rath GK, Kochupillai V. Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study. *Gynecol Oncol* 1994 Sep;54(3): 307-15.
- Kumar L, Nandy M, Biswal BM, Kumar S, Kriplani A, Singh R, Rath GK, Kochupillai V. Induction chemotherapy in locally advanced cervical cancer: a randomized study. *G Ital Oncol* 1995;15(1):39-42.
- Liao GW. [Treatment of advanced cervix carcinoma with hypogastric artery infusion chemotherapy plus radiotherapy]. *Chung Kuo Chung Liu Lin Chuang* 1994; 21(8):592-4. (Chi).
- Lin JC, Ho ES, Jan JS, Yang CH, Hsu WP. Concomitant chemoradiotherapy for advanced epidermoid carcinoma of the uterine cervix: a preliminary report. *Chung Hua I Hsueh Tsa Chih (Taipei)* 1994 Jul;54(1):26-32.
- Lippman SM, Kavanagh JJ, Paredes M, Delgadillo F, Hong WK, Figuerda F, Olguin A, Freedman RS, Massimini G, Holdener EE, et al. 13-cis-retinoic acid (13CRA), interferon-alpha 2a (IFN-a2a) and radiotherapy for locally advanced cancer of the cervix [abstract]. Proc Annu Meet Am Soc Clin Oncol 1993;12:A816.
- Lorvidhaya V, Tonusin A, Sukthomya W, Changwiwit W, Nimmolrat A. Induction chemotherapy and irradiation in advanced carcinoma of the cervix. *Gan To Kagaku Ryoho* 1995 Aug;22 Suppl 3:244-51.
- Louvet C, Moreau S, de Gramont A, Varette C, Demuynck B, Beerblock K, Marpeau L, Zylberait D, Pigne A, Soubrane D, Zylberait D, Krulik M. Bleomycin, Ifosfamide and Carboplatin in advanced uterine cervix carcinoma: preliminary results. In: Banzet P, Holland JF, Khayat D, Weil M, editors. *Cancer treatment: an update*. Presentations given at the 4th International Congress on Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France. Paris: Springer-Verlag; 1994. p. 488-91.
- Macia M, Novo A, Ces J, Gonzalez M, Huidobro C, Yuste J, Diab T. Neoadjuvant and salvage chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5-FU) in cervical carcinoma. *Eur J Gynaecol Oncol* 1993;14(3): 192-6.
- Malfetano J, Keys H, Kredentser D, Cunningham M, Kotlove D, Weiss L. Weekly cisplatin and radical radiation therapy for advanced, recurrent, and poor prognosis cervical carcinoma. *Cancer* 1993 Jun 1; 71(11):3703-6.
- Maneschi F, Benedetti-Panici P, Scambia G, Salerno MG, D'Agostino G, Mancuso S. Menstrual and hormone patterns in women treated with high-dose cisplatin and bleomycin. *Gynecol Oncol* 1994 Sep;54(3):345-8.
- Maruyama Y, Bowen MG, Van Nagell JR, Gallion HH, DePriest P, Wierzbiicki J. A feasibility study of 252Cf neutron brachytherapy, cisplatin + 5-FU chemo-adjuvant and accelerated hyperfractionated radiotherapy for advanced cervical cancer. *Int J Radiat Oncol Biol Phys* 1994 Jun 15;29(3):529-34.
- Moja LM, Maseela T. Neo-adjuvant chemotherapy in carcinoma of the cervix-bulky disease. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Morris M, Eifel PJ, Burke TW, McNamara MM, Levenback C, Kavanagh JJ, Gershenson DM. Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy. *Gynecol Oncol* 1995 Apr;57(1):72-8.
- Nagata Y, Ishigaki T, Okajima K, Fujiwara K, Kinashi T, Mitumori M, Ooya N, Kitakabu Y, Hiraoka M, Abe M, et al. Transcatheter arterial infusion therapy combined with radical hysterectomy in the treatment of advanced cervical cancer. *Cardiovasc Intervent Radiol* 1993 Jan-Feb;16(1):14-8; discussion 18-20.

- Namkoong SE, Park JS, Kim JW, Bae SN, Han GT, Lee JM, Jung JK, Kim SJ. Comparative study of the patients with locally advanced stages I and II cervical cancer treated by radical surgery with and without preoperative adjuvant chemotherapy. *Gynecol Oncol* 1995 Oct;59(1):136-42.
- Narimatsu A, Kobayashi M, Ito T. [Neoadjuvant chemotherapy with intra-arterial infusion (CDDP, MMC, PEP, AT-II) in the treatment of stage III cervical cancer]. *Nippon Gan Chiryō Gakkai Shi* 1994;29(12):1948-55. (Jpn).
- Nevin J, Bloch B, Van Wijk L, Soeters R, Dehaeck K, Ball H, Denny L. Primary chemotherapy with bleomycin, ifosfamide and cisplatin (BIP) followed by radiotherapy in the treatment of advanced cervical cancer. A pilot study. *Eur J Gynaecol Oncol* 1995;16(1):30-5.
- Ohsugi F, Yamada T, Tada S. [Low-dose consecutive intra-arterial infusion of CDDP to treat advanced cervical carcinoma: usefulness of a vascular access device with alteration of intrapelvic blood flow]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1995 May;55(6):380-9. (Jpn).
- Okawa T, Niibe H, Arai T, Sekiba K, Noda K, Takeuchi S, Hashimoto S, Ogawa N. Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase III, multicenter, randomized, controlled study. *Cancer* 1993 Sep 15;72(6):1949-54.
- Paladini D, Raspagliesi F, Fontanelli R, Ntousias V. Radical surgery after induction chemotherapy in locally advanced cervical cancer. A feasibility study. *Int J Gynecol Cancer* 1995;5(4):296-300.
- Panici P, Greggi S, Scambia G, Salerno MG, Battaglia F, Amoroso M, Mancuso S. Responsiveness to neoadjuvant chemotherapy (NAC) as a major prognostic factor in locally advanced cervical cancer (LACC). Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Panici PB, Greggi S, Scambia G, Battaglia F, Amoroso M, Salerno MG, Mancuso S. Response to neoadjuvant chemotherapy (NAC) as a major prognostic factor in locally advanced cervical cancer (LACC) [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A792.
- Panici PB, Greggi S, Scambia G, Maneschi F, Salerno MG, Amoroso M, Rabitti C, Mancuso S. Neoadjuvant chemotherapy (NAC) followed by radical surgery (RS) in locally advanced cervical cancer (LACC): a multivariate survival analysis (MSA). Paper presented at: 4th International Congress on Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France.
- Paredes Espinoza M, Lippman SM, Kavanagh JJ, Delgadillo Madrueno F, Paredes Casillas P, Banelos Acosta O, Alvarez Marquez V, Buenrostro Ahued MA, de Alba Ayala I, Arias Castro G. [Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha]. *Rev Invest Clin* 1994 Mar-Apr;46(2):105-11. (Spa).
- Parham G, Hicks M. Retroperitoneal lymphadenectomy followed by concomitant chemoradiation and tailored surgical debulking: a pilot multimodality protocol for advanced cervical and vaginal cancer [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A809.
- Park SY, Kim BG, Kim JH, Lee JH, Lee ED, Lee KH, Park KB, Lee BH, Kim KH. Phase I/II study of neoadjuvant intraarterial chemotherapy with mitomycin-C, vincristine, and cisplatin in patients with stage IIb bulky cervical carcinoma. *Cancer* 1995;76(5):814-23.
- Park SY, Kim BG, Kim JI, Lee JH, Lee ED, Lee KH, Park KP, Lee BH, Kim KH, Hong WS. Neoadjuvant intra-arterial chemotherapy in patients with stage IIB bulky cervical carcinoma [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1994;13:A849.
- Park TK, Lee SK, Kim SN, Hwang TS, Kim GE, Suh CO, Loh JK. Combined chemotherapy and radiation for bulky stages I-II cervical cancer: comparison of concurrent and sequential regimens. *Gynecol Oncol* 1993 Aug;50(2): 196-201.
- Pearcey RG, Stuart GC, MacLean GD, Nation JG, Arthur K, Lukka H, Jeffrey J, James K, Brundage M. Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix. *Gynecol Oncol* 1995 Jul;58(1):34-41.
- Potish RA, Twigg LB. On the lack of demonstrated clinical benefit of neoadjuvant cisplatin therapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 1993 Nov 15;27(4): 975-9.
- Rabinovich M, Vallejo C, Perez J, Cuevas MA, Machiavelli M, Lacava J, Leone B, Focaccia G, Suttora G, Romero A, et al. Neoadjuvant chemotherapy (NCH) with ifosfamide (IFX) and cisplatin (P) in advanced cervical carcinoma (ACC) [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A836.
- Resbeut M, Cowen D, Viens P, Noirclerc M, Perez T, Gouvernet J, Delpero JR, Gannerre M, Boubli L, Houvenaeghel G. Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma. *Gynecol Oncol* 1994 Jul;54(1):68-75.
- Resbeut M, Noirclerc M, Gravis G, d'Ercole C, Pechikoff P, Hovenaeghel G, Delpero JR, Blache JL, Viens P. Concomitant chemotherapy and radiotherapy in the treatment of advanced cervix carcinomas. In: Banzet P, Holland JF, Khayat D, Weil M, editors. *Cancer treatment: an update. Presentations given at the 4th International Congress on Anticancer Chemotherapy*; 1993 Feb 2-5; Paris, France. Paris: Springer-Verlag; 1994. p. 476-8.

- Resbeut M, Noirclerc M, Viens P, d'Ercole C, Houvenaeghel G, Boubli L, Gamarre M, Delpero JR. [Simultaneous radiotherapy and chemotherapy in the treatment of advanced cancer of the cervix uteri]. *Bull Cancer (Paris)* 1993 Nov;80(11):984-93. (Fre).
- Roberts WS, Lapolla JP, Greenberg H, Berman C, McDonald T. Continuous intra-arterial cisplatin combined with radiotherapy in locally advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group pilot study. *Int J Gynecol Cancer* 1995;5(5):335-40.
- Sardi J, Giaroli A, Sananes C, Ferreyra M, Bastardas M, Di Paola GR. [Evaluation of a randomized prospective trial with a new therapeutic approach for stage IIIB carcinoma of the cervix uteri]. *Prensa Med Argent* 1994; 81(3):236-48. (Spa).
- Sardi J, Sananes C, Giaroli A, Bayo J, Rueda NG, Vighi S, Guardado N, Paniceris G, Snaidas L, Vico C, et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. *Gynecol Oncol* 1993 May;49(2): 156-65. Comment in: *Gynecol Oncol* 1993 May;49(2): 153-5.
- Scambia G, Benedetti Panici P, Foti E, Amoroso M, Salerno G, Ferrandina G, Battaglia F, Greggi S, De Gaetano A, Puglia G, et al. Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. *J Clin Oncol* 1994 Nov;12(11):2309-16.
- Scarabelli C, Zarrelli A, Gallo A, Visentin MC. Multimodal treatment with neoadjuvant intraarterial chemotherapy and radical surgery in patients with stage IIIB-IVA cervical cancer: a preliminary study. *Cancer* 1995;76(6):1019-26.
- Shimamoto T, Tateyama H, Kohso T, Hamada M. Neoadjuvant chemotherapy using a platinum, vincristine and peplomycin (CVP) combination in patients with carcinoma of the uterine cervix. *Asia Oceania J Obstet Gynaecol* 1993 Sep;19(3):261-9.
- Shimizu Y, Umezawa S, Hasumi K. Neoadjuvant chemotherapy followed by radical surgery for bulky adenocarcinoma of the uterine cervix [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A804.
- Skoog LA, Waggoner SE, Williams SF, Rotmensch J, Heimann R, Fleming GF. Response to cisplatin (P), continuous infusion (CIV) 5-fluorouracil (5-FU), and leucovorin (L) (PFL) neoadjuvant chemotherapy in carcinoma of the uterine cervix [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A802.
- Souhami L, Seymour R, Roman TN, Stanimir GW, Trudeau M, Clark BG, Freeman CR. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. *Int J Radiat Oncol Biol Phys* 1993 Nov 15;27(4):871-8.
- Souhami L, Trudeau M, Seymour R, Roman T, Stanimir G, Clark B, Freeman C. Synchronous chemoradiation in advanced carcinoma of the cervix. In: Salmon SE, editor. *Adjuvant therapy of cancer VII. Proceedings of the 7th International Conference on the Adjuvant Therapy of Cancer*; 1993 Mar 10-13; Tucson, AZ. Philadelphia: J.B. Lippincott Co.; 1993. p. 377-82.
- Stehman FB, Bundy BN. Carcinoma of the cervix treated with chemotherapy and radiation therapy. Cooperative studies in the Gynecologic Oncology Group. *Cancer* 1993 Feb 15;71(4 Suppl):1697-701.
- Sueyama H, Nakano M, Sakumoto K, Toita T, Takizawa Y, Moromizato H, Kakihana Y, Kushi A, Moromizato H, Higashi M, et al. Intra-arterial chemotherapy with cisplatin followed by radical radiotherapy for locally advanced cervical cancer. *Gynecol Oncol* 1995 Dec; 59(3):327-32.
- Sueyama H, Nakano M, Toita T, Takizawa Y, Moromizato H, Kakihana Y, Kushi A, Sasaki K, Higashi M, Kanazawa K, Sekiya T. [Intra-arterial chemotherapy with cisplatin followed by radical radiotherapy for locally advanced cervical cancer]. *Rinsho Hoshasen* 1994;39(6):691-8. (Jpn).
- Takashima H, Hosokawa N, Hino I, Sato K, Kojima K, Ohkawa M, Tanabe M, Jinbo T, Hando T, Seo H. [Results of radiotherapy for stage III uterine cervical carcinomas and preliminary study of combined radiotherapy and transarterial infusion chemotherapy]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1994 Nov 25; 54(13):1270-6. (Jpn).
- Tattersall MH, Lorvidhaya V, Vootiprux V, Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A, Yen MS, et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. *J Clin Oncol* 1995 Feb;13(2):444-51. Comment in: *J Clin Oncol* 1995 Aug;13(8):2141-2.
- Tchan Kyu Park, Sung Ki Lee, Soo Nyung Kim, Tai Sik Hwang, Gwi Eon Kim, Chang Ok Suh, Juhn Kyu Loh. Combined chemotherapy and radiation for bulky stages I-II cervical cancer: comparison of concurrent and sequential regimens. *Gynecol Oncol* 1993;50(2):196-201.
- Villena-Heinsen C, Mink D, Lung-Kurt S, Kramann B, Kujat C, Schnabel K, Schmidt W. Preoperative intraarterial chemotherapy for bulky cervical carcinoma in stage IB - IIB. *Reg Cancer Treat* 1994;7(1):17-21.

Potential Improvements in Radiobiology

- Wadler S, Beitler JJ, Rubin JS, Haynes H, McGill F, Rozenblit A, Goldberg G, Cohen C, Speyer J, Runowicz C. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study. *J Clin Oncol* 1993 Aug;11(8):1511-6.
- Wadler S, Haynes H, Beitler JJ, Goldberg G, Holland JF, Hochster H, Bruckner H, Mandeli J, Smith H, Runowicz C. Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group. *J Clin Oncol* 1993 Aug;11(8):1517-22. Comment in: *J Clin Oncol* 1994 Jan;12(1):232.
- Xiao XH. [Operation combined with chemotherapy for 63 cases of cervical carcinoma in the Xinjiang Kashi area]. *Chung Hua Fu Chan Ko Tsa Chih* 1993 Oct;28(10): 610-2, 636. (Chi).
- Yacoub SF, Shaeffer J, el-Mahdi AM, Faris L, Zhu A. Nuclear morphometry as a predictor of response to neoadjuvant chemotherapy plus radiotherapy in locally advanced cervical cancer. *Gynecol Oncol* 1994 Sep; 54(3):327-32.
- Zanetta G, Colombo A, Maneo A, Colombo M, Nava S, Landoni F, Mangioni C. Postoperative treatments for stage Ib-IIa cervical carcinoma with lymph node metastases after primary surgery: complications and efficacy of three different methods. *Ital J Gynaecol Obstet* 1995;7(2):45-50.
- Zanetta G, Colombo A, Milani R, Placa F, Mangioni C. Long-term results of sequential postoperative treatment with vincristine, bleomycin, mitomycin C, cis-platin and radiotherapy after surgery for high-risk patients with cervical carcinoma stage IB-IIA. *Int J Gynecol Cancer* 1995;5(1):40-4.
- Zanetta G, Landoni F, Colombo A, Pellegrino A, Maneo A, Leventis C. Three-year results after neoadjuvant chemotherapy, radical surgery, and radiotherapy in locally advanced cervical carcinoma. *Obstet Gynecol* 1993 Sep;82(3):447-50.
- Acharya DK. Role of metronidazole in radiation therapy (a review of 717 cancer cases). *Indian J Med Sci* 1994 May; 48(5):111-6.
- Balmukhanov S, Abdrahmanov J, Philippenko V, Mustafin J, Aidarhanov A, Shibanova A. Intratumoral sensibilization: a new strategy in radiation therapy [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 401.
- Brizel DM, Rosner GL, Prosnitz LR, Dewhurst MW. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. *Int J Radiat Oncol Biol Phys* 1995 Jul 15; 32(4):1121-5.
- Chapman JD, Parliament MB. Can individual tumor oxygenation status be measured and does it predict treatment response [abstract]? In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 133.
- Chougule A. Linear quadratic model compared with TDF and TSD concepts for malignancy of cervix uteri treated with twice daily fractionated schedules. *Strahlenther Onkol* 1994 Jan;170(1):30-5.
- Chougule AA, Supe SJ. Hyperfractionated radiotherapy of carcinoma of the uterine cervix and predictivity of empirical models. *Indian J Radiol Imaging* 1994;4(2): 109-13.
- Dusenbery K, McGuire W, Carson L, Potish R, Fowler J, Twiggs L. Recombinant human erythropoietin (R-huepo) increases hemoglobin during radiation therapy for cervix cancer [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A828.
- Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, Potish RA. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 1994 Jul 30;29(5):1079-84.
- Feldmann HJ, Seegenschmiedt MH, Molls M. Hyperthermia --its actual role in radiation oncology. Part III: Clinical rationale and results in deep seated tumors. *Strahlenther Onkol* 1995 May;171(5):251-64.
- Geard CR, Jones JM. Radiation and taxol effects on synchronized human cervical carcinoma cells. *Int J Radiat Oncol Biol Phys* 1994 Jun 15;29(3):565-9.
- Herskovic TM, Pineda A, Pereira M, Behnam K,

- Murthy S, Piesla T, Ashford P. Hyperfractionated template treatment of cancer of cervix using the MicroSelectron high dose rate remote afterloader. *Endocuriether Hyperthermia Oncol* 1995;11(2):97-9.
- Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P. Intratumoral pO₂ predicts survival in advanced cancer of the uterine cervix. *Radiother Oncol* 1993 Jan;26(1):45-50.
- Hockel M, Vorndran B, Schlenger K, Baussmann E, Knapstein PG. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. *Gynecol Oncol* 1993 Nov;51(2):141-9. Comment in: *Gynecol Oncol* 1993 Nov;51(2):139-40.
- Komaki R, Pajak TF, Marcial VA, Rotman M, Grigsby PW, Leibel SA, Eifel PJ. Twice-daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. Phase I/II study of the Radiation Therapy Oncology Group 88-05. *Cancer* 1994 May 15;73(10): 2619-25.
- Li RY. [Intracavitary microwave hyperthermia combined with external irradiation in the treatment of cervical carcinoma]. *Chung Kuo Chung Liu Lin Chuang* 1993; 20(1):32-5. (Chi).
- Marcial VA, Marcial LV. Radiation therapy of cervical cancer. New developments. *Cancer* 1993 Feb 15; 71(4 Suppl):1438-45.
- Maruyama Y, Bowen MG, Van Nagell JR, Gallion HH, DePriest P, Wierzicki J. A feasibility study of ²⁵²Cf neutron brachytherapy, cisplatin + 5-FU chemo-adjuvant and accelerated hyperfractionated radiotherapy for advanced cervical cancer. *Int J Radiat Oncol Biol Phys* 1994 Jun 15;29(3):529-34.
- Maruyama Y, van Nagell JR, Yoneda J, Gallion HH, DePriest P, Feola JM, Wierzicki J. Schedule in ²⁵²Cf neutron brachytherapy: complications after delayed implant therapy for cervical cancer in a phase II trial. *Am J Clin Oncol* 1993 Apr;16(2):168-74.
- Matthews RH, Ercal N, Murrell HJ. Transvaginal electron beam cone used in treating an advanced squamous cell carcinoma of the cervix. *Mo Med* 1993 Apr;90(4): 188-90.
- Minarik L, Hall EJ. Taxol in combination with acute and low dose rate irradiation. *Radiother Oncol* 1994 Aug;32(2): 124-8. Comment in: *Radiother Oncol* 1994 Aug;32(2): 95-7.
- Mitsuhashi N, Takahashi I, Takahashi M, Hayakawa K, Niibe H. Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer. *Int J Radiat Oncol Biol Phys* 1993 Jun 15;26(3):407-11.
- Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. *Oncol Res* 1994; 6(10-11):509-18.
- Robertson J, Johnston C, Eisbruch A, Reynolds K, Roberts J, Lawrence T. A phase I/II study of bromodeoxyuridine (BRDU) and radiation therapy (RT) for locally advanced cervix cancer [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A481.
- Rodriguez M, Sevin BU, Perras J, Nguyen HN, Pham C, Steren AJ, Koechli OR, Averette HE. Paclitaxel: a radiation sensitizer of human cervical cancer cells. *Gynecol Oncol* 1995 May;57(2):165-9.
- Rubin JS, Wadler S, Beitler JJ, Haynes H, Rozenblit A, McGill F, Goldberg G, Runowicz C. Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. *J Laryngol Otol* 1995 Aug;109(8):744-7.
- Rui-Ying Li, et al. Intracavitary hyperthermia combined with radiation in the treatment of uterine cervix cancer [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 337.
- Runsen L, Tiezhuang Y, LingYu Y, Manchang L, Guoying P, Yonghui S, Ding Jeo L. Hyperthermia in combination with radiation in the treatment for carcinoma of the urine cervix [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 336.
- Stehman FB, Bundy BN. Carcinoma of the cervix treated with chemotherapy and radiation therapy. Cooperative studies in the Gynecologic Oncology Group. *Cancer* 1993 Feb 15;71(4 Suppl):1697-701.
- Stehman FB, Bundy BN, Thomas G, Keys HM, d'Ablaing G 3d, Fowler WC Jr, Mortel R, Creasman WT. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. *J Clin Oncol* 1993 Aug;11(8): 1523-8.
- Stelzer KJ, Koh WJ, Kurtz H, Greer BE, Griffin TW. Caffeine consumption is associated with decreased severe late toxicity after radiation to the pelvis. *Int J Radiat Oncol Biol Phys* 1994 Sep 30;30(2):411-7.
- Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. *Radiat Res* 1993 Dec;136(3):422-34.
- Strnad V, Sauer R, Tacev T. [Hypoxic radiotherapy. The radioprotective effect of acute hypoxia in the radiotherapy of tumors in the abdominal

- area]. *Strahlenther Onkol* 1994 Dec;170(12):700-3. (Ger).
- Thomas GM. Hypoxia and carcinoma of the cervix. *Semin Radiat Oncol* 1994;4(1):9-15.
- Uehara S, Masuda K, Hata K. [Hyperthermia in cervical cancer]. *Rinsho Hoshasen* 1994;39(6):685-90. (Jpn).
- Vaupel P. Tissue oxygenation predicts survival in advanced cervical cancer [abstract]. *Eur J Cancer* 1993; 29A Suppl 6:S40.
- Warenius HM. Fast neutron therapy. The UK experience. *Acta Oncol* 1994;33(3):289-92.
- West CM, Davidson SE, Burt PA, Hunter RD. The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data. *Int J Radiat Oncol Biol Phys* 1995 Feb 15; 31(4):841-6.
- West CM, Davidson SE, Roberts SA, Hunter RD. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. *Br J Cancer* 1993 Oct;68(4):819-23.
- Wiley AL Jr, Alqaisi ME, Vermund H, Scarantino CW, Rakfal SM, Nelson CE, Christie KI. Interstitial thermoradiotherapy in the management of refractory malignant tumors [abstract]. In: *ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme*; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 335.
- Wolfson AH. Advances in definitive radiation therapy for invasive cervical carcinoma. *Clin Consult Obstet Gynecol* 1995;7(2):135-40.
- Yang HD. [Study of relationship between local and systemic temperature during radiofrequency hyperthermia for cancer of cervix]. *Chung Kuo Chung Liu Lin Chuang* 1994;21(2):98-100. (Chi).
- Zimmermann M, Schorcht J, Andree W. Theoretical and experimental investigations of a newly developed intracavitary applicator system for the radiothermotherapy of gynaecological tumours. *Int J Hyperthermia* 1993 May-Jun;9(3):463-77.

Radiotherapy ± Chemotherapy for Locally Recurrent Disease

- Choy D, Wong RL, Sham J, Wu PM, Foo DL, Ngan HY, Ma HK. Vaginal template implant for cervical carcinoma with vaginal stenosis or inadvertent diagnosis after hysterectomy. *Int J Radiat Oncol Biol Phys* 1994 Jan 15; 28(2):457-62.
- Garton GR, Gunderson LL, Webb MJ, Wilson TO, Martenson JA Jr, Cha SS, Podratz KC. Intraoperative radiation therapy in gynecologic cancer: the Mayo Clinic experience. *Gynecol Oncol* 1993 Mar;48(3):328-32.
- Gerard JP, Dargent D, Raudrant D, Braillon G, Gilly FN, Romestaing P, Sentenac I, Rocher FP, Berger C, Adeline P, et al. [Role of peroperative radiotherapy in the treatment of uterine cancers. Preliminary experience in Lyon]. *Bull Cancer Radiother* 1994;81(3):186-95. (Fre).
- Hockel M, Bausmann E, Mitze M, Knapstein PG. Are pelvic side-wall recurrences of cervical cancer biologically different from central relapses? *Cancer* 1994 Jul 15;74(2):648-55.
- Karlan BY, Chamorro T, Fowler JM, Muderspach LI, Greenberg S, Lagasse LD. Concurrent interstitial radiotherapy and infusional chemotherapy for recurrent gynecologic malignancies. *Int J Gynecol Cancer* 1993; 3(5):304-10.
- Konski A, Neisler J, Phibbs G, Bronn D, Dobelbower RR Jr. The use of intraoperative electron beam radiation therapy in the treatment of para-aortic metastases from gynecologic tumors: a pilot study. *Am J Clin Oncol* 1993; 16(1):67-71.
- Martinez Monge R, Jurado M, Azinovic I, Aristu JJ, Tangco E, Viera JC, Berian JM, Calvo FA. Intraoperative radiotherapy in recurrent gynecological cancer. *Radiother Oncol* 1993 Aug;28(2):127-33.
- Monk BJ, Walker JL, Tewari K, Ramsinghani NS, Nisar Syed AM, DiSaia PJ. Open interstitial brachytherapy for the treatment of local-regional recurrences of uterine corpus and cervix cancer after primary surgery. *Gynecol Oncol* 1994 Feb;52(2):222-8.
- Seegenschmiedt MH, Sauer R, Miyamoto C, Chalal JA, Brady LW. Clinical experience with interstitial thermoradiotherapy for localized implantable pelvic tumors. *Am J Clin Oncol* 1993 Jun;16(3):210-22.
- Stelzer KJ, Koh WJ, Greer BE, Cain JM, Tamimi HK, Figge DC, Goff BA, Griffin TW. The use of intraoperative radiation therapy in radical salvage for recurrent cervical cancer: outcome and toxicity. *Am J Obstet Gynecol* 1995 Jun;172(6):1881-6; discussion 1886-8.
- Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. *Int J Gynecol Cancer* 1993;3(4):193-8.
- Wilailak S, Srisupandit S, Tangtrakul S, Ballangpoti S, Linasmita V, Bhamarapavati Y. Recurrence of cervical carcinoma following radical hysterectomy and pelvic node dissection. *J Med Assoc Thai* 1993 Jan;76 Suppl 1:69-73.

Surgery for Locally Recurrent Disease

- Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. *Gynecol Oncol* 1994 Oct;55(1):29-35.
- Crozier M, Morris M, Levenback C, Lucas KR, Atkinson EN, Wharton JT. Pelvic exenteration for adenocarcinoma of the uterine cervix. *Gynecol Oncol* 1995 Jul;58(1):74-8.
- Gotsadze D, Charkviani L, Nemsadze G, Tsintsadze I, Pirtskhalaishvili G. Continent urinary diversion (Gotsadze Pouch) after pelvic exenteration for gynaecological malignancies. *Eur J Gynaecol Oncol* 1994;15(5):369-71.
- Gotsadze D, Pirtskhalaishvili G. Abdominal reservoirs for continent urinary diversion. *J Urol* 1995 Sep;154(3): 985-8.
- Janser JC, Rodier JF, Rodier D, Vergnes Y. [Role of pelvic exenterations in the treatment of cervix cancers. Apropos of 41 surgically treated cases]. *Chirurgie* 1994-95;120(8): 409-14; 414-5. (Fre).
- Jurado Chacon M, Berian JM, Zudaire JJ. [Role of pelvic exenteration in the treatment of some advanced or recurrent gynecological cancers]. *Prog Obstet Ginecol* 1995;38(2):104-10. (Spa).
- Jurukovski JN, Davceva B. A personal experience with surgical treatment of 246 patients with invasive cervical carcinoma by Wertheim-Meigs' method. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Lopez MJ, Standiford SB, Skibba JL. Total pelvic exenteration: a 50-year experience at the Ellis Fischel Cancer Center. *Arch Surg* 1994 Apr;129(4):390-5; discussion 395-6. Published erratum appears in *Arch Surg* 1994 Jul;129(7):777.
- Mendez L, Bernal A, Escudero P, Gonzalez G, Fajardo A. [Pelvic exenteration, morbidity and survival]. *Ginecol Obstet Mex* 1994 Jun;62:161-5. (Spa).
- Miller B, Morris M, Rutledge F, Mitchell MF, Atkinson EN, Burke TW, Wharton JT. Aborted exenterative procedures in recurrent cervical cancer. *Gynecol Oncol* 1993 Jul; 50(1):94-9.
- Penalver M. Functional characteristics and follow-up of the continent ileal colonic urinary reservoir. Paper presented at: European Society of Gynaecological Oncology 8th International Meeting: Prevention, early detection, diagnosis, management and follow-up of gynaecological malignancies; 1993 Jun 9-12; Barcelona, Spain.
- Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W, Kirk ME. Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? *Gynecol Oncol* 1994 Mar; 52(3):353-9.
- Selvaggi SM, Haefner HK, Lelle RJ, Pearl ML, Roberts JA. Neovaginal cytology after total pelvic exenteration for gynecological malignancies. *Diagn Cytopathol* 1995 Jul; 13(1):22-5.
- Soeiro Fidalgo de Matos C, Nogaret JM, Philippson C, Veys I, Van Velthoven R. The place for surgery in central recurrences of invasive cancer of cervix uteri. *Acta Chir Belg* 1995 Jan-Feb;95(1):38-43.
- Torres Lobaton A, Bastida Blanco A, Marquez Acosta G, Hernandez Aten D, Roman Bassaure E, Rojo Herrera G. [Pelvic exenteration for cancer of the uterine cervix (prognostic factors)]. *Ginecol Obstet Mex* 1994 Jul;62: 189-93. (Spa).

Chemotherapy for Stage IVB and Recurrent Metastatic Disease

- Ahn WS, Lippman SM, Kavanagh JJ, Silva EG, Hong WK, Krakoff IH, Hittelman WN. Biological basis of response of cervical squamous cell carcinoma to alpha interferon and 13-CIS retinoic acid [abstract]. Proc Annu Meet Am Assoc Cancer Res 1993;34:A446.
- Alberts DS, Garcia DJ. Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix. Semin Oncol 1994 Aug;21(4 Suppl 7):37-46.
- Alberts DS, Modiano MR, Shamdas GJ, Childers J, Surwit E, Hatch K, Pruett L, Garcia D, Lippman SM. Phase II trial of 13-cis-retinoic acid (13-CRA) plus interferon-a2a (IFN) for advanced, heavily treated squamous cell carcinoma of the cervix (SCCC) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1993;12:A852.
- Behbakht K, Massad LS, Yordan E, Winkelman L, Lincoln S, Eriksson J, DeGeest K, Kirschner C, Wilbanks G. A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against recurrent squamous gynecologic cancers [abstract]. Proc Annu Meet Am Soc Clin Oncol 1993;12:A849.
- Cervellino JC, Araujo CE, Sanchez O, Miles H, Nishihama A. Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta Oncol 1995;34(2):257-9.
- Chambers SK, Lamb L, Kohorn EI, Schwartz PE, Chambers JT. Chemotherapy of recurrent/advanced cervical cancer: results of the Yale University PBM-PFU protocol. Gynecol Oncol 1994 May;53(2):161-9.
- Chauvergne J, Fumoleau P, Cappelaere P, Metz R, Armand JP, Chevallier B, Kerbrat P, de Forni M, Lhomme C, Roche H, et al. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1993;29A(3):350-4.
- Chauvergne J, Heron JF, Mayer F, Charrot-Chinet P, Toulouse C. [Chemotherapy of cancers of the uterine cervix with a combination of bleomycin, mitomycin, cisplatin and etoposide]. Bull Cancer (Paris) 1993 Jan; 80(1):70-9. (Fre).
- Eckert RL, Agarwal C, Hembree JR, Choo CK, Sizemore N, Andreatta-van Leyen S, Rorke EA. Human cervical cancer. Retinoids, interferon and human papillomavirus. Adv Exp Med Biol 1995;375:31-44.
- Eisenhauer E, Lippman S, Arnold A, Massimini G. Combination 13-cis-retinoic acid and interferon alpha-2a in clinical trials of solid tumors [abstract]. Ann Oncol 1994;5 Suppl 5:A198.
- Eisenhauer EA, Lippman SM, Kavanagh JJ, Parades-Espinoza M, Arnold A, Hong WK, Massimini G, Schleuniger U, Bollag W, Holdener EE, et al. Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia 1994 Oct;8(10): 1622-5.
- Fanning J, Ladd C, Hilgers RD. Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. Gynecol Oncol 1995 Feb;56(2):235-8.
- Filtborg TA, Hansen HH, Aage Engelholm S, Rorth M. A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix. Ann Oncol 1993 Jun;4(6):485-8.
- Garton GR, Wilson TO, Hartmann LC, Long HJ, Podratz KC. Neo-adjuvant M-VAC (Methotrexate, Vinblastine, Doxorubicin, Cisplatin) chemotherapy for locally advanced or metastatic cervical and vaginal cancer. In: Banzet P, Holland JF, Khayat D, Weil M, editors. Cancer treatment: an update. Presentations given at the 4th International Congress on Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France. Paris: Springer-Verlag; 1994. p. 482-4.
- Glaubitz M, Vahl U, Gunter HH, Petry U, Luck HJ, Kuhnle H. [Chemotherapy in cervical cancer]. Tumordiagn Ther 1993;14(6):209-19. (Ger).
- Gonzales-de Leon C, Lippman SM, Kudelka AP, Edwards CL, Kavanagh JJ. Phase II study of cisplatin, 5-fluorouracil and interferon-alpha in recurrent carcinoma of the cervix. Invest New Drugs 1995;13(1):73-6.
- Hallum AV 3rd, Alberts DS, Lippman SM, Inclan L, Shamdas GJ, Childers JM, Surwit EA, Modiano M, Hatch KD. Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix. Gynecol Oncol 1995 Mar;56(3): 382-6.
- Hirabayashi K, Okada E. Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer. Cancer 1993 May 1;71(9): 2769-75.
- Honda M, Hashimoto T, Matsui S, Kitanosono T, Munechika H, Hishida T, Moriyama S, Morimoto T, Ichikawa K, Yanaihara T. Combination of arterial infusion chemotherapy and irradiation for advanced uterine cervix cancers [abstract]. In: ICRO'93 - International Congress of Radiation Oncology - Preprinted abstracts and programme; 1993 Jun 21-25; Kyoto, Japan. [place unknown]: International Society for Radiation Oncology; 1993. p. 276.
- Hoskins P, Al-Saleh E, Pike J, Swenerton K. Combination cisplatin (DDP) and etoposide (VP16) not only has a high response rate in but also improves the well-being of women with recurrent or advanced cervical cancer [abstract]. Proc Annu Meet Am Assoc Cancer Res 1995; 14:A815.
- Ikeda M, Teshima K, Noda K, Yamagata S, Sugawa

- T, Okamura S, Kubo H, Sugimoto O, Nakajima H, Yamabe T, et al. [Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association]. *Gan To Kagaku Ryoho* 1994 Sep; 21(12):1967-74. (Jpn).
- Kavanagh JJ, Kudelka AP, Edwards CE, Girtanner RE, Durivage HF, Howell ET. CPT-11 (irinotecan): phase II study in refractory squamous cell carcinoma of the cervix [abstract]. *Proc Annu Meet Am Assoc Cancer Res* 1994; 35:A1397.
- Kikkawa F, Kawai M, Oguchi H, Kojima M, Ishikawa H, Iwata M, Maeda O, Tomoda Y, Arie Y, Kuzuya K, et al. Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. *Eur J Cancer* 1993;29A(11): 1542-6.
- Langer CJ, Godfrey S, Richter M, Dabrow M, Rosenblum N. Durable complete remission (CR) in recurrent, metastatic squamous cell carcinoma of the cervix (SCC-C) after treatment with bleomycin, ifosfamide, and cisplatin (BIP) [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A796.
- Lara FU, Garcia-Rdz F, Zinser JW, Alcalá F, Castaneda N, Herrera A, Ramirez JL, Mota A, Martinez J. Adenosquamous carcinoma of the uterine cervix (ACU). Palliative, neoadjuvant (NA) and adjuvant (A) chemotherapy (CT) [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1994;13:A879.
- Lavoie A, Ouellet P, Tessier C. Chemotherapy of advanced cervical cancer [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A889.
- Lira-Puerto V, Martinez R, Palma F, Silva A, Zepeda G. Site of disease and response to chemotherapy in disseminated squamous cell carcinoma of the cervix [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1994;13:A824.
- Long HJ 3rd, Cross WG, Wieand HS, Webb MJ, Mailliard JA, Kugler JW, Tschetter LK, Kardinal CG, Ebbert LP, Rayson S. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. *Gynecol Oncol* 1995 May;57(2):235-9.
- Lorvidhaya V. Epirubicin and cisplatin in recurrent, metastatic or advanced carcinoma of the cervix. *Gan To Kagaku Ryoho* 1995 Aug;22 Suppl 3:252-5.
- Morris M, Burke T, Levenback C, Wharton JT, Gershenson D. Phase II study vinorelbine in advanced squamous carcinoma of the uterine cervix (SCC): preliminary results [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A742.
- Morris M, Gershenson DM, Burke TW, Mitchell MF, Levenback C, Atkinson N, Wharton JT. A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix. *Gynecol Oncol* 1994 May;53(2):234-8.
- Muggia FM, Muderspach L. Platinum compounds in cervical and endometrial cancers: focus on carboplatin. *Semin Oncol* 1994 Apr;21(2 Suppl 2):35-41; quiz 42, 58.
- Murad AM, Medina L, Andrade CA, Froimtchuk M, Yamaguchi N. Single arm, open label multicentric, phase II trial of chemotherapy (CT) with methotrexate (M), vinblastine (V) doxorubicin (D) and cisplatin (C) (MVAC) plus granulocyte colony stimulating factor (filgrastim) in advanced recurrent cervical cancer (CC) [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1994;13:A877.
- Murad AM, Medina L, Andrade CA, Froimtchuk MJ, Yamaguchi N. Phase II open label multicentric trial of MVAC--methotrexate (M), vinblastine (V), doxorubicin (A) and cisplatin (C) plus granulocyte colony stimulating factor (filgrastim) in advanced recurrent cervical carcinoma: final report [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1995;14:A774.
- Murad AM, Oliveira M, Saldanha TM. Phase II trial of isotretinoin and interferon alpha-2a in the treatment of advanced recurrent cervical carcinoma. *Int J Gynecol Cancer* 1994;4(6):414-8.
- Murad AM, Triginelli SA, Ribalta JC. Phase II trial of BIC (bleomycin, ifosfamide and carboplatin) in advanced cervical cancer. Final report [abstract]. *Proc Annu Meet Am Soc Clin Oncol* 1993;12:A802.
- Murad AM, Triginelli SA, Ribalta JC. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. *J Clin Oncol* 1994 Jan;12(1):55-9.
- Ng HT, Yuan CC, Kan YY, Ho ES, Yen MS, Chao KC. An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases. *Arch Gynecol Obstet* 1995;256(1):1-4.
- Noda K, Terajima Y, Ogita Y, Kono I, Hirabayashi K, Yakushiji M, Taguchi T. [Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri]. *Gan To Kagaku Ryoho* 1994 Oct; 21(14):2471-7. (Jpn).
- Obasaju CK, Cowan RA, Wilkinson PM. Recurrent cervical cancer treated with cisplatin and methotrexate. *Clin Oncol (R Coll Radiol)* 1993;5(4):203-6.
- Omura GA. Chemotherapy for cervix cancer. *Semin Oncol* 1994 Feb;21(1):54-62.
- Omura GA, Blessing J, Vaccarello L, Berman M, Mutch D, Clarke-Pearson D, Anderson B. A randomized trial of cisplatin (C) versus C + mitolactol (CM) versus C + ifosfamide (CIFX) in advanced squamous carcinoma of the cervix (SCC) by the Gynecologic Oncology Group

- (GOG) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995;14:A736.
- Onishi Y, Hatae M, Hokanishi H. [Long time survival after combination chemotherapy with cisplatin, vinblastine and peplomycin for cervical cancer]. Nippon Sanka Fujinka Gakkai Zasshi 1993 Jul;45(7):657-64. (Jpn).
- Park RC, Thigpen JT. Chemotherapy in advanced and recurrent cervical cancer. A review. Cancer 1993 Feb 15; 71(4 Suppl):1446-50.
- Petersen IA, Long HJ, Abu-Ghazaleh S, Brindle JS, Keeney GL, Cha SS. North Central Cancer Treatment Group (NCCTG) study of neoadjuvant methotrexate, vincristine, adriamycin, cisplatin (MVAC) in locally advanced cervical carcinoma [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995;14:A765.
- Potkul RK, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ. Irinotecan (CPT11) in advanced squamous cell carcinoma of the cervix (phase II) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995;14:A785.
- Rebattu P, Fumoleau P, Roche H, Krakowski Y, Lentz A, Mathieu Boue A, Van Glabbecke M. Phase II trial of CPT11 in advanced cervical carcinoma [abstract]. Proc Annu Meet Am Soc Clin Oncol 1995;14:A737.
- Rietbroek R, Postma A, Vording PZ, Gonzalez D, Gonzalez M, Schilthuis M, Kurth K, Bakker A, Bakker P, Veenhof C. Phase I/II trial of locoregional hyperthermia (HT) and weekly cisplatin (CDDP) in patients with a local recurrence of a cervical carcinoma or locally advanced bladder carcinoma [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994;13:A847.
- Rietbroek R, Shilthuis M, Postma A, Zum Vorde Sive Vording P, Gonzalez Gonzalez D, Bakker A, Bakker P, Veenhof C. Weekly locoregional hyperthermia (HT) and cisplatin (CDDP) in patients with a local recurrence of a cervical carcinoma (CC) [abstract]. Proc Annu Meet Am Assoc Cancer Res 1995;14:A816.
- Roig LMV, Lotfi H, Olcese JE, Castro GL, Ciocca DR. Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res 1993; 13(6B):2457-63.
- Rose PG, Piver MS, Malfetano JH, Baker TR, Hempling RE, Recio FO. A phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent cervical carcinoma. Cancer 1993 Apr 1;71(7):2245-9.
- Scarabelli C, Zarrelli A, Gallo A, Campagnutta E, Visentin C, Giorda G, De Marco L, Sopracordevole F, De Piero G, Sasso GM, Parin A. Pelvic recurrences in cervical cancer: multimodal treatment with sequential intra-arterial chemotherapy and surgery. Reg Cancer Treat 1994;7(1):12-6.
- Singhal RM, Jindel R, Gupta AK. Bleomycin, cisplatin and ifosfamide infusion chemotherapy in advanced/recurrent cancer of cervix. Indian J Cancer 1993 Dec;30(4):158-63.
- Smith HO, Stringer CA, Kavanagh JJ, Gershenson DM, Edwards CL, Wharton JT. Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy. Gynecol Oncol 1993 Jan;48(1):11-5.
- Stornes I, Mejlholm I, Jakobsen A. A phase II trial of ifosfamide, 5-fluorouracil, and leucovorin in recurrent uterine cervical cancer. Gynecol Oncol 1994 Oct;55(1): 123-5.
- Sutton GP, Blessing JA, DiSaia PJ, McGuire WP. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1993 Apr;49(1):48-50.
- Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993 Mar; 168(3 Pt 1):805-7.
- Taguchi T. Clinical studies of CPT-11 in Japan. In: Banzet P, Holland JF, Khayat D, Weil M, editors. Cancer treatment: an update. Presentations given at the 4th International Congress on Anticancer Chemotherapy; 1993 Feb 2-5; Paris, France. Paris: Springer-Verlag; 1994. p. 809-12.
- Thigpen JT, Vance R, Punecky L, Khansur T. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 1995 Apr;22(2 Suppl 3):16-24.
- Thigpen T, Vance RB, Khansur T. Carcinoma of the uterine cervix: current status and future directions. Semin Oncol 1994 Apr;21(2 Suppl 2):43-54; quiz 55, 58.
- Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995 Oct; 22(5 Suppl 12):67-75.
- Tobias JS. Management of advanced cervical carcinoma with ifosfamide-containing combinations: UK experience with adjuvant chemotherapy. In: Salmon SE, editor. Adjuvant therapy of cancer VII. Proceedings of the 7th International Conference on the Adjuvant Therapy of Cancer; 1993 Mar 10-13; Tucson, AZ. Philadelphia: J.B. Lippincott Co.; 1993. p. 357-65.
- Trinci M, Raffetto N, Salvatori F, Trinci C. [Locoregional intra-arterial chemotherapy combined with radiotherapy in cervical carcinoma]. Radiol Med (Torino) 1993 Mar; 85(3):262-5. (Ita).
- Trudeau M, Souhami L, Seymour R, Arthur L, Stanimir G, Roman T, Tsatoumas A, Thirlwell M, Leyland-Jones B, Reinhold C, et al. A phase II

Palliative Radiotherapy for Stage IVB Disease

- trial of mitomycin, ifosfamide and cisplatin (MIC) in patients (pts) with recurrent or advanced cervical cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994;13:A841.
- Tsuji K, Yamada R, Kawabata M, Mitsuzane K, Sato M, Iwahashi M, Kitayama S, Nakano R. Effect of balloon occluded arterial infusion of anticancer drugs on the prognosis of cervical cancer treated with radiation therapy. *Int J Radiat Oncol Biol Phys* 1995 Jul 30;32(5): 1337-45.
- Vargas Roig LM, Lotfi H, Olcese JE, Lo Castro G, Ciocca DR. Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. *Anticancer Res* 1993 Nov-Dec;13(6B):2457-63.
- Verma S, Prefontaine M, Bertrand M, Genest P, Dahrouge S. A pilot study of intra-arterial carboplatin in patients with recurrent carcinoma of the cervix, postradiation. *Gynecol Oncol* 1994 Jun;53(3):290-3.
- Wadler S, Haynes H, Burk RD, Gallagher R, Schwartz EL, Jennings S, Wallach R, Goldberg G, Smith H, Runowicz C. Clinical/pharmacokinetic (PK) trial of all-trans retinoic acid (TRA) + interferon-alpha (IFN) in advanced cervix cancer (CC) [abstract]. Proc Annu Meet Am Soc Clin Oncol 1994;13:A818.
- Woolfson AD, McCafferty DF, McCarron PA, Price JH. Liquid scintillation spectrometry of 5-fluorouracil in cervical tissue following in vitro surface application of a bioadhesive cervical patch. *Pharm Res* 1994 Sep;11(9): 1315-9.
- Yanase T, Takayanagi T, Hanaoka JI, Takeuchi Y, Tokunaga A. [A pilot study of CBDCA-ETOP-CDDP combination therapy in refractory uterine cervical cancer recurring with lymph node metastasis]. *Gan To Kagaku Ryoho* 1995;22(9):1261-4. (Jpn).
- Zanetta G, Leventis C, Lo Monico S, Landoni F, Marzola M, Mangioni C. Bleomycin, ifosfamide and cis-platin chemotherapy in recurrent and persistent cervical cancer, a prospective study. *Int J Gynecol Cancer* 1995; 5(1):56-60.
- Zanetta G, Torri W, Bocciolone L, Lucchini V, Mangioni C. Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: a multivariate analysis. *Gynecol Oncol* 1995 Jul;58(1):58-63.
- Biswal BM, Lal P, Rath GK, Mohanti BK. Hemostatic radiotherapy in carcinoma of the uterine cervix. *Int J Gynaecol Obstet* 1995;50(3):281-5.
- Kraiphibul P, Srisupundit S, Kiatgumjaikajorn S, Pairachvet V. The experience in using whole pelvic irradiation in management of massive bleeding from carcinoma of the uterine cervix. *J Med Assoc Thai* 1993 Jan;76 Suppl 1:78-81.

NEW DIRECTIONS FOR RESEARCH IN CERVICAL CANCER

Radiation Biology

Angioli R, Sevin BU, Perras JP, Untch M, Koechli OR, Nguyen HN, Steren A, Schwade JG, Villani C, Averette HE. In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines. *Cancer* 1993 Jun 1;71(11):3717-25.

Durand RE, LePard NE. Modulation of tumor hypoxia by conventional chemotherapeutic agents. *Int J Radiat Oncol Biol Phys* 1994 Jun 15;29(3):481-6.

HPV Biology

Akasofu M, Oda Y. Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18. *Virchows Arch* 1995;425(6):593-602.

Alonio LV, Dalbert D, Mural J, Bartt O, Bazan G, Teyssie AR. Early herpes simplex virus proteins as risk markers for progression of papillomavirus cervical lesions: a retrospective study. *Cervix Low Female Genital Tract* 1993;11(4):161-4.

Alvarez-Salas LM, Wilczynski SP, Burger RA, Monk BJ, DiPaolo JA. Polymorphism of the HPV-16 E6 gene of cervical carcinoma. *Int J Oncol* 1995;7(2):261-6.

Anderson SM, Brooke PK, Van Eyck SL, Noell H, Frable WJ. Distribution of human papillomavirus types in genital lesions from two temporally distinct populations determined by in situ hybridization. *Hum Pathol* 1993; 24(5):547-53.

Arends MJ, Donaldson YK, Duvall E, Wyllie AH, Bird CC. Human papillomavirus type 18 associates with more advanced cervical neoplasia than human papillomavirus type 16. *Hum Pathol* 1993 Apr;24(4):432-7.

Baker VV. Molecular genetic abnormalities and cervical cancer. *Clin Consult Obstet Gynecol* 1995;7(2):86-93.

Baker VV. Oncogene expression in cervical cancer. *Cancer Treat Res* 1994;70:43-51.

Band V, Dalal S, Delmolino L, Androphy EJ. Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. *EMBO J* 1993;12(5):1847-52.

Berumen J, Casas L, Segura E, Amezcua JL, Garcia-Carranca A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. *Int J Cancer* 1994 Mar 1;56(5):640-5.

Berumen J, Unger ER, Casas L, Figueroa P. Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer. *Hum Pathol* 1995 Jun;26(6):676-81.

Bornstein J, Rahat MA, Abramovici H. Etiology of cervical cancer: current concepts. *Obstet Gynecol Surv* 1995 Feb; 50(2):146-54.

Cardillo MR, Stamp GW, Pignatelli MN, Lalani EN. Immunohistochemical analysis of p53 oncoprotein and proliferating cell nuclear antigen (PCNA) in the cervix uteri. *Eur J Gynaecol Oncol* 1993;14(6):484-90.

Chee YH, Namkoong SE, Kim DH, Kim SJ, Park JS. Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins. *Gynecol Oncol* 1995 May;57(2):226-31.

- Chen TM, Pecoraro G, Defendi V. Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells. *Cancer Res* 1993 Mar 1;53(5): 1167-71.
- Choo CK, Rorke EA, Eckert RL. Retinoid regulation of cell differentiation in a series of human papillomavirus type 16-immortalized human cervical epithelial cell lines. *Carcinogenesis* 1995;16(2):375-81.
- DiPaolo JA, Popescu NC, Alvarez L, Woodworth CD. Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus DNA. *Crit Rev Oncog* 1993;4(4):337-60.
- Gu Z, Pim D, Labrecque S, Banks L, Matlashewski G. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. *Oncogene* 1994 Feb; 9(2):629-33.
- Hagmar B, Christensen JJP, Johansson B, Kalantari M, Ryd W, Skyldberg B, Walaas L, Warleby B, Kristensen GB. Implications of human papillomavirus type for survival in cervical squamous cell carcinoma. *Int J Gynecol Cancer* 1995;5(5):341-5.
- Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. *Proc Natl Acad Sci U S A* 1995 Feb 28; 92(5):1654-8.
- Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. *Proc Natl Acad Sci U S A* 1993;90(9):3988-92.
- Kinoshita M, Shin S, Hamada SI, Aono T. Human papillomavirus integration into the host cell genome during the developmental stage of cervical cancer. *Rinsho Kagaku* 1993;22(3):162-7.
- Koffa M, Koumantakis E, Ergazaki M, Malamoumitsi V, Spandidos DA. Detection of ras gene mutations and HPV in lesions of the human female reproductive tract. *Int J Oncol* 1994 Aug;5(2):189-95.
- Konya J, Veress G, Hernadi Z, Soos G, Czegledy J, Gergely L. Correlation of human papillomavirus 16 and 18 with prognostic factors in invasive cervical neoplasias. *J Med Virol* 1995 May;46(1):1-6.
- Koulos JP, Wright TC, Mitchell MF, Silva E, Atkinson EN, Richart RM. Relationships between c-Ki-ras mutations, HPV types, and prognostic indicators in invasive endocervical adenocarcinomas. *Gynecol Oncol* 1993 Mar; 48(3):364-9.
- Lee JH, Kang YS, Koh JW, Park SY, Kim BG, Lee ED, Lee KH, Park KB, Seo YL. p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences. *Int J Gynecol Cancer* 1994;4(6):371-8.
- Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett S, Herman B. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. *J Cell Biochem* 1995 Mar;57(3): 509-21.
- Liang XH, Volkmann M, Klein R, Herman B, Lockett SJ. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. *Oncogene* 1993 Oct;8(10):2645-52.
- Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. *Int J Cancer* 1995 Nov 27;63(5):639-45.
- Park TW, Fujiwara H, Wright TC. Molecular biology of cervical cancer and its precursors. *Cancer* 1995; 76(10 Suppl):1902-13.
- Patrick DR. Biochemical characterization of the human papillomavirus type 16 e7 oncoprotein and its interaction with the retinoblastoma growth suppressor gene product [dissertation]. [Philadelphia]: Univ. of Pennsylvania; 1993. 221 p. Available from: University Microfilms International, Ann Arbor, MI; AAD94-13887.
- Rose BR, Thompson CH, Tattersall MH, Elliott PM, Dalrymple C, Cossart YE. Identification of E6/E7 transcription patterns in HPV 16-positive cervical cancers using the reverse transcription/polymerase chain reaction. *Gynecol Oncol* 1995 Feb;56(2):239-44.
- Unger ER, Vernon SD, Thoms WW, Nisenbaum R, Spann CO, Horowitz IR, Icenogle JP, Reeves WC. Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer. *J Infect Dis* 1995;172(5):1184-90.
- Wake N. [Application of antisense oligonucleotides into treatment of human cervical carcinoma]. *Nippon Sanka Fujinka Gakkai Zasshi* 1994 Aug;46(8):742-8. (Jpn).
- Watanabe S, Kanda T, Yoshiike K. Growth dependence of human papillomavirus 16 DNA-positive cervical cancer cell lines and human papillomavirus 16-transformed human and rat cells on the viral oncoproteins. *Jpn J Cancer Res* 1993 Oct;84(10):1043-9.
- Yamada T, Yamashita T, Nishikawa T, Fujimoto S, Fujinaga K. Biologic activity of human papillomavirus type 16 E6/E7 cDNA clones isolated from SiHa cervical carcinoma cell line. *Virus Genes* 1995;10(1):15-25.
- Ylitalo N, Bergstrom T, Gyllensten U. Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization. *J Clin Microbiol* 1995;33(7):1822-8.

HPV Immunology and Vaccine Prospects

- Apple RJ, Becker TM, Wheeler CM, Erlich HA. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. *J Natl Cancer Inst* 1995 Mar 15; 87(6):427-36.
- Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. *Nat Genet* 1994 Feb;6(2):157-62.
- Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ disease associations with cervical carcinoma show human papillomavirus-type specificity [abstract]. *Proc Annu Meet Am Assoc Cancer Res* 1994;35:A1723.
- Baay MF, Duk JM, Burger MP, de Bruijn HW, Stolz E, Herbrink P. Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma. *J Med Virol* 1995 Mar;45(3):342-7.
- Baay MF, Duk JM, Burger MP, Walboomers J, ter Schegget J, Groenier KH, de Bruijn HW, Stolz E, Herbrink P. Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma. *J Clin Pathol* 1995 May;48(5):410-4.
- Bell MC, Edwards RP, Partridge EE, Kuykendall K, Conner W, Gore H, Turbat-Herrera E, Crowley-Nowick PA. CD8+ T lymphocytes are recruited to neoplastic cervix. *J Clin Immunol* 1995 May;15(3):130-6.
- Coleman N, Stanley MA. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. *Int J Cancer* 1994 Feb 1;56(3):314-9.
- Connor ME, Davidson SE, Stern PL, Arrand JR, West CML. Evaluation of multiple biologic parameters in cervical carcinoma: high macrophage infiltration in HPV-associated tumors. *Int J Gynecol Cancer* 1993;3(2):103-9.
- Crawford L. Prospects for cervical cancer vaccines. *Cancer Surv* 1993;16:215-29.
- Cromme FV, van Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ, Meijer CJ. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. *Br J Cancer* 1994 Jun;69(6):1176-81.
- Cromme FV, Walboomers JMM, Van Oostveen JW, Stukart MJ, De Gruijl TD, Kummer JA, Leonhart AM, Helmerhorst TJM, Meijer CJLM. Lack of granzyme expression in T lymphocytes indicates poor cytotoxic T lymphocyte activation in human papillomavirus-associated cervical carcinomas. *Int J Gynecol Cancer* 1995;5(5): 366-73.
- Das S, Bal N, Roychowdhury J, Chattopadhyay U. Immunoglobulins, immune complexes and antitumor antibodies as prognostic indicators in carcinoma of uterine cervix. *J Exp Clin Cancer Res* 1993;12(2):91-9.
- Dillner J, Lenner P, Lehtinen M, Eklund C, Heino P, Wiklund F, Hallmans G, Stendahl U. A population-based seroepidemiological study of cervical cancer. *Cancer Res* 1994 Jan 1;54(1):134-41.
- Dillner J, Wiklund F, Lenner P, Eklund C, Frederiksson-Shanazarian V, Schiller JT, Hibma M, Hallmans G, Stendahl U. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. *Int J Cancer* 1995 Jan 27;60(3):377-82.
- Dillner L, Fredriksson A, Persson E, Forslund O, Hansson BG, Dillner J. Antibodies against papillomavirus antigens in cervical secretions from condyloma patients. *J Clin Microbiol* 1993 Feb;31(2):192-7.
- Dillner L, Zellbi A, Avall-Lundqvist E, Heino P, Eklund C, Pettersson CA, Forslund O, Hansson BG, Grandien M, Bistoletti P, et al. Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer. *Cancer Detect Prev* 1995;19(5):381-93.
- Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS, et al. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. *Nat Med* 1995 May; 1(5):464-70.
- Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Gallee MP, Hart AA, Muller M, Trimbois JB, Helmerhorst TJ. Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. *Cancer* 1994 Oct 15;74(8): 2307-13.
- Gemignani M, Maiman M, Fruchter RG, Arrastia CD, Gibbon D, Ellison T. CD4 lymphocytes in women with invasive and preinvasive cervical neoplasia. *Gynecol Oncol* 1995 Dec;59(3):364-9.
- Gupta MM, Jain R, Parashari A, Singh V, Sharma S. Circulating immune profile in patients with pre-cancer and cancer of the cervix: a cross sectional study among Indian women. *Bull Cancer (Paris)* 1993 Oct;80(10): 852-6.
- Helland A, Borresen AL, Kristensen G, Ronningen KS. DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis. *Cancer Epidemiol Biomarkers Prev* 1994 Sep;3(6):479-86.

- Hellstrom I, Hellstrom KE. Tumor immunology--an overview. *Ann N Y Acad Sci* 1993 Aug 12;690:24-33.
- Hilders CG, Houbiers JG, Krul EJ, Fleuren GJ. The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. *Am J Clin Pathol* 1994 Jan;101(1):5-12.
- Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, Veldhuizen RW, Fleuren GJ. Association between HLA-expression and infiltration of immune cells in cervical carcinoma. *Lab Invest* 1993 Dec;69(6):651-9. Comment in: *Lab Invest* 1993 Dec;69(6):635-8.
- Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. *Gynecol Oncol* 1995 Jun;57(3):366-75.
- Hilders CG, Ras L, van Eendenburg JD, Nooyen Y, Fleuren GJ. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. *Int J Cancer* 1994 Jun 15;57(6):805-13.
- Hines JF, Ghim SJ, Schlegel R, Jenson AB. Prospects for a vaccine against human papillomavirus. *Obstet Gynecol* 1995;86(5):860-6.
- Hines JF, Jenson AB, Barnes WA. Human papillomaviruses: their clinical significance in the management of cervical carcinoma. *Oncology (Huntingt)* 1995 Apr;9(4):279-85; discussion 286-8, 291.
- Honma S, Tsukada S, Honda S, Nakamura M, Takakuwa K, Maruhashi T, Kodama S, Kanazawa K, Takahashi T, Tanaka K. Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix. *Int J Cancer* 1994 Jun 1;57(5):650-5.
- Juranic Z, Vuckovic-Dekic L, Durbaba M. Humoral immunity in patients with carcinoma of the uterine cervix --effects of radiation therapy. *Neoplasma* 1993;40(5): 297-300.
- Juranic Z, Vuckovic-Dekic L, Durbaba M. Immune reactive proteins in patients irradiated for cervical cancer. One year follow up. *Neoplasma* 1994;41(4):225-8.
- Kast WM, Brandt RMP, Drijfhout JW, Melief CJM. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. *J Immunother* 1993;14(2): 115-20.
- Labeit D, Labeit S, Berger M, Gallati H, Rosenberg R, Friese K. [Interferon-alpha controls HPV infection in cervix epithelium]. *Zentralbl Gynakol* 1995;117(11): 566-77. (Ger).
- Lenner P, Dillner J, Wiklund F, Hallmans G, Stendahl U. Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix. *Cancer Immunol Immunother* 1995 Mar;40(3):201-5.
- Mandelblatt J. Squamous cell cancer of the cervix, immune senescence and HPV: is cervical cancer an age-related neoplasm? *Adv Exp Med Biol* 1993;330:13-26.
- Melief CJ, Kast WM. Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides. *Ciba Found Symp* 1994;187: 97-104; discussion 104-12.
- Mercedes Bravo M, Lucia Combata A, Mesa M, Varela A, Orozco O, Martinez G. [Antiprotein E7 humoral response of papilloma virus type 16 recognized by means of synthetic peptides and recombinant protein]. *Rev Colomb Obstet Ginecol* 1995;46(1):33-40. (Spa).
- Muller M, Viscidi RP, Ulken V, Bavinck JN, Hill PM, Fisher SG, Reid R, Munoz N, Schneider A, Shah KV, et al. Antibodies to the E4, E6, and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated diseases and in the normal population. *J Invest Dermatol* 1995 Jan;104(1):138-41.
- Nakano T, Oka K, Sugita T, Tsunemoto H. Antitumor activity of Langerhans cells in radiation therapy for cervical cancer and its modulation with SPG administration. *In Vivo* 1993 May-Jun;7(3):257-63.
- Onda T, Kanda T, Zanma S, Yasugi T, Watanabe S, Kawana T, Ueda K, Yoshikawa H, Taketani Y, Yoshiike K. Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA. *Int J Cancer* 1993 Jun 19;54(4):624-8.
- Paez CG, Yaegashi N, Sato S, Yajima A. Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls. *Tohoku J Exp Med* 1993 Jun;170(2): 113-21.
- Soutter WP, Kesic V. Treatment of cervical intraepithelial neoplasia reverses CD4/CD8 lymphocyte abnormalities in peripheral venous blood. *Int J Gynecol Cancer* 1994;4(4): 279-82.
- Stoian M, Repanovici R. Identification of antibodies against human papillomavirus type 16 E4 and E7 proteins in sera of patients with cervical neoplasias. *Rev Roum Virol* 1994 Jul-Dec;45(3-4):185-92.
- Strickler HD, Dillner J, Schiffman MH, Eklund C, Glass AG, Greer C, Scott DR, Sherman ME, Kurman RJ, Manos M. A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions. *Viral Immunol* 1994;7(4):169-77.

- Sun Y. Serologic markers of human papillomavirus associated cervical cancer [dissertation]. [Baltimore (MD)]: Johns Hopkins Univ.; 1994. 193 p. Available from: University Microfilms International, Ann Arbor, MI; AAD94-29578.
- Sun Y, Eluf-Neto J, Bosch FX, Munoz N, Booth M, Walboomers JM, Shah KV, Viscidi RP. Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil. *Cancer Epidemiol Biomarkers Prev* 1994 Jun;3(4):341-7.
- Sun Y, Shah KV, Muller M, Munoz N, Bosch XF, Viscidi RP. Comparison of peptide enzyme-linked immunosorbent assay and radioimmuno-precipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins. *J Clin Microbiol* 1994 Sep;32(9):2216-20.
- Torres LM, Cabrera T, Concha A, Oliva MR, Ruiz-Cabello F, Garrido F. HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix. *Tissue Antigens* 1993 Feb;41(2):65-71.
- Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Munoz N, Shah KV. Serologic response in human papillomavirus-associated invasive cervical cancer. *Int J Cancer* 1993 Nov 11;55(5):780-4.
- Vuckovic-Dekic L, Spremo B, Stanojevic-Bakic N, Garzicic B, Durbaba M. Immunosuppressive and cytogenetic effects of pelvic irradiation on the peripheral lymphocytes of patients with cervical cancer. One year follow-up. *Arch Immunol Ther Exp (Warsz)* 1994;42(1): 63-6.